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Abstract 
Clozapine is an atypical antipsychotic known to be uniquely effective in patients with treatment-
resistant schizophrenia, but associated with numerous adverse reactions. Despite substantial 
research efforts, we lack a full understanding of the mechanistic processes underlying clozapine’s 
efficacy and identification of the most relevant mechanisms. Animal studies suggest that clozapine 
induces changes in DNA methylation (a dynamic epigenetic modification which can regulate gene 
expression). However, research in humans is extremely limited. 
This thesis provides an original contribution to the literature as the first study to report positions 
of significant differences in longitudinal DNA methylation trajectories associated with clozapine 
exposure, therapeutic response and adverse reactions. 22 participants with schizophrenia were 
recruited and within-participant sampling was conducted before clozapine initiation and at three 
time-points over the subsequent six months. The Illumina 450k array was used to assay epigenome-
wide DNA methylation in 85 samples of whole blood. I conducted multi-level regression models and 
pathway analysis.  
Across all models, I identified 33 epigenome-wide significant (p<1*10-7) differently methylated 
positions (DMPS), with over-representation of DMPS indicated to have correlated methylation in 
brain tissue. DMPs located on genes involved in signal transduction, glutamatergic and GABAergic 
systems, calcium signalling, glucose homeostasis, immune function and transcription regulation 
were associated with both clozapine exposure and therapeutic efficacy.  Additionally, DMPs located 
on genes involved in cell adhesion, glycine and neuronal development were associated specifically 
with therapeutic efficacy. DMPs located on genes involved in immune function and signal 
transduction were associated with drowsiness, increased appetite and weight, and cardiovascular 
symptoms. DMPs located on genes involved in energy metabolism were associated with increases in 
appetite and weight. 
These results align with literature suggesting that clozapine normalises schizophrenia-associated 
disruption in glutamatergic and GABAergic systems, calcium signalling and immune function; 
however, further studies of gene expression and downstream effects are required to establish the 
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1 Introduction 
In this chapter, I will provide a broad background to my thesis. For the first half of the chapter I 
will introduce the general issues surrounding treatment-resistant schizophrenia and clozapine and 
for the second half of the chapter I will introduce the concepts of genetic and epigenetic variation, 
their association with schizophrenia and antipsychotic use, and the limitations of the current 
literature. Subsequent chapters will provide more detailed reviews of the literature regarding 
associations with clozapine exposure, clozapine response and adverse reactions to clozapine.  
1.1 Schizophrenia 
Schizophrenia is a debilitating psychiatric illness, consisting of positive symptoms (e.g. persistent 
delusions), negative symptoms (e.g. blunted affect) and cognitive deficits. It has a complex, multi-
faceted aetiology with both genetic and environmental risk factors known to be involved. It is the 
most common psychotic disorder (Perala et al., 2007); the lifetime prevalence rate of schizophrenia 
is 0.4% (Saha, Chant, Welham, & McGrath, 2005), and it is ranked as one of the top ten causes of 
disability in developed countries by the World Health Organisation (Murray & Lopez, 1996). Onset 
usually occurs during the early twenties (Sham, MacLean, & Kendler, 1994), and while it was initially 
conceptualised by Emil Kraepelin as “dementia praecox” (Kraepelin, 1899) - a degenerative disorder 
with no favourable outcome – it is now known to be treatable, with pharmacological treatment in 
the form of antipsychotics available and full recovery possible. Unfortunately, some patients are less 
responsive to treatment than others, with some patients showing no meaningful response to current 
antipsychotic treatment, other than clozapine. The majority of these patients are non-responsive 
from first onset, suggesting that treatment-resistance is an enduring trait (Demjaha et al., 2017).   
1.2 Treatment-resistant schizophrenia 
The existence of a group of “therapy resistant” patients, showing limited or no response to 
treatment has been evident since the 1950s. This is when the first antipsychotic – chlorpromazine – 
was discovered; a major breakthrough in psychiatric care, providing the first evidence-based 
treatment for reducing psychotic symptoms in patients with schizophrenia (Ban, 2007). However, 
since some of the first early antipsychotic trials (Cole, Goldberg, & Davis, 1966; Klein & Davis JM, 
1969) most estimates have agreed that approximately a third of patients are treatment-resistant (R. 
R. Conley & Kelly, 2001; Elkis, 2007; Lehman et al., 2004). Some studies consider this an 
underestimate, reporting higher figures of 40 or 60% (Essock, Hargreaves, Covell, & Goethe, 1996; 
Juarez-Reyes et al., 1995). Similarly, Hegarty, Baldessarini, Tohen, Waternaux and Oepen (1994) 
found that a minimum of patients - only 35-45% - achieve good outcomes with conventional 
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antipsychotics; and this is without considering cognitive impairment, quality of life assessment, or 
the negative impact of adverse reactions, which would all reduce that number further. These 
differing estimates of the proportion of schizophrenia patients who are treatment-resistant are in 
part down to differing definitions of treatment-resistance. 
1.2.1 Defining treatment-resistant schizophrenia 
“Treatment resistance in schizophrenia is difficult to define and criteria still 
remain controversial” (Painuly, Gupta, & Avasthi, 2004) 
Initially, treatment-resistance was equated with chronic hospitalisation (hospitalisation for more 
than two years) (Small, Kellams, Milstein, & Moore, 1975) on the assumption that remaining 
hospitalised reflected a lack of improvement in symptoms preventing discharge; however, 
hospitalisation can be required for numerous reasons including poor compliance or issues with 
housing – neither of which indicate an inferior response to antipsychotic treatment – and the 
threshold for admission differs between countries and has changed rapidly over the past 40 years. 
Since then, the key feature of treatment-resistance has been the persistence of positive symptoms 
despite adequate drug therapy. To rule out inadequate treatment as the reason for persistent 
symptoms, time frames and dosage for previous antipsychotic trials began to be specified. One of 
the first well-operationalised sets of criteria including these features was provided by Kane, 
Honigfeld, Singer and Meltzer (1988), reporting on a seminal trial discussed in the following section: 
1. Persistent positive psychotic symptoms: item score > 4 (moderate) on at least two of 
four positive symptom items of the Brief Psychiatric Rating Scale (BPRS; rated on a 1-7 
scale) - hallucinatory behaviour, suspiciousness, unusual thought content, and 
conceptual disorganization. 
2. Current presence of at least moderately severe illness as rated by the total BPRS score 
(>4 on the 18-item scale) and a score of >4 (moderate) on the Clinical Global Impression 
(CGI) scale. 
3. Presence of illness: no stable period of good social and/ or occupational functioning 
within the last five years (inability to maintain work and relationship). 
4. Drug-refractory condition: at least three periods of treatment in the preceding five years 
with conventional antipsychotics (from at least two chemical classes) at doses 
equivalent to > 1,000 mg per day of chlorpromazine of six weeks each, without 
significant symptom relief; and either failure to improve by at least 20% in total BPRS 
score or intolerance to a six week prospective trial of haloperidol at a dose of 10-60 mg 
per day. 
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Most current definitions are refined, condensed or modified versions of these criteria; however, 
this still allows for significant heterogeneity in definitions used by research groups. To address this, 
the Treatment Response and Resistance in Psychosis (TRRIP) working group has established 
consensus criteria to standardize the definition of treatment resistance, aiding study designs and 
facilitating comparison of results across different studies (Howes et al., 2016). 
They recommend minimum requirements including:  
 at least moderately severe current symptoms 
 resistance, assessed by interview using a standardised rating scale, lasting a minimum of 
12 weeks 
 at least moderate functional impairment with validated scale 
 minimal improvement in past response, and assessment of past response using 
information from patient/carer/staff reports, pill counts and dispensing charts 
 at least two past adequate treatment episodes with different antipsychotics 
 at least six weeks at a therapeutic dose of at least 600mg of chlorpromazine equivalent 
per day with minimum and maximum durations and doses for each treatment episode 
recorded 
 current adherence assessed using at least two sources and meeting at least 80% 
prescribed doses taken, with antipsychotic plasma levels monitored on at least one 
occasion.  
Optimally, they advise prospective evaluation of treatment, a prospective trial of an 
antipsychotic demonstrating less than 20% symptom reduction over six weeks, and a long acting 
injectable antipsychotic trialled for at least four months, and antipsychotic serum levels measured at 
least twice two weeks apart. 
 Two key modifications since Kane et al., (1988) are: the shift away from a focus on positive 
psychotic symptoms and onto negative and cognitive symptoms (Suzuki et al., 2012), as research has 
since demonstrated that these can be the most persistent and disabling symptoms for treatment-
resistant patients, contributing significantly to outcome (Conley & Kelly, 2001); and the gradual 
decrease in the duration of illness necessary for a diagnosis of treatment-resistance. From the 
original Kane criteria specifying five years with persistent symptoms, Brenner et al., (1990) 
considered two years sufficient, Peuskens (1999) accepted just one year as adequate, and now TRRIP 
specify only a minimum of 12 weeks to allow for two six-week antipsychotic trials. Concurrently, the 
number of failed drug trials necessary has also reduced from three to two. This push for earlier 
diagnosis of treatment-resistant schizophrenia is due to the combination of a) evidence indicating 
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that patients who don’t respond to two adequate trials have less than 7% chance of responding to 
another (Kinon et al., 1993) and b) evidence indicating that delays in diagnosis of resistance and 
appropriate treatment lead to worse outcomes for treatment-resistant patients (Üçok et al., 2015).   
Also note that the exact choice of standardised rating scale and specific cut-offs for determining 
e.g. “minimal improvement” are not specified. This is the area in which definitions of treatment-
resistance vary most significantly. For example, many use the >20% reduction in symptoms used by 
Kane but some studies require reductions in symptom scores of at least 40% (Breier et al., 1994) or 
50% (Farooq, Agid, Foussias, & Remington, 2013). Additionally, some long-term studies use broader 
ranges of outcome criteria than solely symptom reduction and this leads to some of the findings that 
poor response is the norm (Hegarty et al., 1994; Helgason, 1990; Meltzer, 1997). If the norm in 
psychiatric care and research was to aim for remission, which in non-psychiatric disorders is 
characterised as the disappearance of symptoms, and definite treatment-resistance as patients who 
do not achieve remission this would set a very different standard. Within psychiatry, remission is 
often defined not as the complete absence of symptoms, but by minimal symptoms (Doyle & 
Pollack, 2003); and within schizophrenia, even this definition of remission is rarely used to discuss 
treatment efficacy, instead assessing reductions in symptoms of 20-50% as discussed above.  
Meltzer (1990) proposed defining treatment-resistance as the failure of patients to return to their 
best premorbid level of functioning; an intuitive definition based on the aim of remission. However, 
the problem with this approach is that this unfortunately applies to the significant majority of 
patients with schizophrenia and thus does not provide any differentiation for guiding clinical 
decision making or prioritising those most in need.  
Meltzer (1997) has proposed that “it may be more useful to evaluate treatment responsiveness 
as a continuum and include all relevant outcome criteria” (p. 3). Others have also challenged the 
dichotomous concept, with Brenner et al., (1990) proposing a continuum of response, with seven 
levels from full clinical remission to severely refractory. However, while this may capture clinical 
reality in a more nuanced way, dichotomous definitions allow for more powerful study design in 
research, clearly highlights a group with significant need (Peuskens, 1999), and are used by most 
research groups and therefore allow comparisons throughout the literature.  
Ultimately, while there is no universal agreement on a complete set of criteria, there is broad 
consensus that consistent minimum requirements for a diagnosis of treatment-resistance include at 
least two periods of treatment with antipsychotics at doses equivalent to or greater than 600mg 
chlorpromazine, each for at least 6 weeks, without at least 20% reduction in symptoms; this is also 
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the basis for clinical guidelines diagnosing treatment-resistance and prescribing appropriate 
treatment (IPAP, 2004; Lehman et al., 2004; NICE, 2009). 
Within treatment-resistant patients, there are further subdivisions. Treatment-resistant patients 
can be divided into those who are responsive to clozapine, and to those who are non-responsive to 
clozapine and are considered “ultra-treatment resistant” (Howes et al., 2016). Also, while a 
longitudinal cohort study of first-episode patients demonstrated that over 80% of patients with 
treatment-resistance appear to be resistant from first presentation, never showing response to 
antipsychotics (early onset treatment-resistant schizophrenia), a minority of patients appear to 
develop resistance on average five years after first presentation (delayed onset treatment-resistant 
schizophrenia) (Demjaha et al., 2017). These differing courses of illness and treatment response may 
reflect meaningful differences between patients.   
1.2.2 Significance of treatment-resistant schizophrenia 
Regardless of discrepancies in prevalence figures, it is undeniable that treatment-resistant 
schizophrenia is a severe problem; patients are amongst the most severely distressed and disabled 
of all mental health patients with high levels of suicidal ideation, a lower quality of life and increased 
comorbid substance abuse problems and subsequently require higher levels of health and social care 
(Kennedy, Altar, Taylor, Degtiar, & Hornberger, 2014). Fortunately, an effective pharmacological 
treatment does exist for these patients – clozapine – but, unfortunately, numerous issues remain.  
1.3 Clozapine 
After the initial discovery of chlorpromazine and the subsequent discovery of patients who did 
not respond, there was continued development of antipsychotic drugs, notably the development of 
clozapine in the 1960s (Hippius, 1989). Clozapine is the first atypical antipsychotic – an antipsychotic 
with lower antagonism of D2 dopamine receptors and relatively greater antagonism of D3 and 5-
HT2A serotonin receptors - and was found to be a highly effective antipsychotic. Initial reports were 
positive, as patients experienced few of the extrapyramidal adverse reactions that typical 
antipsychotics (such as chlorpromazine and haloperidol) induced; but unfortunately, a number of 
patients in Finland died from agranulocytosis – severe acute lowering of white blood cell count - and 
the drug was withdrawn from the market for a few decades. Throughout this time, the group of 
patients failing to respond to the antipsychotics on offer remained untreated, with very few options.  
Then, in the late 80s, a seminal multi-centre trial was carried out (Kane et al., 1988). Two-
hundred-and-sixty-eight patients with treatment-resistant schizophrenia were recruited for a trial 
comparing clozapine to chlorpromazine, using the stringent criteria for treatment-resistance 
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outlined above. Patients with confirmed treatment-resistance were then randomly assigned to a six-
week double-blind treatment trial with either clozapine or chlorpromazine. Their results showed 
that clozapine led to superior results across psychotic symptoms: within six weeks 30% of those on 
clozapine responded to treatment compared to 4% of those on chlorpromazine. In their conclusion, 
they stated: 
We believe that the apparently increased comparative risk of 
agranulocytosis requires that the use of clozapine be limited to selected 
treatment-resistant patients for whom the potential benefits are judged to 
outweigh the risks… 
Careful, regular monitoring of blood cell counts is necessary in patients 
receiving clozapine… 
For individuals suffering from treatment-resistant schizophrenia, the 
availability of clozapine, a potentially helpful treatment, is, in our view, a useful 
therapeutic advance. If even a small proportion of these patients can go on to 
adjust to life in the community, with the associated reduced need for long-term 
institutionalization, this has significance for public health and health financing. 
Clozapine was therefore brought back onto the market, but this time with strict regulations 
following recommendations by Kane et al. In most countries, its prescription is confined to patients 
with demonstrated treatment-resistance and there is regular monitoring of blood cell counts. 
Clozapine’s superior efficacy has been demonstrated again and again (Azorin et al., 2001; Green et 
al., 2000; Lieberman et al., 1994; McEvoy et al., 2006; Meltzer et al., 1989; Solanki, Singh, & Swami, 
2007), with hospital admission studies (Kirwan, O’Connor, Sharma, & McDonald, 2017), studies of 
mortality and self-harm (Wimberley et al., 2017), and meta-analyses confirming this (Stefan Leucht 
et al., 2013; Siskind, Mccartney, Goldschlager, & Kisely, 2016); it is the most effective antipsychotic 
available, and its ability to reduce clinical symptoms is especially pronounced in those resistant to 
conventional treatment. A relatively recent meta-analysis contradicted this body of evidence, 
concluding there was no real difference in efficacy between clozapine and other antipsychotics 
(Samara et al., 2016), but Taylor (2017) convincingly refutes this conclusion. Firstly, this meta-
analysis was diluted by trials which seem to have recruited non-refractory patients. Secondly, this 
meta-analysis included several studies using relatively low mean doses of clozapine, particularly in 
trials comparing clozapine to a second generation antipsychotic (with a mean dose of 392 mg per 
day across these trials). Both of these methodological factors seem to be driven by drug companies 
seeking to prove comparable effects to clozapine,  and inclusion of these studies could have biased 
this meta-analysis to not find strong evidence for superiority of clozapine to other antipsychotics. 
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Meta-analyses such as Siskind et al., (2016) which were limited to studies with strict confirmation of 
true treatment-resistance (as the original Kane study did) show the strongest superiority of 
clozapine, and Siskind et al also found that limiting analysis to studies with equivalent doses of 
clozapine and comparator drug resulted in clear superiority of clozapine. Taylor states “the effect of 
clozapine in refractory psychosis is one of the few things in psychiatry that is clearly visible to the 
naked eye”.  
  However, patients can wait years after treatment-resistance is established to be prescribed 
clozapine. This is in part due to its notorious history and the perception of clozapine as dangerous. 
There is also reluctance due to the range of potential adverse reactions to clozapine; weight gain, 
hyper-salivation and sedation are all common, and – while not fatal in the same way as 
agranulocytosis – they all have significant impact on quality of life and can be highly distressing. 
Another problem is that the monitoring of cell counts has a very rigid timetable, requiring frequent 
blood collection; in the UK, for the first eighteen weeks patients must have blood drawn at least 
every week, then every two weeks until one year has passed, and then at least every four weeks 
indefinitely (“Joint Formulary Committee,” 2017). This can be disruptive to patients’ lives, and, 
combined with the potential adverse reactions, many patients do not wish to be prescribed 
clozapine. As a result of these combined factors, numerous papers have noted that the drug is 
heavily underutilised with clinicians appearing reluctant to prescribe (Mistry & Osborn, 2011; Üçok 
et al., 2015). This is particularly concerning when delays in initiation appear to be associated with 
polypharmacy (Grover, Hazari, Chakrabarti, & Avasthi, 2015; Thompson et al., 2016; Üçok et al., 
2015) – which carries various risks – and with worse response to clozapine after initiation (Üçok et 
al., 2015). Moreover, once clozapine is prescribed, there is no guarantee that patients will respond. 
While clozapine is currently the best option available for treatment-resistant schizophrenia, a 
significant number of patients still do not experience reduction in symptoms (Cipriani, Boso, & 
Barbui, 2009). These “ultra-treatment resistant” patients currently have very limited options 
available to them. Therefore, while clozapine has provided an effective treatment for many patients 
with treatment-resistant schizophrenia, there are numerous problems regarding its use in clinical 
practice.  
Our understanding of clozapine’s mechanism of action and the physiological systems involved is 
also limited, as is our understanding of what differs in patients who have different responses to 
clozapine. Kane et al., (1988) states: 
 “Given these findings, there is an obvious need for further research to 
explore the mechanisms by which clozapine accomplishes its clinical effects and 
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to identify possible predictors that might help to select, if possible, the subgroup 
of patients most likely to benefit.”  
Despite ongoing research over the last three decades since this paper, the specific mechanisms 
which underlie clozapine’s unique therapeutic efficacy and reliable predictors of appropriate 
patients have yet to be established. This creates barriers for both optimising clozapine treatment 
and developing new treatments. Improving our understanding of clozapine could help us identify 
novel targets for pharmacological interventions which more directly and selectively address the 
primary dysfunctions in treatment-resistant schizophrenia. Understanding the mechanism of 
clozapine and clozapine response could also give us insight into what differentiates between 
treatment-responsive patients (who don’t require clozapine), treatment-resistant patients (who only 
respond to clozapine) and ultra-treatment resistant patients (who do not respond to standard 
antipsychotics or clozapine); this distinction could be used to identify patient groups much earlier on 
in their psychiatric treatment, enabling prompt prescription of appropriate interventions.       
My thesis extends the literature addressing clozapine’s mechanism and differing outcomes in 
treatment-resistant schizophrenia in a novel way: through analysing data on longitudinal 
trajectories of DNA methylation in patients following clozapine initiation. It uses this data to 
explore three broad questions:  
 What changes in DNA methylation are associated with exposure to clozapine?  
 What changes in DNA methylation are associated with therapeutic response to 
clozapine?  
  What changes in DNA methylation are associated with adverse reactions to clozapine?  
Chapter two will outline the methodology of the study, including design, data collection and 
laboratory procedure for measuring DNA methylation. Chapters three, four and five will then 
address the above three questions in turn, each presenting a focused background, an outline of the 
specific statistical analysis used to address the question, the results of this analysis, and then a 
discussion. Chapter six will then summarise and discuss these results as a whole.  
Before moving on to chapter two, the rest of the introduction will introduce the concepts of 
genetic and epigenetic variation and explain why I have chosen to study the role of DNA methylation 
in clozapine’s mechanism of action.  
  
Introduction 
- 21 - 
 
1.4 What is DNA methylation and why study its role in clozapine?  
The next section will introduce DNA methylation and its potential utility in furthering our 
understanding of clozapine – starting with a brief overview of genetic biology and its importance in 
schizophrenia and antipsychotic response, before moving onto epigenetics and DNA methylation.  
1.4.1 The genome and gene expression 
The genome is housed within deoxyribonucleic acid (DNA). DNA is formed of nucleotides which 
are made up of a nitrogenous base, a five carbon sugar, and a phosphate group. The nucleotides 
have one of four bases: cytosine, thymine, guanine and adenine. Each base is connected to another 
base via hydrogen bonds, and the phosphate groups bond with one of the carbons on the sugar, and 
form the two “sugar phosphate backbones” to DNA. As the hydrogen bonds connecting the 
nucleotides are not covalent, they can be broken and re-joined relatively easy – this is essential for 
gene expression, replication of DNA, and DNA sequencing.  DNA wraps around a cluster of eight 
histone proteins, called a histone core, to form nucleosomes (Figure 1). Nucleosomes create the 
structure of chromatin, which chromosomes are made of. Inside the nucleus of each cell, there are 
46 chromosomes. These chromosomes contain our entire DNA (Annunziatio, 2009).  
Genes are distinct sequences of nucleotides which provide code for protein formation or 
another product such as RNA, with segments called exons (coding regions that are translated into 
mRNA) and introns (non-coding regions, which may be regulatory).  For genes that are polymorphic 
– the nucleotide bases can vary - each version of the gene is called an allele and allelic variation can 
have functional consequences. When one nucleotide in a gene is known to vary, this is called a single 
nucleotide polymorphism (SNP) (Bush & Moore, 2012).  
To study a gene, determining the nucleotides within a relevant section of DNA is necessary. The 
specific method of genotyping depends on the aim, methodological priorities and the resources 
available – for example, whether you want to assess a small number of specific genes based on an a 
priori hypothesis or whether you want to assess a huge number of genes across the genome. 
Genome sequencing involves determining the exact sequence of nucleotide bases within a gene, and 
can be done for individual genes or the whole genome, but the latter is incredibly costly. A more 
cost-efficient method for getting broad coverage across the genome, and a very popular method of 
gene-association research over the last decade, is genome-wide association studies (GWAS) (Bush & 
Moore, 2012). GWAS uses SNP arrays which have probes to identify a selection of common SNPs – 
loci where a SNP variant is present in at least 1% of the population – which function as tag SNPs. Tag 
SNPs can predict other SNPs in high linkage disequilibrium i.e. where there is non-random 
association between alleles of a SNP, and so possessing a specific allele of one SNP predicts the 
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possession of a specific allele for another SNP. This allows for efficient use of resources; however, it 
means that any statistical associations with a SNP found through gene arrays may actually reflect a 
causal association with another SNP in the same linkage disequilibrium block.     
 
 
Figure 1: Image of DNA and chromosome structure, taken from Annunziato (2008) 
 
Gene expression is the process in which information from a gene is used to synthesise either a 
protein or another gene-product (Clancy & Brown, 2008). Ribonucleic acid (RNA) – generally a single 
strand of nucleotides, with uracil replacing thymine – is involved in the regulation and process of 
gene expression and protein synthesis. Gene expression occurs through transcription and 
translation. Transcription occurs in the nucleus and is triggered by an enzyme, RNA polymerase. This 
enzyme attaches to a region of the DNA – called the promoter region – which is upstream of the 
transcription start site (TSS) of the gene being expressed.  Proteins called transcription factors bind 
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to promoter regions and facilitate RNA polymerase binding. Once attached, RNA polymerase 
separates the two strands of DNA, and then reads the sequence, adding matching RNA nucleotides 
to the complementary nucleotides of one DNA strand. This produces a complementary antiparallel 
RNA strand called a primary transcript. This is modified into mRNA, which carries information from 
the DNA to the ribosome and serves as a template for protein synthesis through translation. 
Translation occurs in cytoplasm, when ribosome – ribosomal RNA and proteins – assemble around 
the mRNA. A small ribosomal subunit binds to the mRNA and reads the sequence, then ribosome 
induces the binding of complementary transferRNA to mRNA – these select, collect and carry amino 
acids to ribosome. The ribosome translocates – moves – along the mRNA creating an amino acid 
chain, until the polypeptide is released and folds to produce a specific protein (Figure 2).  
 
Figure 2: Image of gene expression taken from Clancy and Brown (2008) 
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1.4.2 Genetic variation and schizophrenia 
Through twin and family studies, schizophrenia has been well-established as a highly heritable 
disorder with heritability estimates of approximately 80% (Cardno et al., 1999); this can be 
interpreted to mean that up to 80% of the phenotypic variation (variation in diagnosis of 
schizophrenia) in the population is attributable to genetic variation. Therefore, significant research 
resources have been invested in determining the location of genetic variation associated with 
schizophrenia, in the hope that this will provide insight into the biological pathways underlying the 
aetiology and course of schizophrenia. 
Early studies focused on multi-generational families with numerous occurrences of 
schizophrenia, using a linkage study design – this was based on the assumption that there would be 
a small number of relevant genes of high penetrance (the higher the penetrance of a gene, the 
higher the likelihood that an individual with that gene will develop the disorder) (Riley, 2004). When 
this didn’t yield results, the field shifted towards the assumption that the genetic architecture of 
schizophrenia involves a large number of common variants of low penetrance that, in combination, 
increase risk (Becker, 2004). Common variants are those which are present in more than 1% of the 
population. Currently, to identify these common variants, GWAS using gene arrays (as described 
earlier) are dominant. In GWAS, large numbers of patients with schizophrenia and controls are 
recruited, blood samples are collected and DNA extracted to measure hundreds of thousands of 
SNPs across the genome (“genome wide”) via the probes on the arrays.  By comparing the SNP 
variants of patients with the variants of controls, SNPs with allelic variation that are associated with 
having schizophrenia can be identified.   
Well-powered, carefully conducted GWAS have recently proven to be more fruitful, with a 
ground-breaking study by the Psychiatric Genetics Consortium (PGC) in over 35,000 patients with 
schizophrenia identifying over 100 genetic regions associated with schizophrenia, 87 of these novel, 
which were collectively able to account for 33% of genetic liability  (Ripke et al., 2014). 75% of these 
regions include protein-coding genes (35% of the regions include multiple associated genes), 
including genes associated with dopaminergic systems, glutamatergic neurotransmission, synaptic 
plasticity and voltage-gated calcium channel subunits – these are all biological systems which have 
previously been implicated in schizophrenia and which studies of rare genetic variants have also 
implicated. One of the strongest risk associations was in the major histocompatibility complex 
(MHC), which is located on chromosome 6 and contains genes involved in innate and acquired 
immunity. In particular, a recent study linked different genetic combinations of copy numbers at a 
locus near gene C4 and HERV status with increased RNA-expression data and increased risk of 
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schizophrenia (Sekar et al., 2016); this has been further linked to increased synaptic pruning during 
late adolescence, long postulated as a neurodevelopmental mechanism underlying schizophrenia. 
Even excluding the MHC region, Ripke et al., (2014) found enrichment for associations at enhancers 
active in tissues with immune functions.  
As well as investigating associations with schizophrenia diagnosis, genetic studies have also 
studied other facets of schizophrenia including treatment-resistance and response to anti-
psychotics.  
1.4.2.1 Genetics of treatment-resistant schizophrenia 
Two GWAS of treatment-resistant schizophrenia have been conducted. Both implicated genetic 
variants associated with the immune system: one compared treatment-resistant patients to healthy 
volunteers and found an association with polymorphisms of SLAMF1, a gene associated with 
lymphocyte activation (Liou et al., 2012), while another studied response to a single antipsychotic 
trial and found an association with polymorphisms of RTKN2, a gene believed to be involved in 
lymphopoiesis (Drago et al., 2014).  
Outside of GWAS, there have been candidate-gene association studies. These follow the same 
basic design as GWAS, comparing patients to controls to identify genetic variation associated with 
schizophrenia, but in contrast to GWAS only compare genetic variation at pre-identified loci 
(candidate genes) instead of across the whole genome. Candidate gene studies are plagued by weak 
biological justification for the candidate gene, small underpowered samples, lack of consideration 
for underlying population structure, inadequate adjustment for explicit multiple-comparisons, 
inadequately conservative significance thresholds considering the high likelihood of type I errors, 
and subsequent lack of replication for reports of significant associations.  
The strongest finding from candidate gene studies is an association between (proxies of) 
treatment-resistance with the minor allele of the Val66Met polymorphism of the BDNF gene. One 
study reporting robust associations when comparing clozapine users to non-clozapine users (Zhang, 
Lencz, et al., 2013) avoids some of the issues mentioned above, selecting candidates based on the 
CATIE trial (described below) and controlling for explicit multiple-comparisons. There is also some 
form of replication, with another study reporting an association with lack of response to a single 
antipsychotic trial (Zai et al., 2012). However, these are small samples by current standards, 
continue to have a high likelihood of type I error and are investigating potentially distinct 
phenotypes. 
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During my thesis I conducted a systematic review (Gillespie, Samanaite, Mill, Egerton, & 
MacCabe, 2017) (Appendix I) of all studies comparing patients with treatment-resistant 
schizophrenia (defined as either a lack of response to two antipsychotic trials or clozapine 
prescription) and treatment-responsive schizophrenia (defined as known response to non-clozapine 
antipsychotics). There were no GWAS meeting this criteria and while studies implicated an 
association between treatment-resistance and numerous variants (the short allele of BDNF 
dinucleotide repeat polymorphism, C/C genotype of the serotonin 2A receptor (5-HT2A) gene T102C 
polymorphism, C/A genotype for the tryptophan hydroxylase enzyme (TPH1) gene, ccG10 alleles of 
the 5’UTR (ccG repeat) polymorphism of the reelin gene, and less homozygosity with the Bal I 
polymorphism of the dopamine receptor 3 (DRD3) gene), these were all findings from studies with 
small samples and “exploratory” analyses which did not report surviving correction for multiple 
testing, and none of these findings were replicated.   
Another finding of my systematic review was that studies reported first and second degree 
relatives of treatment-resistant patients had a significantly higher morbidity risk of schizophrenia 
spectrum disorders compared to relatives of treatment-responsive patients, and a significantly 
higher familial-loading score was found for treatment-resistant patients. Similar findings are evident 
in the broader literature, as an earlier study investigating response to a single antipsychotic trial 
similarly found that first-degree relatives of non-responders to haloperidol had higher lifetime risk 
for schizophrenia spectrum disorders than relatives of responders (Silverman et al., 1987). More 
recent studies have found associations between a history of clozapine treatment and a higher 
polygenic risk score (Frank et al., 2015), and between treatment-resistance and higher genome-wide 
burden of rare duplications (Martin & Mowry, 2016). These cumulatively suggest that treatment-
resistant schizophrenia may be a more heritable form of schizophrenia. 
1.4.2.2 Genetics of anti-psychotic response 
Numerous studies have investigated genetic predictors of anti-psychotic response; in 
chapter 4 I will specifically review the literature on genetic predictors of clozapine response but one 
of the largest studies spanning multiple antipsychotics is the CATIE (clinical antipsychotic trails of 
intervention effectiveness) study. A GWAS was conducted on data from 738 patients with 
schizophrenia (not resistant or first episode) prescribed either olanzapine, quetiapine, risperidone, 
ziprasidone or perphenazine, to identify associations between SNPs and PANSS scores (McClay et al., 
2011). One overall conclusion was that there were no associations common to all antipsychotics, 
which coincides with the clinical observation that a good clinical response to one antipsychotic 
doesn’t predict the same response to another. Significant associations were found for specific 
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antipsychotics and subscales, for example negative symptom response to olanzapine was associated 
with ANKS1B, with the top SNPs explaining as much as 10-15% of the variance in antipsychotic 
response.   
Candidate gene testing using this data-set was conducted by McClay et al., as well as by Xu 
et al., (2016), and Need et al., (2009), selecting different candidate genes and different measures of 
responses and reporting significant associations. However, we should remain cautious about the 
high rate of false positives in candidate-gene studies and require replication studies, particularly if 
findings are to be used for selecting and dosing medication. A review by Zhang and Malhotra, (2011) 
notes that none of the candidate genes indicated by previous literature (DRD2 -141C Ins/Del, DRD3 
Ser9Gly, HTR2A -1438G/A , 5HTTLPR, COMT Val108Met) reached genome wide significance in the 
CATIE GWAS, highlighting the need for scepticism, and as Reynolds (2012) states there is a “striking 
paucity of consistently reproducible effects”.  
1.4.2.3 Limitations of genetics research 
The findings from the PGC have restored confidence that genetic research will prove a fruitful 
avenue in understanding schizophrenia. However, despite decades of genetics research for 
schizophrenia increasing in quality and power with each year, the fact remains that there have been 
no new successful treatments developed in decades, and key questions of aetiology remain. There 
are, of course, non-genetic and non-biological factors of significance to schizophrenia and 
schizophrenia outcomes e.g. (Morgan & Fisher, 2006) but there remains a fascinating discrepancy 
between the solid evidence for a genetic basis to schizophrenia and the lack of deep understanding 
provided by the research findings so far. 
The genetic architecture of schizophrenia is evidently complex as, despite high heritability 
estimates, over half of patients with schizophrenia have no first or second degree relative with 
schizophrenia (Gottesman & Shields, 1982). It could be that our underlying assumptions – for 
example, the focus on common variants of low effect driving GWAS – are faulty. It could be that 
gene-gene interactions, gene-environment interactions or the regulatory influence of genes are 
more significant than previously realised. Relevant to the latter suggestion, a common finding from 
GWAS is that a high proportion of the variants associated with schizophrenia are involved in 
transcription regulation e.g. (Ripke et al., 2013). This suggests that we need a broader understanding 
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1.4.3 The epigenome 
Epigenetic variation refers to “mechanisms that control chromatin remodelling and the 
accessibility of genes to transcriptional machinery” (Ibi & González-Maeso, 2015) or “changes in the 
physical structure of the chromatin, without a change in the DNA sequence itself” (Teroganova, 
Girshkin, Suter, & Green, 2016). The epigenome provides information regulating gene expression, 
providing the mechanism for genetic information to lead to phenotype. The existence of epigenetic 
mechanisms is demonstrable in the ability of somatic cells containing identical DNA sequences to 
vary widely in phenotype and function, through cellular differentiation guided by tissue-specific 
epigenetic variation (Li, 2002); the tens of thousands of genes in the human genome must be 
expressed at specific times in specific tissues to lead to specific protein formation. Epigenetic 
variation can effectively activate or silence genes, through their influence on processes involved in 
gene expression.  
There are two primary mechanisms of epigenetic variation. The first is histone modification 
(Bannister & Kouzarides, 2011). The histones which DNA wraps around have tails which insert 
themselves into minor groves of the DNA and are accessible for chemical modification. These 
histone modifications can change the structure of chromatin. For example, acetylation loosens 
chromatin structure by creating negative charges which repel the negatively charged DNA phosphate 
group and vice versa for deacetylation. When loosely packed, chromatin becomes accessible for 
transcription factors and RNA polymerases (“euchromatin”), allowing gene expression; in contrast, 
when tightly packed it becomes less accessible (“heterochromatin”), limiting gene expression. 
Histone deacetylases (HDACs), histone acetylases and histone methyltransferases all regulate 
histone modifications.  Inhibition of histone deacetylase activity seems to be the primary trigger for 
histone hyperacetylation, which happens in conjunction with DNA demethylation to increase 
transcriptional activity. 
DNA methylation is the second form of epigenetic mediation (Jin, Li, & Robertson, 2011). This 
involves a methyl group (one carbon bound to three hydrogens) covalently binding to the 5’ cytosine 
within CpG (cytosine-phosphate-guanine) dinucleotide pairs in DNA sequences; this binding is 
catalysed by DNA methyltransferases (DNMTs), a group of enzymes. DNMTs establish and maintain 
DNA methylation patterns, MeCP2 is a methyl-CpG binding protein that recognises methylation 
patterns and mediates the process, and ten-eleven translocation (TET) proteins convert 5-
methylycytosine into 5-hydroxymethylcytosine and cause subsequent demethylation (Schübeler, 
2015).  CpG sites can cluster together in regulatory areas of the gene, such as promoter regions, 
where transcription is initiated; these regions are called “CpG islands”. While most CpG sites are 
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methylated throughout the genome, CpG islands tend to have a high number of unmethylated CpG 
sites. Methylation of CpG sites appears to disrupt the binding of transcription factors and the 
subsequent process of gene expression, usually leading to reduced gene expression (Klose & Bird, 
2006). Two mechanisms have been proposed: the “critical site” model which places emphasis on the 
reduced transcription of mRNA due to methylation at transcription-factor binding sites of specific 
cytosines, while the “methylation density” model places emphasis on the transcriptional potential of 
a gene due to a proportion of methylated cytosines across a region controlling chromatin structure.  
However, while the majority of associations between methylation and gene expression are 
negative (i.e. higher levels of methylation are associated with lower levels of gene expression), there 
are a reasonable proportion of CpG sites which have a positive association between methylation and 
gene expression, particularly sites with trans (distant) effects (van Eijk et al., 2012). This has been 
supported by others study such as one which reports that almost half of genes with high levels of 
methylation at promoter regions show high expression rates, especially when these promoter 
regions are outside of CpG islands (Sarda, Das, Vinson, & Hannenhalli, 2017). van Eijk et al., (2012) 
also reports two other things of note: that only a fifth of the associations between methylation and 
expression identified in their study involved probes from the same gene, and that causal modelling 
indicated that in a minority of these associations expression levels regulated methylation rather than 
vice versa.  
As well as directing gene expression, DNA methylation also controls and mediates genomic 
imprinting (information on whether the allele came from the mother or father, allowing only one-
parent’s allele to be expressed due to hypermethylation of the other alleles CpG islands), 
chromosomal stability and genetic recombination (Robertson, 2005).  
A key feature of the epigenome is the ability for dynamic rapid change and reversal, making it 
distinctly different from the genome and the nucleotide bases which make up somatic DNA. DNA 
methylation patterns undergo major changes during gametogenesis and embryogenesis (when all 
epigenetic markings are removed and then rewritten, with the likelihood of de novo epimutations 
one or two orders of magnitude greater than that for somatic DNA mutations), development, and 
throughout aging; they change in response to the cell environment; they change in response to 
environmental exposure, providing a physical mechanism for gene-environment interaction. A study 
in rats sparked considerable interest in the importance of epigenetics as a dynamic interaction 
between environment exposure and cellular biology  when it reported that maternal nursing 
behaviour altered the epigenome of their offspring at a glucocorticoid receptor and subsequent HPA 
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response to stress, and that this persisted into adulthood unless reversed by cross-fostering (Weaver 
et al., 2004).  
The dynamic nature of the epigenome can also be demonstrated by the reduction in 
concordance of DNA methylation and histone acetylation in monozygotic twins over their lifetime 
from age three to age fifty (Fraga et al., 2005). The dynamic nature of the epigenome provides 
plasticity in development and adaption to environment, with an obvious evolutionary function to 
increase chances of survival in changing environments.  
It is important to note that the genome informs the epigenome, and – while perhaps less 
influential later in the life course (Gaunt et al., 2016)- there are genes which affect CpG methylation 
called methylation quantitative trait loci (mQTL) which account for approximately 20% of variance in 
DNA methylation (Gaunt et al., 2016; McRae et al., 2014). Therefore, the genome and epigenome 
should not be considered in isolation, but viewed as complementary systems which interact bi-
directionally.  
1.4.3.1  DNA Methylation Measurement 
DNA methylation is one of the most studied epigenetic modifications (Portela & Esteller, 2010), 
in part because of the development of technologies that can efficiently perform epigenome-wide 
association studies (EWAS) in a similar way to genome-wide studies. The most common method for 
epigenome-wide analysis of DNA methylation is to analyse sodium-bisulfite treated DNA. Sodium-
bisulfite treatment converts unmethylated cytosines to uracil, while methylated cytosine remains 
unchanged. The sites where the conversion to uracil have happened indicate that the sites are 
unmethylated. The sodium-bisulfite method allows an epigenome-wide approach in a way that 
previous methods such as southern blot hybridisation did not, because they relied on methylation-
sensitive restriction enzymes which could only provide information on specific sites.   
The most commonly used method is to use Illumina micro-arrays such as the Illumina 450k. After 
DNA has been bisulfite-treated, the DNA is amplified (creating thousands to millions of copies of the 
piece of DNA) and then applied to the beads on the micro-array, with each bead specific to a CpG 
site. Reversible dye-terminators are then applied to the micro-array, with each nucleotide base 
fluorescently labelled with a different colour. A laser is then used to excite the dyes and a 
photograph is taken from which the degree of methylation at each locus can be identified.  
As with GWAS, the results for cases vs controls at each probe can be compared to identify 
positions with different levels of methylation associated with case status – these are called 
differentially methylated positions (DMPs).   
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1.4.4 Epigenetic variation and schizophrenia 
Numerous observations have indicated that epigenetic processes are relevant to understanding 
schizophrenia. The existence of discordant monozygotic twins, the fluctuating course of 
schizophrenia with remission and relapse, and parent of origin effects all indicate that inherited 
genes cannot provide all of the answers, but epigenetic differences between individuals and over 
time may be able to explain these phenomena. Similarly, epigenetics may be able to explain the 
cases of schizophrenia without first or second degree relatives, with epimutations occurring or being 
corrected during the reprogramming that occurs in gametogenesis and driving differences between 
parent and child. Information about methylation or other epigenetic modifications may also be able 
to refine the signal detected in GWAS; a relevant gene may only be associated with schizophrenia if 
methylated or unmethylated, so without knowledge of methylation levels there will be unmeasured 
noise reducing the association between a gene and schizophrenia. Understanding epigenetic 
processes involved in schizophrenia may also identify biological pathways underlying schizophrenic 
symptoms.    
Specific evidence for the importance of methylation comes from a range of sources, as one 
review highlights (Maric & Svrakic, 2012). For example, increasing methylation levels via a high 
methionine diet worsens psychotic symptoms (Brune & Himwich, 1962), and schizophrenia patients 
have high plasma levels of homocysteine (demethylated methionine) during acute episodes 
(Petronijević et al., 2008) and increased levels of S-Adenosyl methionine (SAM) – a methyl group 
donor – in prefrontal cortex (Guidotti et al., 2007). Interestingly, research into discordant 
monozygotic twins has found that while they do not differ in underlying DNA sequence they show 
striking differences in methylation at DRD2, to the extent that an affected twin is more 
epigenetically similar to a non-related affected individual than their own unaffected twin (Mill et al., 
2006). Similar research conducting an EWAS analysis of discordant monozygotic twins indicated no 
systemic changes in genome-wide epigenetic programming, but individual CpG sites showed 
considerable variability (Dempster et al., 2011)– the top eight were located by genes PUS3, SYNGR2, 
KDELR1, PDK3, PPARGC1A, ACADL, FLJ90650 and TUBB6. Pathway analysis revealed significant 
enrichment for the “nervous system development and function” functional network, the 
“psychological disorders” biological functional pathway, and the dopamine and glutamate receptor 
signally canonical pathways; all aetiologically relevant gene networks for schizophrenia. Additionally, 
post-mortem research (Mill et al., 2008) has found aberrant global hypermethylation and ~100 loci 
with disease-associated aberrant DNA methylation in the frontal cortex of schizophrenia patients; 
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these findings similarly implicate aetiologically relevant pathways including glutamatergic, 
GABAergic, stress response and neurodevelopmental pathways. More generally, there is evidence 
that genetic risk variants for schizophrenia may cause altered DNA methylation and subsequent 
disrupted gene regulation: fetal mQTLs have been shown to be enriched in schizophrenia risk loci 
identified through the PGC GWAS; analysis combining GWAS and EWAS data from a sample of 
schizophrenia patients found differential methylated CpG sites overlapped with schizophrenia risk 
loci from GWAS and these risk loci co-localise with mQTLs; and mQTLs in which the relevant CpG site 
is associated with differential gene expression are enriched for schizophrenic risk loci (Hannon et al., 
2016; Hannon, Spiers, et al., 2015; van Eijk et al., 2015)  
 In 2016, Teroganova et al.,  conducted a systematic review of all studies measuring DNA 
methylation in schizophrenia using peripheral blood and saliva; there were 22 studies included, 
which ranged considerably in sample size and methodology, and which had inconsistent reporting of 
relevant confounds. Nine of these were candidate gene studies, with the most studied genes RELN, 
BDNF, COMT and HTR1A. 12/13 of the EWAS reported differential methylation associated with 
schizophrenia and the majority of differentially methylated regions showed hypermethylation (or did 
not specify direction of effect). The results implicated the glutamate, GABA and dopamine system, 
calcium signalling, immune function and inflammation, potassium voltage-gated channels, and 
monoamine systems, among others.  
This research supports epigenetic models of schizophrenia, which have been discussed for well 
over a decade. Petronis, Paterson, and Kennedy (1999) demonstrated that an epigenetic model 
could integrate data supporting multiple hypotheses within schizophrenia (including 
neurodevelopmental, dopamine, and viral) and suggested that epigenetic alterations could mediate 
the genetic, developmental and environmental influences on risk for schizophrenia. A mouse model 
of adolescent exposure to isolation stress (Niwa et al., 2013) demonstrates how the interaction 
between a genetic risk factor (DISC-1) and environmental risk factor (isolation stress) can lead to 
hypermethylation of a gene which occurs alongside disruption of the mesocortical projection of 
dopaminergic neurons and behavioural changes indicative of a schizophrenia phenotype.  
 Epigenetic theories of psychosis have focused on epigenetic modifications associated with 
GABAergic and glutamatergic gene promoters. One suggestion is that promoter hypermethylation of 
loci within a gene for a GABAergic neuron leads to downregulation of telencephalic GABAergic 
function, disinhibiting pyramidal neurons and driving a hyper dopaminergic state through excitatory 
input to dopamine cells in the ventral tegmental area, or a hyper serotonergic state through 
excitatory input to serotonin cells in the raphe nucleus (Guidotti, Auta, Chen, Davis, Dong, Gavin, 
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Grayson, 2012). Teroganova et al., (2016) did identify a study showing hypermethylation of a locus 
within GABRB2 (GABA A receptor beta 2) in peripheral blood, supporting this hypothesis and 
supporting the ability of peripheral blood studies to identify differential methylation at positions 
indicated by theory.  
1.4.4.1 Epigenetic modifications as a result of anti-psychotics 
Interest in epigenetic theories of schizophrenia as well as pharmacological research 
demonstrating the epigenetic effects of numerous medications has led to research into epigenetic 
mechanisms of psychiatric medication including anti-psychotics, many of which are known to have 
epigenetic consequences (Petronis et al., 1999). Boks et al., (2012) summarised the existing 
literature on epigenetic alterations induced by psychopharmacology and concluded that a number of 
antidepressants and antipsychotics had “compelling evidence”; in particular, clozapine was singled 
out as the antipsychotic with the strongest evidence for epigenetic alterations based on a number of 
animal studies (discussed further below).  
There have been few studies of treatment-induced DNA methylation changes in humans. Mill et 
al., (2008) found a strong correlation between DNA methylation in the MEK1 gene promoter region 
and lifetime antipsychotic use in schizophrenia patients, supporting the proposal that antipsychotics 
have epigenetic consequences and suggesting that one mechanism of antipsychotic action could be 
epigenetic modifications, perhaps (for example) normalising aberrant DNA methylation in 
schizophrenia. Bönsch et al., (2012) found that the methylation status of patients on antipsychotics 
was similar to healthy controls. Another study (Rukova et al., 2014) studied six patients with 
schizophrenia who were in remission, comparing their DNA methylation profile before treatment to 
healthy controls (n=220) and then their DNA methylation profile after treatment to healthy controls, 
with the aim of identifying both sites with abnormal methylation that became normalised and sites 
with normal methylation that became abnormal. Focusing on the three male patients, they found 
significant methylation differences, implicating genes involved in transcription regulation, 
sphingolipid metabolism, protein degradation, and a potassium channel protein. They also studied 
fourteen patients who had not experienced remission, and found their methylation profiles did not 
differ significantly from healthy controls. However, this if an incredibly small sample, it is unclear if 
they control for any relevant confounds other than matching on age and sex, and the medication 
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1.4.4.2 Limitations of existing DNA methylation research 
1.4.4.2.1 Study design 
Use of cross-sectional designs is a significant issue with nearly all of the human psychiatric 
epigenetic literature. In genetic studies, many concerns about confounding and causation can be 
dismissed: environmental exposures typically cannot cause changes in genetic variation, and 
similarly later outcomes cannot cause changes in genetic variation. Therefore, cross-sectional 
designs are appropriate as the independent variable (genetic variation) remains static and has a 
clear causal direction. In contrast, epigenetic variation can be caused by environmental exposures 
and could be either the cause or the result of outcomes of interest; therefore cross-sectional designs 
raise numerous concerns about causality and confounding in psychiatric epigenetics (Relton & Smith, 
2012).  
In addition, many genetic studies recruit participants on a very large scale to increase power 
with minimal need to collect detailed information on participants or ensure participant groups are 
matched for e.g. drug use, due to the static unidirectional nature of genetic variation. However, in 
epigenetic studies these variables could be highly relevant if they are potential causes of epigenetic 
variation and therefore potential confounding variables.  In psychiatric epigenetics, there are 
numerous environmental exposures associated with disorders such as schizophrenia (psychiatric 
medication use, rate of smoking, lifestyle, social environment, childhood experiences etc.) that pose 
potential issues of confounding. Similarly, within schizophrenia, different patient groups may have 
different symptomatology, medication histories, and lifestyles.   
Another concern with cross-sectional epigenetic studies is that of genetic confounding. The fact 
that epigenetic variation is not independent from genetic variation means that a significant 
proportion of inter-individual epigenetic variation can be explained by genomic variation. Therefore, 
a certain proportion of variation in methylation can be considered heritable, with any group 
differences more directly attributable to the inherited genetic variants.  
Unfortunately, these issues make many previous studies difficult to interpret as conclusions of 
epigenetic variation causing schizophrenia/clinical outcomes may actually reflect epigenetic 
variation caused by schizophrenia/clinical outcome, epigenetic variation as a result of a confounding 
variable, or epigenetic variation purely as a result of genetic variation. Therefore, reviews and 
comment pieces (e.g. Heijmans & Mill, 2012; Relton & Smith, 2012) have called for increased use of 
longitudinal cohort studies, with a sample collected before the event of interest (e.g. onset of illness, 
initiation of an antipsychotic) and serial samples collected subsequently.  
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1.4.4.2.2 Selection of tissue 
Another significant issue in psychiatric epigenetic research is selection of tissue. A key 
consideration in all epigenetic research is the tissue being studied, as different tissue types show 
significant epigenetic variation; Lister & Ecker (2009) report on some of the first genome-wide, single 
base-pair resolution maps of methylated cytosine which demonstrate that tissue types in samples 
from mammals have widespread differences. This becomes a problem when studying psychiatric 
disorders such as schizophrenia because the primary tissue of interest is the brain where the core 
dysfunction is assumed to be located, but accessing samples of brain tissue from live patients is not 
possible. Post-mortem research provides access to brain tissue however epigenetic variation 
changes considerably throughout the lifespan and is likely to change after death. Current research 
therefore relies predominantly on peripheral tissue, such as whole blood, as this is far easier to 
access; however, there remains heated debate about the extent to which epigenetic variation in 
blood cells (usually lymphocytes) approximates epigenetic variation in brain tissue (Relton & Davey 
Smith, 2012; Relton & Smith, 2010). Even if a true association with schizophrenia / clinical outcomes 
is detected, the epigenetic variation in peripheral tissue may be due to effects considerably 
downstream of epigenetic variation in the brain. Therefore, it is unclear how much insight into the 
aetiology and course of schizophrenia can be gained from the loci and pathways implicated by 
peripheral tissue studies.  
Nonetheless, recent studies comparing methylation in brain tissue and blood tissue provide 
some optimism. Firstly, results from EWAS using post-mortem brain tissue and results from the 
schizophrenia EWAS using peripheral tissue have been compared (Dempster et al., 2011; Mill et al., 
2008) and five of the 100 top ranked genes in the latter (GGN, SLC117A, SMUG1, SOX1 and TCF7L2) 
were also found to be significantly associated with psychosis in the post mortem study; this supports 
the utility of peripheral blood to identify epigenetic variation simultaneously occurring in the tissue 
of interest. Similarly, a study of psychosis found that 94% of CpG SNPs sites methylated in brain were 
also methylated in blood - significantly more than expected by chance (Van Den Oord et al., 2016). 
Secondly, a few studies have compared methylation in brain tissue and blood tissue from the same 
individuals to directly ascertain correlation across these tissues. Analysis for 122 participants and 
using brain tissue from four regions – prefrontal cortex, entorhinal cortex, superior temporal gyrus 
and cerebellum found that, while the majority of CpG sites did not show a significant correlation 
between methylation in blood and methylation in brain, a subset of probes did show a strong 
correlation across tissue (Hannon, Lunnon, Schalkwyk, & Mill, 2015). Moreover, the authors created 
a searchable-database of their data to identify whether CpG sites implicated in blood-based EWAS 
appear to show correlated methylation in tissue from each of the four brain regions. A similar study 
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on twelve patients also found that a subset of CpG sites – 7.9% - showed a statistically significant, 
large correlation across blood and brain tissue (Walton et al., 2015). These studies propose a way 
forward: we can’t assume that methylation at all CpG sites will give us biological insight into 
psychiatric disorders when we use peripheral blood, but we can use findings from studies such as 
these to identify the CpG sites which will give us most insight into what is occurring in the brain.   
Distinct from providing biological insight, peripheral tissue has the benefit of being a good choice 
for potential biomarkers. If epigenetic variation in blood is consistently associated with outcomes in 
schizophrenia and can provide robust predictive validity, the underlying biological mechanism is not 
necessary for it to have significant clinical utility. For example, in cancer research, a study 
demonstrated that leukocyte DNA obtained from peripheral blood (significantly less invasive than 
existing methods involving analysis of pancreatic juice and primary tumour tissue) had utility in 
diagnosing pancreatic adenocarcinoma, with five CpG sites acting as good predictive discriminators 
(Pedersen et al., 2011). 
These two key limitations – study design and use of tissue - contribute to scepticism about the 
utility of psychiatric epigenetic research, with arguments that the findings from most published 
studies provide minimal information of value due to the difficulties in deciding whether they the 
results truly tell us about the questions we are interested in. However, neither of these limitations is 
insurmountable: longitudinal study designs with rich data on potential confounders and databases 
identifying sites of epigenetic variation that correlate between brain and blood tissue can be used. 
More broadly, numerous fields of science are becoming increasingly aware of the need to prioritise 
independent replication of significant findings, and psychiatric epigenetics is no exception; indeed, 
epigenetic research has caught the public imagination and become somewhat of a buzzword, 
warranting extra caution about bold conclusions on preliminary data. To negate this, we must be 
honest about the limitations of our methods, highlight the appropriate caveats in our conclusions, 
and demand both validation of methodology and replication of associations.   
1.4.4.3 My thesis 
 
As stated above, my thesis extends the literature addressing clozapine’s mechanism of action, 
both in its therapeutic and adverse effects, through analysing data on DNA methylation changes 
over the first six months of clozapine treatment for patients with treatment-resistant schizophrenia. 
I chose to study DNA methylation based on the evidence presented above (and evidence explored 
further in later chapters) suggesting that not only are epigenetic mechanisms involved in the 
aetiology of schizophrenia but epigenetic mechanisms may explain the mechanisms underlying 
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antipsychotics effects, in particular clozapine - above and beyond the role of genetic variation in 
schizophrenia and treatment outcomes. I chose a longitudinal approach to address many of the 
concerns raised about previous psychiatric epigenetic studies; using a within-participant design 
means that individual differences are controlled for, significantly increasing the statistical power and 
ease of interpretation. I also use previously collected data on blood-brain correlations in DNA 
methylation to aid interpretation of the results. The next chapter will now outline my methodology 
in greater detail.  
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2 Overall Method   
2.1  Longitudinal study 
Note: My data was collected as part of a larger, ongoing project investigating a range of 
physiological variables related to treatment-resistance and clozapine funded by both the MRC and 
EU initiative, CRESTAR. This included genome-wide assays, gene-expression levels, protein levels, and 
structural and functional neuroimaging data; however, I shall only describe the methodology 
relevant to the collection of epigenetic and clinical data, as this forms the basis of my thesis and my 
independent work. I recruited and assessed a number of the participants recruited to this project, but 
data is also included from participants recruited by the broader recruitment team.  
2.1.1 Study design 
The study used a longitudinal design, recruiting participants before they commenced clozapine 
and then assessing them at three follow up visits over six months of taking clozapine. At each time 
point, myself or another member of the recruitment team, collected clinical information as well as a 
blood sample for DNA methylation analysis. This allowed me to analyse epigenome-wide DNA 
methylation before and after commencing clozapine and over time, as well as the relationship 
between DNA methylation and clinical outcomes (changes in symptoms and adverse reactions). As 
stated above, a primarily within-participant design was chosen to eliminate many of the issues with 
cross-sectional epigenetic studies; participants effectively act as their own control, with genetic 
variation (including mQTLs), demographic characteristics, early environment, age of onset, 
underlying illness etc. remaining stable across all time points and other variables in the environment 
such as general lifestyle likely to have minimal variation over six months (relative to the amount of 
variation seen between people). This increases the likelihood that any identified changes in 
methylation are due to clozapine, instead of alternative explanations. 
A baseline assessment (Visit A) was carried out to capture information on their DNA methylation 
profile and clinical state before clozapine commenced, typically in the week before clozapine 
initiation (median= 4.5 days, four patients had baseline assessment over a month before initiation). 
The second follow up (Visit B), completed six weeks after the date of clozapine initiation (not six 
weeks after the baseline assessment), was intended to capture any changes in methylation patterns 
seen after clozapine reached a therapeutic plasma level; this timing was chosen based on typical 
timelines for clozapine titration. Plasma levels at this time-point were either assessed by the 
research or clinical team. If clozapine levels were sub-therapeutic at six weeks, a sample was 
collected at eight weeks after clozapine initiation (Visit C). It was not expected that participants 
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would show a full response to clozapine at this early stage, having just met therapeutic thresholds so 
a full clinical assessment was not conducted. However, data on any changes in smoking habits was 
collected as this is known to induce significant changes in DNA methylation (at all other time points, 
this was part of the clinical assessment). At twelve weeks - after at least six weeks of clozapine at a 
therapeutic level - evidence demonstrates that patients who are responsive to clozapine will have 
shown a response; therefore, participants were visited at 12 weeks (Visit D) and a full clinical 
assessment was conducted. Participants were then categorised as a responder or non-responder to 
clozapine based on their reduction in PANSS score (>20% reduction = responder), alongside 
obtaining a blood sample to assess methylation now that response or non-response to clozapine was 
evident. Finally, six months after clozapine initiation (Visit E), another assessment was conducted to 
capture clinical state and DNA methylation profile after a stable period of time on clozapine. 
Information on current medication was collected at each time point. 
Figure 3 provides an outline of the assessments conducted at each time point (further details on 
the specific assessments and reasons for these are provided later in the chapter).  
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•Alcohol, Drug, and Tobacco Screen
•Glasgow Antipsychotic Adverse Reaction Scale (GAS) - clozapine edition
•Positive and Negative Syndrome Scale (PANSS)
•Personal and Social Performance Scale (PSP)
•Global Assessment of Functioning (GAF)
•Operational Criteria Checklist (OPCRIT)
•Blood samples
•10ml EDTA tube for DNA analysis
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Eligible participants were adult patients (aged 18 or over) diagnosed with either schizophrenia or 
schizoaffective disorder (confirmed by OPCRIT), due to be prescribed clozapine by their clinical team. 
Members of the research team did not influence the prescription of clozapine in any way throughout 
the six months, so this was a naturalistic study. All patients were recruited from South London and 
Maudsley (SLaM) NHS Foundation Trust for which we had ethical approval.  
Ideally, all participants would have been clozapine naïve. This would have eliminated the 
possibility of the baseline assessment of DNA methylation including any lasting changes in 
methylation induced by prior clozapine use, which could potentially reduce the power to identify 
methylation changes induced by clozapine. However, setting prior clozapine exposure as an 
exclusion criterion may have significantly limited recruitment and subsequent statistical power, an 
unacceptable sacrifice when already faced with a likely small sample size. Participants were 
therefore only excluded if they had taken clozapine at any point in the three months before the 
current clozapine initiation. Due to the limited prior research on the epigenetic effects of clozapine, 
it is unclear whether clozapine leads to long-term changes in methylation (and whether these 
continue after clozapine is discontinued), but this exclusion criterion was both practically viable for 
recruitment numbers while simultaneously limiting the potential residual effects of DNA methylation 
changes induced by recent clozapine use. Additionally, within-individual analysis will not be 
confounded by differences in prior clozapine exposure. 
Participants were recruited from a variety of clinical teams within SLaM including community 
care teams, assertive outreach teams, locked inpatient wards, rehabilitation wards, and supported 
accommodation. A significant number of participants were recruited either from the National 
Psychosis Unit, an inpatient ward which takes referrals for complex cases of treatment-resistant 
schizophrenia, or the TREAT team at Maudsley Outpatients, which supports patients commencing 
clozapine while remaining in the community. As our recruitment wasn’t limited to a specific type of 
clinical setting this helped ensure our data was not restricted to particularly severe or particularly 
mild cases of schizophrenia, and the heterogeneity of our sample did not raise a significant issue due 
to the primarily within-participant design.    
2.1.2.2 Recruitment 
Potentially eligible participants were identified through contact between members of the 
research team (including myself) and a range of sources including pharmacists, consultant 
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psychiatrists, junior doctors, and research nurses from psychiatric teams across SLaM. We presented 
the study to clinical teams with the aims of increasing awareness about the study, encouraging staff 
to contact us if they had eligible patients, and feeding back educational information and any early 
results to the clinical teams.  
Potentially eligible participants were first approached by a clinical staff member, and asked if 
they would be happy to talk to one of the research team about our study. I or another member of 
the clinical team would then arrange to meet with the patient and the study was described verbally 
to potential participants alongside presentation of the written information sheet and providing a 
copy of this for the participant to read over. They were encouraged to ask questions about the 
research, with the researchers clarifying matters such as the distinction between their clinical care 
and the research. If happy to take part, they were led through the consent sheet and consent was 
taken for each item. Once consent was gained, participants were informed that they could withdraw 
consent at any point with no repercussions.  
Participants were offered financial reimbursement for their participation - £5 for each blood 
collection, £5 for each set of clinical assessments, and £30 for each scanning session.   
2.1.2.2.1 Capacity 
In our patient group, there was increased likelihood of lacking capacity to give informed consent 
as patients necessarily had a severe psychiatric illness with active symptoms. The Mental Capacity 
Act provides criteria for approving research which involves patients who do not have capacity to 
consent, as a protective measure to avoid engaging particularly vulnerable patients in research if 
unnecessary. This study met the Mental Capacity Act approval criteria for involving patients who do 
not have capacity to consent as: 1) the research is directed at their impairing condition (treatment 
resistant schizophrenia), 2) research of equal effectiveness cannot be carried out in only patients 
with capacity (as this would reduce generalisability of our results - creating a bias towards patients 
with less severe symptoms - which is vital if results are to be used to improve understanding and 
clinical care for patients who do lack or fluctuate in capacity); 3) the research has the potential to 
provide knowledge on the treatment of others with the same condition; 4) the research involves 
negligible risk to the participant, is not associated with reduced freedom and is not unduly invasive 
(no part of the procedure would be outside the scope of standard clinical care and where possible 
blood samples were collected during routine clinical blood collection). 
The Mental Capacity Act is clear that capacity should be assumed, and only assessed if there is 
reason to doubt capacity, for a specific circumstance. A person is said to lack capacity if they meet 
two criteria: 1) an impairment or disturbance of the functioning of the mind or brain, and 2) they are 
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unable to achieve at least one of four decision-making elements. In this study, as a diagnosis of 
schizophrenia is necessary for clozapine prescription and necessary to be eligible for recruitment, 
capacity to consent was automatically assessed due to them necessarily meeting the first criteria. To 
demonstrate capacity, participants needed to show an ability to understand the information 
relevant to the decision, retain the information for long enough to make the decision, weigh the 
information relevant to the decision, and communicate the decision by any means. For example, 
asking relevant questions about the research based on information provided to help them make an 
informed decision (e.g. “how often will I need to provide blood samples? I already have blood tests 
so wouldn’t want many more”), would indicate the ability to do the above. This was then 
documented by the research team. 
In cases where patients did lack capacity, positive assent from the patient was required at all 
times (e.g. they still were required to agree to take part), alongside consent from a consultee 
(someone non-professionally involved in caring for the patient, who would look out for their 
interests in the decision - this would normally be their next-of-kin but could be an independent 
patient advocate or representative.). The consultee would be given a copy of the information sheet 
for consultees, have the study and the role of the consultee explained to them, and be invited to ask 
any questions they may have; they would then make a decision about whether they believed the 
patient would consent if they had capacity.  If there was any indication that the patient would not 
wish to participate (from the patient, their clinical team or carers, or any advance statement of their 
wishes) they would not be enrolled in the study. 
Once the patient was enrolled in the study, if at any point the participant objected to the study, 
or indicated that they would like to be withdrawn, they were withdrawn from the study 
immediately. The research team maintained close contact with both the clinical team and the 
consultee, to ensure awareness of the patient’s wishes or any change in their feelings about 
participation. It was clearly explained to the consultee that if for any reason they suspected that the 
patient’s wishes about participation may have changed, that they should contact the study team so 
that this can be discussed and the patient can be withdrawn if necessary. If capacity improved to the 
extent where a patient was able to consent, at that stage consent would be sought and documented 
as explained above. 
Alternatively, for those patients who initially consented when deemed to have capacity, 
researchers remained aware of the possibility that they may lose capacity and would need to be re-
assessed and a consultee found if necessary. However, for all but three participants, mental state 
either improved throughout the study as they responded to clozapine, or remained relatively stable. 
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2.1.3 Clinical assessments 
To complete these clinical assessments, information was collected primarily through interview 
with participants and clinical notes were used to provide supporting material where necessary e.g. 
when patients lacked the insight or concentration for clinical assessments, or were otherwise unable 
to provide a detailed medical history themselves. 
2.1.3.1.1 Clinical Information 
The clinical information form collected data on primary diagnosis, predominant symptoms 
(positive/negative/disorganised), date of illness onset, presence of co-morbid psychiatric diagnoses, 
prior clozapine use, number of hospitalisation, date of obtaining treatment resistant diagnosis, and 
date clozapine was started. This information was collected to confirm participant eligibility, allow 
description of the characteristics of the sample, and collect data to be used as covariates in analysis 
if necessary.  
2.1.3.1.2 Medication history/changes 
The medication history/medication changes form documented information on medication type, 
dosage, reason for use (primary or secondary symptoms), start and stop date, and whether 
medication was ongoing, for all CNS and non-CNS medications. This information was collected to 
allow for medication history or changes in medication over the course of the study to be controlled 
for in analysis, as other medications may induce changes in DNA methylation.  
2.1.3.1.3 Alcohol, Drug, and Tobacco Assessment 
The Alcohol, Drug and Tobacco Assessment includes 21+ questions collecting detailed 
information on history and current usage of tobacco, caffeine, alcohol, cannabis and other drugs 
(inhalant, cocaine, amphetamines, heroin, hallucinogens, ketamine and any other drugs including 
legal highs). Questions were included on frequency, amount/quantity and - in the case of cannabis - 
the type (hash, skunk etc.). Participants were also specifically asked about their intake of caffeine, 
tobacco and cannabis on the day of assessment, with tobacco intake especially relevant for 
methylation analysis.  
2.1.3.1.4 Glasgow Antipsychotic Adverse reaction Scale (GASS-C) 
The GASS-C includes 18 items outlining different adverse reactions (e.g. “I have felt breathless”) 
and requires participants to answer how often they have experienced the adverse reaction over the 
past week, with options of “Never”, “Once” “A few times”, and “Everyday” which score 0-3 
respectively. Participants then report if any adverse reactions they have experienced were severe or 
Overall Method 
- 45 - 
 
distressing. There is also an additional option for writing down adverse reactions not included above. 
A total score of 0-16 is classified as “absent/mild adverse reactions”, 17-32 as “moderate adverse 
reactions” and 33-48 as “severe adverse reactions”. This scale was developed specifically for patients 
commencing clozapine, as previous scales for the adverse reactions of generic antipsychotics 
(ANNSERS, SRA-34) neglect common clozapine adverse reactions such as dry mouth, heartburn, and 
tachycardia, as well as being lengthy clinician-rated scales which require training. Patient-rated 
scales have been shown to be highly consistent with clinician rated scales (Takeuchi, Fervaha, & 
Remington, 2016). The original GASS is a patient-rated scale but did not specifically enquire about 
hypersalivation, heartburn or constipation (one of the most life-threatening common adverse 
reactions if left untreated), while mentioning adverse reactions irrelevant to clozapine such as 
hyperprolactinaemia. Therefore, the GASS-C was chosen as the primary measure of adverse 
reactions in participants. 
2.1.3.1.5 Positive and Negative Syndrome Scale (PANSS) 
The PANSS is a commonly used scale for assessing severity of schizophrenic symptoms, 
developed by Kay, Fiszbein, & Opler (1987) and extensively validated since. It has a total of 30 items, 
with each scored from 1-7 with higher scores indicating more severe symptoms (1=absent, 
2=minimal or within normal range, 3=mild, 4=moderate, 5=moderate-severe, 6=severe, 7=severe). 
The first 7 items (P1-P7) cover positive symptoms (delusions, conceptual disorganisation, 
hallucinatory behaviour, excitement, grandiosity, suspiciousness, hostility) and form the Positive 
Syndrome scale, where scores can range from 7-49.  The next 7 items (N1-N7) cover negative 
symptoms (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal, 
difficulty in abstract thinking, lack of spontaneity, stereotyped thinking) and form the Negative 
Syndrome scale, where scores can range from 7-49. The final 16 items (G1-G16) cover general 
psychopathology (somatic concern, anxiety, guilt feelings, tension, mannerisms and posturing, 
depression, motor retardation, uncooperativeness, unusual thought content, disorientation, poor 
attention, lack of judgement and insight, disturbance of volition, poor impulse control, 
preoccupation, active social withdrawal), and form the General Psychopathology scale, where scores 
can range from 16-112. The overall PANSS score across all 30 items ranges from 30-210.    
Scores are primarily based upon a semi-structured interview with the participant. Responses to 
questions and observation of behaviour (physical, interpersonal, cognitive-verbal) throughout the 
interview enable scoring, combined with some additional information gained from reports of clinical 
teams/family. The PANSS rating manual provides detailed descriptions for scoring the severity of 
each item. The PANSS should be completed by trained researchers or clinicians and therefore all 
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members of the research team were trained by more experienced researchers initially, shadowed 
assessments by experienced researchers, and conducted their first interviews under observation and 
scored participants together, before conducting them independently.  
Participants were deemed responders or non-responders to clozapine based on their PANSS 
scores. The change in PANSS Total score between baseline (Visit A) and twelve weeks (Visit C) was 
the primary outcome measure for symptom change in participants, with the criteria for being a 
responder a minimum of a 20% reduction in PANSS total. 
2.1.3.1.6 Personal and Social Performance Scale (PSP) 
The PSP is a quick measure of four areas of personal and social functioning of patients with 
psychiatric disorders: socially useful activities, personal and social relationships, self-care and, 
disturbing and aggressive behaviour. It assesses the degree of difficulty a participant demonstrates 
with these four domains over a one month period. For each domain, a participant is judged as having 
absent, mild, manifest, marked, severe or very severe difficulties. The overall score ranges from 1 to 
100, divided into 10 equal intervals to rate the degree of difficulty in social functioning. The score is 
given based upon how severe the difficulties are (e.g. “70-61 Manifest, but not marked difficulties in 
one or more of areas a-c, or mild difficulties in d”), with functioning in a wide range of areas 
(household, physical, social network) determining judgement of the exact number. A score of 71 to 
100 indicates a mild degree of difficulty; from 31 to 70, varying degrees of difficulty; and from 1 to 
30, functioning so poorly as to require intensive supervision. This assessment was completed by a 
member of the research team based on the semi-structured interview and reports from clinical staff 
and family members in clinical notes. This was a secondary measure of response to clozapine, as 
some clinicians and patients argue that functioning is a higher priority than symptom reduction 
alone, or it may capture changes that symptom scales do not; for example, hallucinations may score 
similarly but be better managed or less distressing, or a minor reduction in a prominent debilitating 
symptom may lead to a very significant improvement in functioning. 
2.1.3.1.7 Global Assessment of Function (GAF)  
The GAF is a tool from the Diagnostic and Statistical Manual of Mental Disorders IV (p34). It is a 
numeric scale (1-100) used to rate the psychological, social, and occupational functioning of adults, 
on a hypothetical continuum of mental-health illness e.g. 70-61 indicates “Some mild symptoms (e.g. 
depressed mood and mild insomnia) OR some difficulty in social, occupational, or school functioning 
(e.g., occasional truancy, or theft within the household), but generally functioning pretty well, has 
some meaningful interpersonal relationships.” This was another secondary measure of response, 
providing a global summary measure of functioning. It was also completed by a member of the 
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research team based on the semi-structured interview and reports from clinical staff and family 
members in clinical notes. 
2.1.3.1.8 Operational Criteria Checklist (OPCRIT) 
The OPCRIT generates diagnoses according to 12 operational diagnostic systems (e.g. DSM-III, 
DSM-III-R, Research Diagnostic Criteria, ICD-10). It includes 90 items, on Details and History, 
Appearance and Behaviour, Speech and Form of Thought, Affect and Associated Features, Abnormal 
Beliefs and Ideas, Abnormal Perceptions, Substance Abuse or Dependence, and General Appraisal. 
Items are given a numbered score based on a code (e.g. 0=no, 1=at least 4 days, 2=at least 1 week, 
3=at least 2 weeks). This assessment was used to provide independent confirmation of the diagnosis 
of schizophrenia or schizoaffective disorder. It was completed by a member of the research team 
based on the semi-structured interview and reports from clinical staff and family members in clinical 
notes (especially for historical information).   
2.1.4 Blood samples 
2.1.4.1 Collection 
Blood samples were collected by venepuncture, by trained phlebotomists. As all patients on 
clozapine must have regular blood samples for clinical purposes, sample collection was often co-
ordinated alongside regular monitoring samples taken by the clinical team to ensure no additional 
burden or distress.  
The following samples were collected at the same time: 
 10ml EDTA tube for DNA analysis  
 4ml EDTA tube for cell counts (if not collected by clinical team) 
 6ml EDTA tube for plasma clozapine levels (if not collected by clinical team) 
Samples for cell counts and plasma clozapine levels were frequently collected by clinical teams, 
as part of standard clinical monitoring. As I did not need access to the sample to run specific analysis 
(unlike the samples for DNA analysis), only the results of the cell count and plasma clozapine level 
analysis, in these scenarios we did not collect these samples ourselves to reduce unnecessary 
burden on the participants and unnecessary use of resources; instead, we accessed their clinical 
records to gain the relevant results. However, unfortunately this information was often incompletely 
uploaded or not uploaded to clinical records. Additional samples were collected for other portions of 
the larger project. 
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2.1.4.2 Sample processing 
Note: I did not carry out any of the sample processing, but shadowed every step taken for one of 
the batches of samples assayed.   
All bloods reached our laboratory at the BRC Bioresource within two hours of collection. On 
reaching the lab, EDTA tubes for DNA and cell counts were immediately stored on ice and then 
either processed for DNA extraction or stored at -20oC before processing. All samples were labeled 
with linked-anonymised barcodes prior to storage. This allowed for a sample tracking system to 
transfer DNA samples for epigenetic analysis. 1.5ug of DNA diluted to 25ng/ul was sent from the BRC 
Bioresource labs to the Complex Disease Epigenetics Group labs within Exeter Medical School. Arrays 
were organised so that all samples from the same individual were placed on the same array to 
prevent batch effects being misconstrued for longitudinal changes. The official guidance for Illumina 
450k microarrays was followed (Figure 4). 
Day 1: Bisulfite treatment was used to convert unmethylated cytosine into uracil, while 
methylated cytosines remained as unconverted cytosines, due to different sensitivities of cytosine 
and 5-methylcytosine to deamination by bisulfite. The samples were then denatured (because the 
conversion only works on single-stranded DNA), a bisulfite conversion reagent added, and the 
samples were then incubated overnight in a thermal cycle.  
Day 2: The reagent was then cleaned-up, samples centrifuged, and a desulfonation buffer was 
applied and samples were incubated at room temperature for 15 minutes. Samples were then 
cleaned and washed twice to remove the buffer, and the bisulfite converted DNA (BCD) was eluted 
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Figure 4: Workflow for Illumina 450k BeadChip assays, from Infinium HD Methylation Assay Protocol GuideManual 
 
Whole genome amplification was used to uniformly increase the amount of DNA while 
minimising locus bias and mutation rates. This entails random hexamer primers annealing to the 
template DNA, and when DNA synthesis starts Phi29 DNA polymerase displaces newly produced 
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DNA strands, generating newly synthesis single stranded DNA for more primers to anneal. To 
achieve this, a new plate for multi-sample amplification was created. Multi-sample amplification mix 
(MA1) was added first, followed by the 4 µl  of the BCD samples, and then 0.1N sodium hydroxide 
(NaOH) to denature the BCD samples. Plates were vortexed, centrifuged and incubated, and then 
RPM reagent was added to neutralise the sample. Lastly, MSM was added and the plates were again 
vortexed and centrifuged.  
The denatured samples were then incubated and isothermally amplified overnight in the 
Illumina Hybridization Oven, leading to a hyper-branched network. 
Day 3: Enzymes are used to fragment these branches in a controlled way. Endpoint 
fragmentation was used to prevent over-fragmentation. The plate was centrifuged, fragmentation 
solution (FMS) added, the plate was vortexed, centrifuged and put on a heat block. 
The DNA was then precipitated (purified/concentrated). PM1 was added to the plate, it was 
vortexed, incubated, centrifuged and then isopropanol added. The plate was then inverted to mix, 
incubated, centrifuged, and liquid was drained from the plate – after the plate had dried, blue 
pellets were left for each sample.  
The DNA was then re-suspended in hybridisation buffer – RA1 was added, and the plates were 
incubated, vortex and centrifuged.  
Finally, the single stranded DNA was hybridised to the Illumina 450k BeadChip assays. The assays 
were silicon based and each sample section contains oligonucleotide probe sequences that are 
attached to beads – they have microscopic DNA for the samples to hybridise to. The 450k array 
covers CpG sites on 99% of RefSeq genes, with an average of 17 CpG sites per gene region 
distributed across the promoter, 5'UTR (untranslated region which immediately precedes the 
translation initiation codon), first exon, gene body, and 3'UTR (untranslated region which 
immediately follows the translation termination codon). It covers 96% of CpG islands, with additional 
coverage in island shores and the regions flanking them. 
To avoid batch effects creating the appearance of differences over the follow up period, all 
samples from a participant were included on the same assay/within the same batch. The samples 
were placed on the heat block to denature them, the plate was centrifuged and then the samples 
were added to the BeadChips. These were loaded into the hybridisation chamber inserts, which have 
PB2 as humidify buffer, and the chambers were incubated in the Illumina hybridization oven 
overnight. During hybridization, the amplified and fragmented DNA samples annealed to locus-
specific 50mers – two bead types correspond to each CpG locus – one bead types corresponds to 
methylated cytosine and another to unmethylated.  
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Day 4: After hybridisation, the BeadChips were washed in two PB1 reagent washes. 
Unhybridized and non-specifically hybridized DNA was washed away, leaving only strongly paired 
strands, and the BeadChip was prepared for staining and extension. Then each BeadChip was 
prepared for processing, with black-frames, clear spacers and clean glass back plates clamped to the 
BeadChip.  
A robot was used to extend and stand the chips in capillary flow-through chambers, in a heated 
chamber rack. RA1 was used to further wash away unhybridized and non-specifically hybridized DNA 
sample. XC1 and XC2 were used. TEM reagent extended the primers hybridised to the DNA, 
incorporating labelled nucleotides into the extended primers. 95% formamide/1 mM EDTA was 
added to remove the hybridized DNA, and then XC3 reagent used to neutralise. The labelled 
extended primers could then undergo multilayer staining on the Chamber Rack with STM, ATM and 
XC3. Afterwards, the BeadChips were washed in PB1, coated with XC4 and dried using the vacuum 
desiccator.  
The Illumina iScan System (two-channel high-resolution laser imagers) then imaged the 
BeadChip, using a laser to excite fluorophore (a fluorescent chemical compound) into emitting light, 
scanning at two wavelengths simultaneously. This produced a high resolution image which the 
scanner records. Signal intensity is dependent on the amount of target sample binding to the probes 
present at the spot, so is measured to generate regression coefficient values, a measure of the 
degree of methylation at each locus. 
2.1.5 Quality control (QC) assessments 
Ninety six samples from twenty-six participants with follow-up data were assayed at the 
laboratory. Six samples from three participants were excluded because they dropped out of the 
study before twelve-week follow-up and therefore had no response data. I ran comprehensive 
quality control (QC) assessment on the methylation data from the remaining samples leading to the 
final inclusion of eighty-five samples from twenty two participants (Figure 5). 
Firstly, I checked median methylation intensities for each sample were not noticeably below (or 
above) the average, suggesting an issue had occurred with the sample at some stage. One sample 
with median methylation intensity below 2500 was excluded. I also checked that methylated and 
unmethylated intensities were roughly correlated when plotted against one another, as a sign of 
good samples, and there was good correlation. I then ran tests to assess if the bisulfite conversion 
for each sample had been successful. This is done by comparing sequences to bisulfite conversion 
control probes provided specifically by Illumina for QC purposes, and allows the calculation of 
percentage of bisulfite conversion for the sample. One sample with conversion of only 80% was 
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excluded. All the other samples had above 90% conversion, with all but one indicating conversion of 
95% or above.  
I then carried out a number of tests to identify any potential sample switches or mislabelling of 
samples – if any were identified, I looked back into records of sample collection and handling to 
correct mistakes. This included comparing reported gender with predicted gender based on probes 
indicating X or Y chromosome, as well as comparing methylation at SNPs where methylation is 
expected to stay stable on repeated samples from the same individual to ensure that there is 
expected consistency between samples from the same individual. One participant with three 
samples was excluded because there was a query which could not be resolved over whether the 
analysed samples belonged to the participant. The correlations between the remaining samples 
from the same participants are plotted. I also uploaded data to Horvath’s DNAm age calculator 
(Horvath, 2013) to run two additional quality assessment checks. Firstly, that samples were correctly 
predicted to come from human blood – this was true for all samples. Secondly, that the predicted 
age had a strong correlation with reported age – there was a correlation of 0.90, as expected. 
Horvath’s age calculator was also used to estimate cell composition for use as a covariate in analysis.  
Probe filtering was then used to remove any probes that had failed to hybridise (indicated by 
over 1 % of samples with a detection p-value greater than 0.05), as well as probes represented by 
less than 3 bead counts on the array in 5% of samples. 1982 sites were removed because 1 % of 
samples had a detection p-value > 0.05 at these sites and 548 sites were removed due to a 
beadcount <3 at these sites in 5 % of samples. Regression coefficients were then normalised across 
all samples. For further analysis, probes that overlap with SNPs and those that cross hybridise to 
multiple genomic locations were removed. Probes on sex chromosomes were removed due to 
difficulties in interpreting differential methylation on the X chromosome caused by X inactivation in 
females; the sample was too small to do analysis divided by sex.  
All plots can be found in Appendix II. 
2.1.6 Power  
This is one of the first studies to investigate longitudinal epigenetics changes induced by any 
antipsychotic, so effect sizes are hard to predict. However, the study benefited from  increased 
statistical power due to  a longitudinal within-participant design, with data collected to control for 
multiple potential known confounds. This is somewhat comparable to studies of discordant MZ 
twins, which use paired statistical analysis and can study the epigenome independent of underlying 
genetic structure in a similar way to a within-participant design. One such epigenome-wide study 
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with 22 MZ twin pairs (44 individual samples) had 80% power to detect a Δβ (DNA methylation 
difference) of 0.06, using a strict Bonferroni correction (Dempster et al., 2011). 
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Figure 5: Flowchart of QC assessments 
96 samples from 26 participants assayed at laboratory
3 participants excluded (2 samples each) due to no response data
Check median methylation: 1 sample excluded
Check correlation between methylated and unmethylated intensities: 0 samples excluded
Check bisulfite conversion: 1 sample excluded
Check matching gender and SNPs for repeated measures from same participant: 1 participant (3 
samples) excluded due to unresolved mismatches
Check samples correctly predicted from human blood: 0 samples excluded
Check correlation between predicted and actual age: 0 samples excluded 
85 samples from 22 participants left 
1982 sites for each sample removed due to low hybridisation
548 sites removed for each sample due to low bead counts
Probes overlapping SNPs, cross-hybridising probes and probes on 
sex chromsomes removed
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2.2 Cross-sectional dataset 
To investigate the similarities between the current dataset and a previous dataset based on 
analysis of clozapine exposed patients, and see if DMPs were replicated, I was given access to data 
from a previously collected and analysed cross-sectional sample. The IMPACT (Improving Physical 
health and Substance Use in Severe Mental Illness trial) study and the CRESTAR clozapine clinics 
study both recruited large cohorts of patients with schizophrenia, primarily from SLaM NHS Trust. 
Combined, these projects provided cross-sectional samples of 155 chronic patients on clozapine and 
135 chronic patients not on clozapine. The same method of bisulfite conversion and Illumina 450k 
array described above was used to determine epigenome-wide profiles of DNA methylation for all of 
these patients. An EWAS was conducted to determine differentially methylated CpG sites associated 
with clozapine exposure, controlling for age, sex, chip, smoking status, and predicted cell 
composition. I was provided with the results of the regression model.  
2.3 Summary 
To summarise, this longitudinal study recruited patients with treatment-resistant schizophrenia 
or schizoaffective disorder due to be initiated on clozapine and collected samples of whole blood 
alongside clinical assessments before initiation and at three subsequent time points. Clinical 
assessments covered symptom severity, psychosocial functioning and quality of life. We also 
collected information on medication use and smoking at each time point. DNA was extracted from 
whole blood samples, treated with sodium-bisulfite, and then processed using Illumina 450k arrays 
to profile DNA methylation at hundreds of thousands of CpG sites across the epigenome. A total of 
eighty-five samples from twenty-two participants passed QC and were included in subsequent 
analysis.  
The following three chapters report on analysis of this data to investigate DNA methylation 
trajectories over the study period associated with 1) exposure to clozapine, 2) therapeutic efficacy 
and 3) adverse reactions.  
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3 Exposure to Clozapine and Associated DNA Methylation Changes  
3.1 Background: Exposure to clozapine 
Before reporting on my analysis investigating changes in DNA methylation associated with 
exposure to clozapine, I will explore in greater depth previous research findings on the physiological 
consequences of clozapine exposure. First I will discuss broad literature from numerous fields, and 
then I will focus on epigenetic research, largely from rodent models.  
As the first atypical antipsychotic, clozapine is known for being distinct from traditional 
antipsychotics in its pharmacology. Firstly, clozapine is a relatively weak antagonist of D2 dopamine 
receptors (Farde et al., 1992), whereas for the vast majority of antipsychotics greater effectiveness is 
strongly correlated with higher D2 occupancy (Yilmaz et al., 2012). In vitro data indicates 
approximately equivalent affinities for D2 and D1 receptors (Farde et al., 1992) which makes 
clozapine a greater D1 antagonist than most antipsychotics. It has an even higher D4 antagonism as 
well as an affinity for serotoninergic receptors, particularly 5-HT2A and 5-HT2C (Meltzer & Gudelsky, 
1992). Some have suggested that the ratio between serotonergic and dopaminergic receptor 
affinities is critical to clozapine (Kapur, Zipursky, & Remington, 1999). Additionally, clozapine has an 
affinity for noradrenergic receptors, leading to increased noradrenaline plasma levels (Breier et al., 
1994). In addition, one of the metabolites of clozapine, N-Desmethylclozapine (known as 
norclozapine), is pharmacologically active; it is a weak partial agonist of D2 and D3 receptors as well 
as being an agonist of the M1 and delta opioid receptors.  
Clozapine appears to have a regional selectivity that also distinguishes it from other 
antipsychotics. Studies suggest a higher affinity for limbic D2 receptors than striatal D2 receptors, in 
contrast to most antipsychotics (Kessler et al., 2006). Clinical and neurophysiological studies have 
found clozapine to have more selective and restricted effects on the striatum than typical 
antipsychotics; for example, in the nucleus accumbens/ventral striatum, rodent studies (Deutch & 
Cameron, 1992) have found that clozapine increases gene expression in the shell regions (associated 
with limbic and prefrontal circuitry) whereas typical antipsychotics also increase gene expression in 
the core (associated with motor function – which would explain why typical antipsychotics are more 
likely to induce motor symptoms such as extra-pyramidal adverse reactions (Painuly et al., 2004). 
Alongside this research into the pharmacological profile of clozapine, to understand the 
immediate consequences of clozapine on receptor binding, research has also investigated the effects 
of clozapine use on structural volume and regional perfusion. Garcia et al. (2015) identified 23 
studies of structural and functional correlates of the use of clozapine in schizophrenia: the most 
Exposure to Clozapine and Associated DNA Methylation Changes 
- 57 - 
 
consistent findings were that clozapine use with associated with volume reductions in the caudate 
nucleus (part of the basal ganglia), reduced frontal lobe perfusion and decreased activation in the 
basal ganglia. Some recent longitudinal studies have studied other structural characteristics such as 
white matter integrity using diffusion tension imaging and found an increase after clozapine use 
(Ozcelik-Eroglu et al., 2014). Clozapine also appears to increase neuroplasticity, with rodent models 
demonstrating increased dendritic spine formation and synaptogenesis in the hippocampus 
(Critchlow, Maycox, Skepper, & Krylova, 2006). 
 However, interpreting many of these findings is challenging when considering other 
antipsychotic use, as – in many countries - all participants will necessarily have undergone two 
antipsychotic trials as a minimum which are likely to have caused structural and functional changes. 
Additionally, while some studies are longitudinal within-participant design, many are between-
groups and comparing to patients on alternative antipsychotics. Therefore, it is often unclear 
whether changes are completely, partly, or not at all due to alternative antipsychotics, whether they 
are normalising or exacerbating changes caused by other antipsychotics, or whether changes are 
masked by other antipsychotics. The between-group design also raises the question of whether 
differences are due to clozapine use or due to an underlying difference between treatment-resistant 
patients who require clozapine and patients who respond to conventional treatment.  
Genetic research in this area has largely focused on genetic variation which predicts outcomes in 
response to clozapine (discussed in Genetic variation associated with response to clozapine), as this 
is the main avenue for genetic variation providing insight into clozapine’s mechanism. Gene 
expression data on the other-hand can provide information about the direct effect of clozapine 
exposure. One study of whole-blood gene expression in 55 patients receiving clozapine and 97 
patients not receiving clozapine did not find any significant associations, only a nominal association 
for a smaller subset of patients on clozapine monotherapy with a module of genes involved in 
functions such as blood coagulation and platelet degranulation (Harrison et al., 2016). However, a 
2017 analysis of expression data from four microarray studies of post-mortem tissue identified three 
genes and four pathways associated with clozapine in all four studies (Lee et al., 2017): upregulation 
of glutamate-cysteine ligase modifier (GCLM) and zinc finger protein 652 (ZNF652) and 
downregulation of glycophorin-C (GYPC); clathrin-mediated endocytosis, SAPK/JNK signalling, 3-
phosphoinositide signalling, and paxillin signalling pathways, which have been implicated in neuronal 
migration and synaptic function, among other phenomena. Epigenetic data is then another source of 
information about physiological changes induced by clozapine. 
3.1.1 Existing epigenetic research 
Exposure to Clozapine and Associated DNA Methylation Changes 
- 58 - 
 
Three studies in rodents have examined the impact of clozapine on epigenetic markers, and 
have driven speculation about epigenetic modifications driving clozapine’s unique efficacy in 
treatment-resistance as each compared clozapine to other antipsychotics which did not induce the 
same epigenetic changes (Aoyama et al., 2013; Dong, Nelson, Grayson, Costa, & Guidotti, 2008; 
Huang et al., 2007) 
Huang et al., (2007) administered clozapine (5 mg/kg), haloperidol (0.5 mg/kg) or saline 
(placebo) to mice acutely or chronically (21 days) and then examined histone trimethylation of H3K4 
at GAD1 (a GABAergic gene locus) in brain tissue. They found that clozapine exposure – but not 
haloperidol or placebo – significantly increased histone trimethylation of H3K4 at GAD1 (a GABAergic 
gene locus), with a threefold increase in the cerebral cortex after chronic treatment compared to 
placebo. They conducted an additional post-mortem comparison of human brain tissue from 
schizophrenia subjects treated with typical antipsychotics and schizophrenia subjects treated with 
clozapine demonstrating a similarly significant association between clozapine exposure and a two-
fold increase in trimethylation at H3K4 at GAD1. They also found clozapine mediated Mll1 (H3K4-
specific histone methyltransferase gene) expression and occupancy at GAD1 chromatin, with a 
twofold increase in occupancy after a single dose and with specificity to that locus, providing a 
mechanism for the increased histone methylation.  
Within the same paper, a different set of post-mortem samples demonstrated that H3K4 
methylation at GABAergic gene promoters in the human prefrontal cortex typically increases 
throughout development and into adulthood, but that in schizophrenia there was a pattern of 
decreased methylation; therefore, these findings combined suggest clozapine may normalise 
aberrant hypomethylation at this locus. However, Huang et al. did not find a corresponding 
significant increase in GAD1 mRNA levels induced by clozapine exposure, so the functional change in 
the cortical GABAergic system is unclear.  
Dong et al., (2008) built upon this study design by first inducing hypermethylation of fronto-
cortical and striatal reelin and GAD67 promotor regions with methione administration to rodents for 
7 days, providing a model of the aberrant hypermethylation of DNA proposed in schizophrenia 
patients. Clozapine (3.8-15µmol/kg), sulpiride (12.5-50 µmol /kg), haloperidol (1.3-4 µmol/kg) or 
olanzapine (4-15 µmol/kg), each either alone or in combination with valproate, was then 
administered each twice a day for three days. They found that clozapine and sulpiride - but not 
haloperidol or olanzapine - induced dose-related reelin and GAD67 promoter demethylation in the 
frontal cortex and striatum, and the demethylation was particularly pronounced (in an interactive, 
not additive way) when valproate was also administered. Similar findings were reported for H3-K9 
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acetylation at reelin promoters in the frontal cortex; clozapine and sulpiride lead to increased 
acetylation, but there was a two-fold increase when valproate was co-administered. Examination of 
nuclear extracts found a similar increase in reelin DNA demethylation associated with clozapine and 
valproate, suggesting that demethylation is caused by activation of pre-existing nuclear demethylase 
enzymes. These epigenetic changes were not found in liver GABAergic neurons, indicating selectivity 
to central nervous system.  
The authors suggest that clozapine is an antipsychotic which normalises the downregulation of 
GABAergic gene expression found in schizophrenia, through inducing DNA demethylation and 
subsequently increasing gene expression to normal levels; and valproate intensifies this effect. As 
these effects were not apparent for olanzapine, this does not seem to be a general mechanism of 
atypical antipsychotics. Alongside Huang et al reporting that typical antipsychotics such as 
haloperidol did not show equivalent epigenetic alternations to clozapine, the implication may be 
that clozapine has especially pronounced epigenetic consequences compared to other 
antipsychotics including other atypicals.   
More recently, Aoyama et al., (2013) induced decreased histone H3 acetylation at lysine 9 
residues in rodent prefrontal cortex, a shift in intracellular HDAC distribution to the nucleus, 
decreased phosphorylated -CaM kinase II in the nuclear extracts and decreased mRNA expression of 
GAD1, GABRA1, and PVALB, with 14 days of phencyclidine (PCP) administration - a non-competitive 
N-methyl-D-aspartate (NMDA) receptor antagonist. This produced behavioural deficits such as 
impaired recognition memory and social deficit, providing a useful model for schizophrenia. They 
then administered haloperidol (1.0mg/kg) or clozapine (10mg/kg), once a day for 7 days.  
Clozapine but not haloperidol was able to significantly attenuate the behavioural deficits, 
normalise the acetylation levels of histone H3 at lysine 9 residues, and reverse the shift in 
intracellular HDAC distribution. All these effects were blocked if a dopamine D1 receptor antagonist 
(SCH-23390 hydro- chloride) was injected 30 minutes before clozapine administration. Clozapine 
also attenuated the decreases in prefrontal mRNA expression of PVALB, but not GAD1 or GABRA1. 
The combined findings of normalising nuclear extracts, acetylation, mRNA expression and 
behavioural deficits suggest a coherent role for clozapine inducing this chain of events.    
Based on studies such as these, Guidotti et al (2012) suggested that clozapine (particularly when 
combined with valproate or other HDAC inhibitors) increases histone acetylation and recruits DNA 
demethylation enzymes, normalising GABAergic promoter hyper-methylation and the 
downregulated gene expression. For human studies, it is significantly easier to obtain epigenome 
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data on DNA methylation from peripheral tissue than obtaining data on histone modifications, so 
existing human studies of clozapine-induced epigenetic changes have measured DNA methylation.  
During my thesis another paper of a similar sample size was published with a similar 
methodology (Kinoshita et al., 2017)– they collected blood samples from patients with treatment-
resistant schizophrenia before clozapine initiation and after a year of clozapine treatment and 
measured changes in epigenome-wide DNA methylation and associations with symptom ratings. 
They report finding ~30,000 CpG sites with a significant change in DNA methylation, 44.8% of which 
indicated an increase in methylation, 40.7% of which were located in promoter regions and 32.5% in 
gene bodies. Furthermore they report that significant sites were notably in the CpG islands of 
promoter regions for GABA, glutamate and other schizophrenia-associated genes, and there was 
enrichment for cell substrate adhesion and cell matrix adhesion gene ontology. 
Despite some of the similarities between this study and the design of my study, there are 
significant differences in methodology and analysis. Firstly, they do not report on any samples in 
between their baseline time-point and a year later, whereas I report on samples collected at three 
clinically significant time-points within the first six months allowing a closer look at trajectories of 
DNA methylation change. Secondly, in our study a subsection of samples had data on clozapine level 
allowing an additional analysis which directly reflects clozapine exposure. Thirdly, relevant to 
chapters four and five, they only report on a correlation with overall symptom percentage change, 
whereas I report on analysis of symptom change as both categorical and continuous variables and 
current symptom severity, as well as analysis of different sub-sets of symptoms (positive, negative, 
social), and they have not reported any analysis of adverse reactions to clozapine, whereas I report 
on associations with increased appetite/weight gain, drowsiness, and cardiovascular symptoms.   
Moreover, their analysis does not control for numerous confounding variables of known 
importance – e.g. smoking status, cell counts, and microarray chip id – whereas I use a multi-level 
model including these variables as covariates. Additionally, while they report controlling for multiple 
comparisons, the details on this are ambiguous and their reported findings of ~30,000 significant 
findings (8.5% of all sites analysed) is highly unusual, whereas I use a clearly stated epigenome-wide 
significance threshold which is standard within the field (Lehne et al., 2015). Cumulatively, these 
methodological failings call their conclusions into question.      
Therefore, this thesis remains an original contribution to the literature, providing a 
methodologically rigorous approach to a longitudinal dataset of clozapine users with comprehensive 
analysis of clinical outcomes. 
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I will now present my analysis of our data on changes in DNA methylation associated with 
exposure to clozapine.  
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3.2 Statistical method: Exposure to clozapine 
To explore the effects of exposure to clozapine on DNA methylation, I conducted analysis of: 
1) Within-individual length of time exposed to clozapine as a predictor of DNA methylation  
Time exposed to clozapine: time on clozapine (in weeks) for each sample was recorded as the 
number of days between clozapine initiation and sample collection divided by seven. The time on 
clozapine for baseline samples, taken before exposure to clozapine, was recorded as 0 weeks.  
2) Within-individual variation in clozapine level as a predictor of DNA methylation 
Clozapine level: the plasma clozapine level for each sample was in mg/l.  
To identify DNA methylation changes associated with clozapine exposure, I conducted mixed 
model regression analyses using lme4 and lmer, R packages for liner mixed-effects models   (Bates, 
Maechler, Bolker, & Walker, 2014; Kuznetsova, Brockhoff, & Christensen, 2015). Time on clozapine 
or clozapine level was used a predictor of methylation at each CpG site. Both models controlled for 
baseline age, sex, predicted cell counts (CD8T, CD4T, NK, B, granulocytes and monocytes), smoking 
at time of sample collection (yes/no), chip ID, current medications1  (number of antipsychotics, 
benzodiazepines or other mood stabilisers, antidepressants, hyoscine, metformin, laxatives), 
number of total prior antipsychotics, as well as controlling for the repeated measures from 
individual participants as a random effect.  
These analyses both produced a model with regression coefficients for each CpG site - 
representing the percentage change in methylation at the CpG site associated with an additional 
week on clozapine / increase in clozapine level of 1 – as well as a p value for the significance of this 
association.  
Global DNA Methylation: I report global DNA methylation change associated with exposure to 
clozapine, calculated using the mean of the regression coefficients for all CpG sites which passed QC. 
To explore global DNA methylation at each time point, I report means of the uncorrected2 
methylation data for all CpG sites which passed QC at each time point.  
                                                          
1 Not all medications were used as individual covariates as this would have involved an additional 20+ 
covariates and risked over-fitting the model. 
2 Uncorrected methylation data was used because the model did not produce regression coefficients for 
each time point and this data provides additional information for interpretation; however note that this is not 
adjusted for covariates and it does not indicate within individual comparisons (as the regression model does) 
but comparisons between all samples.  
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Differentially methylated positions (DMPs): I report the means of the regression coefficients for 
the top ten and top one hundred differentially methylated positions (DMP). The direction of effect in 
the top one hundred DMPs is presented throughout the thesis, even when individual DMPs are not 
significant, as this may indicate broad patterns of hyper or hypo-methylation; this is of interest 
because previous research has proposed a wide-reaching dysfunction in regulation of DNA 
methylation and/or gene expression in schizophrenia. 
I then summarise how many differentially methylated positions were below a standard 
threshold for epigenome wide significance (1*10-7) 3(Lehne et al., 2015) and how many were trend-
level significance (5*10-5). I describe the ten most statistically significant DMPs, including the 
regression coefficient, p value, and uncorrected methylation data demonstrating changes over time 
on clozapine/demonstrating the correlation with clozapine level. Data from the UCSC Genome 
Browser was used for gene annotation. I report the location of the CpG site and a description of the 
function and expression of the associated gene; unless stated otherwise, all information is from the 
GeneCards database (www.genecards.org; Stelzer et al., 2016).  
I also report an estimate of correlation between methylation at this CpG site in whole blood and 
methylation at this CpG site in brain tissue; this information was provided by the blood-brain DNA 
methylation comparison tool at http://epigenetics.iop.kcl.ac.uk/bloodbrain/ which is based on data 
from Hannon et al., (2015).   
Pathway analysis: I used GOSeq to conduct pathway analysis on the results of each regression 
model and identify pathways with an over-representation of DMPs. GOSeq used the UCSC Browser 
gene annotations and ontology categories. DMPs with a p value of 5x10-4 were used and pathways 
were filtered to those including at least ten genes.  
Candidate CpG site methylation: Based on previous literature reporting the differential 
methylation induced by exposure to clozapine (Aoyama et al., 2013; Dong et al., 2008; Huang et al., 
2007; Kinoshita et al., 2017), I identified six genes which have been associated with clozapine 
exposure: GAD1, PVALB, RELN, GRIN2A, GRIN2D and GRM7. In total there were 182 CpG sites for 
these genes included in the 450k assay which passed QC. To adjust for multiple-comparisons, I used 
an adjusted p value of 0.05/182 = 0.275x10-3. 
 Comparison to cross-sectional data: I then compared the results of the models of clozapine 
exposure from my longitudinal dataset to results from the previous dataset of cross-sectional 
                                                          
3 As this is one of the first datasets of its kind, with this thesis intending to present exploratory analysis for 
discussion, significance thresholds were not further corrected for the multiple testing involved in conducted 
numerous models with the same sample.    
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clozapine exposure, firstly to explore whether the cross-sectional model was validated by the 
longitudinal models, and then to explore whether the longitudinal model was validated by the cross-
sectional model.  To investigate replication of the findings from the cross-sectional model, I took all 
the top DMPs with a p value < 5*10-5 from the cross-sectional model and ran a correlation analysis 
on the regression coefficients from the cross-sectional model for these top DMPs and the regression 
coefficients from one of the longitudinal models for these DMPs; this was to establish if there was 
the same direction of effect for DMPs in both cohorts (i.e. if methylation was higher in the clozapine 
exposed group from the cross-sectional dataset, was methylation also higher in samples with greater 
levels of clozapine exposure in the longitudinal dataset). To investigate replication of the findings 
from both longitudinal models of clozapine exposure, I took all the top DMPs with a p value < 5*10-5 
from a longitudinal model and ran a correlation analysis on the regression coefficients from the 
longitudinal model for these top DMPs and the regression coefficients from the cross-sectional 
model for these DMPs; again, this was to establish if there was the same direction of effect for DMPs 
in both cohorts (i.e. if methylation was higher in samples with greater levels of clozapine exposure in 
the longitudinal dataset, was methylation also higher in the clozapine exposed group from the cross-
sectional dataset). 
All analysis was conducted using R 3.1.2. 
The results for each analysis model are reported separately. First I will report the results for 
analysis of time on clozapine, and then I will report the results for analysis of clozapine levels.  
3.3 Results: Time on clozapine (weeks) 
3.3.1 Participant characteristics (time on clozapine) 
All eighty-five samples from twenty-two participants had information on date of collection so all 
samples were included in the analysis of time on clozapine. Information about the characteristics of 
this sample can be found in Table 1, with key details represented in subsequent pie charts (Figure 6): 
the majority of participants were male, had a diagnosis of paranoid schizophrenia, had no psychiatric 
comorbidities, had predominant negative symptoms, had not been previously exposed to clozapine, 
did not smoke, and experienced increased appetite/weight and drowsiness. There were ten 
responders to clozapine and twelve non-responders, and there was a mean decrease of 17.6% in 
PANSS Total (paired t-test comparing baseline total and twelve week total, t=8.420, df=78, p<0. 
1x10-4) and a mean increase of 30.33 in psychosocial functioning and 39.84% in quality of life.  
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Table 1: Characteristics of participants included in Time on Clozapine Analysis 
   
Age (years) Mean 37.80 
Minimum 19.94 
Maximum 61.38 
Gender Male 17 
Female 5 
Ethnicity White 10 
Black 10 
Asian 2 
Diagnosis Schizophrenia 11 
Schizoaffective disorder 3 
Months between diagnosis of treatment-




Inpatient Psychiatric Admissions Mean 3.5 
Minimum 0 
Maximum 10 
Psychiatric Comorbidities Affective 2 
Anxiety 2 
Substance Abuse 3 
None 15 
Prior Clozapine Exposure Yes 5 
No 17 
Number of prior typical antipsychotics Mean 0.77 
Minimum 0 
Maximum 2 
Number of prior atypical antipsychotics Mean 2.91 
Minimum 1 
Maximum 7 
Number of prior mood stabilisers Mean 0.23 
Minimum 0 
Maximum 1 
Smoker at baseline Yes 3 
No 19 
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Baseline PANSS Total Mean 78.32 
Minimum 54 
Maximum 119 
Baseline PANSS Positive Mean 19.57 
Minimum 9 
Maximum 36 
Baseline PANSS Negative Mean 21.864 
Minimum 9 
Maximum 39 
Predominant Baseline Symptoms Positive 7 
Negative 15 
12w PANSS Total Mean 63.45 
Minimum 35 
Maximum 98 
6m PANSS Total Mean 61.20 
Minimum 37 
Maximum 97 
Responder at 12 weeks Yes 10 
No 12 






PSP % Change at 12w Mean 30.33 
Minimum -50 
Maximum 162.50 
GAF % Change at 12w Mean 39.84 
Minimum -25 
Maximum 185.71 
Increased appetite/weight at 12w Yes 13 
No 9 
Cardiovascular symptoms at 12w Yes 4 
No 18 
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Figure 6: Pie charts illustrating key demographics across participants 
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3.3.1.1 Details of Medication 
The five most frequent antipsychotic medications that participants had been previously exposed 
to before baseline were risperidone (n=15, 68.18%), aripiprazole (n=13, 59.09%), olanzapine (n=11, 
50%), amisulpride (n=6, 27.27%), quetiapine (n=6, 27.27%) and promethazine (n=6, 27.27%). The 
mean number of previously prescribed antipsychotics was 3.91, ranging from 2-10. At baseline, 
antipsychotic medication included olanzapine (n=6), aripiprazole (n=3), risperidone (n=3), 
promethazine (n=3), clonazepam (n=3), lithium (n=2), valproate (n=2), mirtazapine (n=2), lurasidone 
(n=1), quetiapine (n=1) and flupentixol (n=1). 
During clozapine treatment, there were four patients on adjunctive antipsychotics; one on 
olanzapine and valproate throughout, one on clonazepam throughout and amisulpride initially, one 
on amisulpride throughout, and one on amisulpride initially. For affective symptoms, three patients 
took SSRIs (citalopram or sertraline) during their treatment, two took mirtazapine, one took 
amitriptyline and one took lithium. Five patients took metformin (a medication to treat diabetes and 
metabolic symptoms) at some point during their clozapine treatment, nine took hyoscine (a 
medication to treat hyper-salivation and nausea) and four took some form of laxative (e.g. senna, 
lactulose). Two participants took antibiotics at some point during their treatment.   
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As described in the previous section on statistical method, this variability in medication was 
incorporated in analysis using covariates.  
3.3.2 Global DNA methylation (time on clozapine) 
Longer time on clozapine was associated with increased global DNA methylation. An additional 
week on clozapine was associated with an average increase in global DNA methylation of 0. 969x10-3 
%. 51.18% of all CpG sites showed an increase in methylation associated with time exposed to 
clozapine, and 48.82 showed a decrease. Moreover, when exploring individual time points: at 
baseline, mean global DNA methylation was 48.285% and this decreased to 48.254% at six weeks, 
but then increased to 48.289% at twelve weeks, and further increased to 48.293% at six months.   
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3.3.3 Differentially methylated positions (time on clozapine) 
One DMP reached the threshold for epigenome wide significance (p<1*10-7) and eighty five 
DMPs were trend-level significant (p<5*10-5). Below, top ten DMPs (Table 2) are described in more 
detail, only when there they are either epigenome wide significant or there is prior evidence for 
correlation between methylation in blood and brain. 
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Table 2: Top ten DMPs associated with time on clozapine (* indicates epigenome wide significance) 
CpG site Beta P value Mean methylation (%) 
 
Gene Location MAPINFO Significant blood-brain 







cg23892310 -0.149x10-2 5.86E-08* 83.456 83.776 81.973 81.319 TBCD Body 80816702 Y – entorhinal cortex 
cg12590655 0.081 x10-2 1.49E-07 84.280 84.030 84.504 85.136   164340525 N 
cg00873351 0.117 x10-2 6.23E-07 
33.242 32.807 33.484 33.853 
CD300LB TSS1500 72527813 
Y – superior temporal gyrus and 
cerebellum 
cg12026992 0.141 x10-2 1.37E-06 79.915 79.882 80.186 82.427   90004011 N 
cg15766571 -0.090 x10-2 2.02E-06 9.839 9.942 8.994 7.909 C19orf43 Body 12845030 N 
cg05842815 0.079 x10-2 2.29E-06 87.111 87.581 87.607 88.727   440159 Y – entorhinal cortex 
cg25037165 -0.097 x10-2 2.85E-06 85.289 84.691 84.660 83.496 TEAD1 Body 12824283 Y – superior temporal gyrus 
cg05195750 0.077 x10-2 3.81E-06 
8.859 8.934 9.127 10.101 
ELP4;IMMP1L Body;TSS1500 31531557 
Y – entorhinal cortex and prefrontal 
cortex 
cg14060296 0.026 x10-2 3.82E-06 3.660 3.456 3.752 4.001 HSPA2 TSS200 65007096 N 
cg01421943 -0.137 x10-2 3.85E-06 81.771 83.111 81.605 80.710 DKK2 3'UTR 107843676 N  
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The most statistically significant DMP associated with time on clozapine was cg23892310. Each 
additional week exposed to clozapine was associated with a decrease in methylation at this site of 
0.149% (p=0.6x10-7). Uncorrected means show an average baseline methylation of 83.456%, with an 
increase to 83.776% at six weeks, then a decrease to 81.973% at twelve weeks and a further 
decrease to 81.319% at six months.  
 
cg23892310 is located in the gene body of TBCD, a protein coding gene for beta-tubulin cofactor 
D. TBCD is located on chromosome 17 and expressed across numerous tissue including brain, with 
ubiquitous expression of mRNA and overexpression of protein in bone. Beta-tubulin cofactor D is 
one of four proteins involved in ensuring correctly folded beta-tubulin, capturing and stabilising 
beta-tubulin intermediates. It acts as a GTPase activating protein and is regulated by ARL2; the 
absence of ARL2 leads to microtubule disruption. It is also implicated in protein metabolism and 
associated with corneal diseases. This CpG site is reported to have a significant weak correlation 
between methylation in blood and methylation in prefrontal cortex (r = 0.271, p=0.0195). 
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The third most statistically significant DMP associated with time on clozapine was cg00873351. 
Each additional week of exposure to clozapine was associated with an increase of 0.117% (p=0.6x10-
6). Uncorrected means show an average baseline methylation of 33.242%, with a decrease to 
32.807% at six weeks, then an increase to 33.484% at twelve weeks and a further increase to 
33.853% at six months. 
 
cg00873351 is located within the TSS1500 (1500 bases upstream of the transcription start site) 
promoter region of CD300LB, a gene which codes for Leukocyte Mono-Ig-Like Receptor 5, a non-
classical activating receptor of the immunoglobin superfamily expressed on myeloid cells. CD300LB 
is located on chromosome 17 and expressed in numerous tissues including brain, with 
overexpression of mRNA in whole blood and overexpression of protein in stomach. This CpG site is 
reported to have a significant weak correlation between methylation in blood and methylation in 
superior temporal gyrus (r = 0.236, p =0.042) and cerebellum (r=0.247, p=0.038). 
Exposure to Clozapine and Associated DNA Methylation Changes 
- 79 - 
 
The sixth most statistically significant DMP associated with time on clozapine was cg05842815. 
Each additional week exposed to clozapine was associated with an increase of 0.079% (p=0.2x10-5). 
Uncorrected means show an average baseline methylation of 87.111%, with an increase to 87.581% 
at six weeks, then a further increase to 87.607% at twelve weeks and a further increase to 88.727% 
at six months. 
 
cg05842815 is located on chromosome 5, outside of any characterised genes. This CpG site is 
reported to have a significant weak correlation between methylation in blood and methylation in 
entorhinal cortex (r=0.239, p=0.045). 
The seventh most statistically significant DMP associated with time on clozapine was 
cg25037165. Each additional week exposed to clozapine was associated with a decrease of 0.097% 
(p= 0.2x10-5). Uncorrected means show an average baseline methylation of 85.289%, with a 
decrease to 84.691% at six weeks, then a decrease to 84.660% at twelve weeks and a further 
decrease to 83.496% at six months. 
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cg25037165 is located within the gene body of TEAD1, which codes for transcriptional enhancer 
factor TEF-1. This gene is located on chromosome 11 and is expressed in numerous tissues including 
brain, with overexpression of mRNA in skeletal muscle and overexpression of protein in breast and 
ovary. Transcriptional enhancer factor TEF-1 is ubiquitous, directing the transactivation of numerous 
genes. This CpG site is reported to have a significant weak correlation between methylation in blood 
and methylation in superior temporal gyrus (r=0.277, p=0.016). 
 
The eighth most statistically significant DMP associated with time on clozapine was 
cg05195750. Each additional week exposed to clozapine was associated with an increase of 0.0765% 
(p= 0.4x10-5). Uncorrected means show an average baseline methylation of 8.859%, with an increase 
to 8.934% at six weeks, then an increase to 9.127% at twelve weeks and a further increase to 
10.101% at six months.  
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cg05195750 is located with the gene body of ELP4, which codes for elongation protein 4 
homolog. This gene is located on chromosome 11 and expressed across numerous tissues including 
brain, with wide expression of mRNA and overexpression of protein in breast and peripheral blood 
mononuclear cells. Elongation protein 4 homolog is a histone acetyltransferase complex that is 
involved in transcriptional elongation, chromatin organisation, and has been associated with 
epilepsy. This CpG site is reported to have a significant moderate correlation between methylation in 
blood and methylation in entorhinal cortex (r = 0.38, p=0.001) and a significant weak correlation 
between blood and prefrontal cortex (r = 0.234, p=0.045).  
3.3.4 Pathway analysis (time on clozapine) 
Pathway analysis indicated that the pathways in Table 3 were the top thirty pathways with an 
over-representation of DMPs associated with time on clozapine.  
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Table 3: Top thirty over-represented pathways - time on clozapine 
Category Name p value over-
representation 





GO:0055080 cation homeostasis 0.0006 23 470 BP 
GO:0032446 protein modification by small protein conjugation 0.0008 30 640 BP 
GO:0033005 positive regulation of mast cell activation 0.0011 3 12 BP 
GO:0009312 oligosaccharide biosynthetic process 0.0011 3 13 BP 
GO:0006700 C21-steroid hormone biosynthetic process 0.0013 4 18 BP 
GO:0070647 protein modification by small protein conjugation or removal 0.0017 31 710 BP 
GO:0004842 ubiquitin-protein ligase activity 0.0017 15 258 MF 
GO:0033866 nucleoside bisphosphate biosynthetic process 0.0018 4 17 BP 
GO:0034030 ribonucleoside bisphosphate biosynthetic process 0.0018 4 17 BP 
GO:0034033 purine nucleoside bisphosphate biosynthetic process 0.0018 4 17 BP 
GO:0008528 G-protein coupled peptide receptor activity 0.0018 8 106 MF 
GO:0001653 peptide receptor activity 0.002 8 108 MF 
GO:0006163 purine nucleotide metabolic process 0.002 54 1290 BP 
GO:0072521 purine-containing compound metabolic process 0.002 55 1328 BP 
GO:0008207 C21-steroid hormone metabolic process 0.003 4 27 BP 
GO:0042623 ATPase activity 0.003 15 243 MF 
GO:0004871 signal transducer activity 0.003 46 1434 MF 
GO:0060089 molecular transducer activity 0.003 46 1434 MF 
GO:0055065 metal ion homeostasis  0.003 20 434 BP 
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Category Name p value over-
representation 





GO:0009150 purine ribonucleotide metabolic process 0.003 53 1269 BP 
GO:0004930 G-protein coupled receptor activity 0.003 19 711 MF 
GO:0032281 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid selective glutamate receptor complex 0.003 4 24 CC 
GO:0016887 ATPase activity 0.003 19 352 MF 
GO:0009259 ribonucleotide metabolic process 0.003 53 1282 BP 
GO:0016567 protein ubiquitination 0.003 26 596 BP 
GO:0050801 ion homeostasis 0.003 23 535 BP 
GO:0019693 ribose phosphate metabolic process 0.003 53 1285 BP 
GO:0042181 ketone biosynthetic process 0.004 4 31 BP 
GO:0046128 purine ribonucleoside metabolic process 0.004 48 1138 BP 
GO:0042278 purine nucleoside metabolic process 0.005 48 1140 BP 
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3.3.5 Candidate CpG site methylation (time on clozapine) 
Of thirty one CpG sites located within GAD1 with methylation data available, one had a 
significant association with time on clozapine before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg15306595 showed a decrease in methylation (-0.022%, p=0.006). Across all 
GAD1 CpG sites, there was a mean decrease in methylation of 0.00182% associated with each 
additional week on clozapine. 
Of fifteen CpG sites located within PVALB with methylation data available, none had a significant 
association with time on clozapine. Across all PVALB CpG sites, there was a mean increase in 
methylation of 0.0159% associated with each additional week on clozapine. 
Of twenty two CpG sites located within RELN with methylation data available, two had a 
significant association with time on clozapine before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg02777934 showed a decrease in methylation (-0.074%, p=0.027), and 
cg24021846 also showed a decrease (-0.087%, p=0.027). Across all RELN CpG sites, there was a 
mean decrease in methylation of -0.292x10-2 % associated with each additional week on clozapine. 
Of fifty three CpG sites located within GRIN2A with methylation data available, two had a 
significant association with time on clozapine before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg06299307 showed a decrease in methylation (-0.059%, p=0.049) and 
cg06193383 also showed a decrease in methylation (-0.031%, p=0.017). Across all GRIN2A CpG sites, 
there was a mean increase in methylation of 0.366x10-2 % associated with each additional week on 
clozapine. 
Of thirty nine CpG sites located within GRIN2D with methylation data available, three had a 
significant association with time on clozapine before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg08525508 showed a decrease in methylation (-0.057%, p=0.020), 
cg26322763 showed an increase in methylation (0.044%, p=0.038), and cg01299779 showed a 
decrease in methylation (-0.044%, p=0.047). Across all GRIN2D CpG sites, there was a mean increase 
in methylation of 0.247x10-2 % associated with each additional week on clozapine. 
Of thirty two CpG sites located within GRM7 with methylation data available, one had a 
significant association with time on clozapine before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg00146655 showed an increase in methylation (0.064%, p=0.004). Across all 
GRM7 CpG sites, there was a mean increase in methylation of 0.546x10-2 % associated with each 
additional week on clozapine. 
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3.3.6 Comparison to cross-sectional data (time on clozapine) 
First I took the top DMPs (p<0.05*10-5) from the cross-sectional dataset and identified these 
within the longitudinal dataset. There was a significant very weak positive correlation between the 
regression coefficients from the longitudinal dataset and the cross-sectional data set of 0.053, p < 
0.4x10-3, df =4528.  
 
I then took the top DMPs (p<0.05*10-5) from the longitudinal dataset and identified these within 
the cross-sectional dataset. There was a non-significant negative correlation between the regression 
coefficients from the longitudinal dataset and the cross-sectional data set of -0.024.  
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3.4 Results: Clozapine levels 
3.4.1 Participant characteristics (clozapine levels) 
All twenty-two baseline samples with clozapine levels of 0 were included. Four participants had 
no further samples with corresponding clozapine level data. Of the eighteen other participants, 
there were forty two samples taken after clozapine use with corresponding clozapine level data. 
Combined with the baseline samples, this led to a total of sixty four samples included in the below 
analysis. 
Clozapine levels significantly increased with time (correlation with days on clozapine =0.688, 
df=64, p<0.1x10-5) – though when baseline samples are excluded, this disappears (0.126, df=42, 
p=0.41); this aligns with typical titration schedules in which patients should have reached a 
therapeutic dose by six weeks and alterations afterwards are individualised adjustments. Clozapine 
levels at twelve weeks are more variable in smokers (mean in smokers =0.434, sd=0.227, mean in 
non-smokers =0.403, sd=0.093). Those with lower clozapine levels at twelve weeks had greater 
reductions in total symptom severity at twelve weeks, though this correlation was not significant 
(0.251, df =13, p=0.3678). When baseline samples are included, higher clozapine levels are 
associated with lower total symptom severity (-0.346, df=48, p=0.0138); however, when baseline 
samples are excluded, there is no longer any association (0.0831, df=26, p=0.674) suggesting lower 
symptom severity is associated with being on clozapine at any dose and there is not a dose-severity 
association.  
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3.4.2 Global DNA methylation (clozapine levels) 
Higher clozapine levels were associated with higher levels of global DNA methylation. An 
increase in clozapine level was associated with an average increase in global DNA methylation of 
0.0501%. 51.02% of all CpG sites showed an increase in methylation associated with clozapine level, 
and 48.98% showed a decrease.  
3.4.3 Differentially methylated positions (clozapine levels) 
Three DMPs reached the threshold for epigenome wide significance (p<1*10-7), and two-
hundred and thirty other DMPs were trend-level significant (p<5*10-5). Below, top ten DMPs (Table 
4) are described in more detail, only when there they are either epigenome wide significant or there 
is prior evidence for correlation between methylation in blood and brain. 
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Table 4: Top ten DMPs associated with clozapine level (* indicates epigenome wide significance) 
CpG site Beta P 
value 
Gene Location MAPINFO Significant blood-brain methylation correlation reported? 
cg24651966 0.060 
1.32E-




08* SLC12A6 TSS1500 34630530 
Y – prefrontal cortex, entorhinal cortex, superior temporal gyrus 
cg13193591 -0.054 
6.16E-
















07 ENOSF1 TSS200 712731 
Y – prefrontal cortex, entorhinal cortex, superior temporal gyrus 
cg06329022 -0.037 
4.79E-
07 SPAG5 TSS1500 26926511 
Y – prefrontal cortex and cerebellum 
cg01731811 -0.061 
4.81E-
07 PTPRN2 Body 157890171 
Y – prefrontal cortex and superior temporal gyrus 
cg08821738 -0.051 
5.19E-
07 C1QTNF1 Body 77043179 
N 
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The most statistically significant DMP associated with clozapine level was cg24651966. An 
increase in clozapine level was associated with an increase in methylation at this site of 6.072% 
(p=0.1x10-9). Using uncorrected means there was a correlation of 0.261 between clozapine levels 
and methylation across samples. 
 
cg24651966 is located in the gene body of BBS12, which codes Bardet-Biedl Syndrome 12 
protein. This gene is located on chromosome 4 and expressed across numerous tissues including 
brain, and defects can cause Bardet-Biedl Syndrome 12. Bardet-Biedl Syndrome 12 protein is a 
molecular chaperone involved in membrane trafficking and protein folding, as well as adipocyte 
differentiation. This CpG site is reported to show no correlation between methylation in blood and 
methylation in brain tissue. 
The second most significant differentially methylated CpG site associated with clozapine level 
was cg11293029. An increase in clozapine level was associated with an increase in methylation at 
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this site of 8.002% (p=0.4x10-7). Using uncorrected means there was a correlation of 0.352 between 
clozapine levels and methylation across samples. 
 
cg11293029 is located in the TSS1500 promoter region of SLC12A6, which codes solute carrier 
family 12 member 6. This gene is located on chromosome 15 and expressed across numerous tissues 
including brain, with overexpression of mRNA in whole blood and overexpression of protein in 
peripheral blood mononuclear cells, plasma and lymph nodes. Solute carrier family 12 member 6 is a 
member of the potassium-chloride cotransporter family; it is an integral membrane protein that 
lowers intracellular chloride to induce electrochemical changes. This CpG site is reported to have a 
significant moderate correlation between methylation at blood and methylation at prefrontal cortex 
(r=0.377, p=0.001), entorhinal cortex (r=0.313, p=0.008) and superior temporal gyrus (r=0.344, 
p=0.003).  
The third most significantly differentiated methylated CpG site associated with clozapine level 
was cg13193591. An increase in clozapine level was associated with a decrease in methylation at this 
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site of 5.409% (p=0.6x10-7). Using uncorrected means there was a correlation of -0.283 between 
clozapine levels and methylation across samples. 
 
cg13193591 is located on chromosome 11 outside of any characterised genes. This CpG site is 
reported to show no correlation between methylation in blood and methylation in brain tissue. 
The seventh most statistically significant DMP associated with clozapine level was cg15158376. 
An increase in clozapine level was associated with a decrease in methylation at this site of 1.106% 
(p=0.4x10-6). Using uncorrected means there was a correlation of -0.256 between clozapine levels 
and methylation across samples. 
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cg15158376 is located in the TSS200 of ENOSF1, which encodes antisense RNA to thymidylate 
synthase and is believed to regulate expression of the thymidylate synthase locus. The gene is 
located on chromosome 18 and expressed across numerous tissues including brain, with 
overexpression of protein in gallbladder and liver. This CpG site is reported to show a significant 
moderate correlation between methylation in blood and methylation in prefrontal cortex (r=0.439, 
p=0.1x10-3), entorhinal cortex (r=0.473, p=0.3x10-4), and superior temporal gyrus (r=0.327, p =0.004). 
The eighth most statistically significant DMP associated with clozapine level was cg06329022. 
An increase in clozapine level was associated with a decrease in methylation at this site of 3.654% 
(p=0.5x10-6). Using uncorrected means there was a correlation of -0.324 between clozapine levels 
and methylation across samples. 
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cg06329022 is located in the TSS1500 promoter region of SPAG5, which encodes sperm 
associated antigen 5. This gene is located on chromosome 17 and expressed across numerous 
tissues including brain, with overexpression of mRNA in testis and kidney and overexpression of 
protein in cervix, plasma, testis and bone. Sperm associated antigen 5 is implicated in regulator of 
mitotic spindles required for normal chromosome segregation. This CpG site is reported to show a 
significant weak correlation between methylation in blood and methylation in pre-frontal cortex 
(r=0.26, p=0.026) and cerebellum (r=0.27, p=0.023), with a trend at entorhinal cortex (r=0.217, 
p=0.069).  
The ninth most statistically significant DMP associated with clozapine level was cg01731811. 
An increase in clozapine level was associated with a decrease in methylation at this site of 6.091% 
(p=0.5x10-6). Using uncorrected means there was a correlation of -0.378 between clozapine levels 
and methylation across samples. 
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cg01731811 is located in the gene body of PTPRN2, which encodes protein tyrosine 
phosphatase, receptor type N2. This gene is located on chromosome 7 and expressed across 
numerous tissues including brain, with overexpression of mRNA in brain (cortex, anterior cingulate 
cortex, frontal cortex, nucleus accumbens and putamen) and overexpression of protein in 
cerebrospinal fluid and frontal cortex. Protein tyrosine phosphatase, receptor type N2 is required for 
normal accumulation of neurotransmitters in the brain, as well as secretion of pituitary hormones 
and secretory vesicles in hippocampus and insulin secretion. This CpG site is reported to show a 
significant moderate correlation between methylation in blood and methylation in prefrontal cortex 
(r=0.491, p=0.9x10-5) and superior temporal gyrus (r=0.471, p=0.2x10-4), with a weak correlation 
between methylation in blood and methylation in entorhinal cortex (r=0.254, p=0.032).   
3.4.4 Pathway analysis (clozapine levels) 
Pathway analysis indicated that the pathways in Table 5Table 3 were the top thirty pathways 
with an over-representation of DMPs associated with clozapine level.  
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Table 5: Top thirty over-represented pathways - clozapine level 
Category Name p value over-
representation 





GO:0010035 response to inorganic substance 0.0003 40 361 BP 
GO:0051219 phosphoprotein binding 0.0009 10 47 MF 
GO:0010038 response to metal ion 0.0011 28 242 BP 
GO:0031929 TOR signalling 0.0021 11 46 BP 
GO:0032007 negative regulation of TOR signalling 0.0024 6 20 BP 
GO:0008092 cytoskeletal protein binding 0.0030 71 674 MF 
GO:0030100 regulation of endocytosis 0.0046 19 151 BP 
GO:0016712 oxidoreductase activity 0.0055 4 24 MF 
GO:2000505 regulation of energy homeostasis 0.0057 4 11 BP 
GO:0042743 hydrogen peroxide metabolic process 0.0064 7 38 BP 
GO:0045807 positive regulation of endocytosis 0.0066 12 81 BP 
GO:0007140 male meiosis 0.0067 6 33 BP 
GO:0033574 response to testosterone 0.0080 5 25 BP 
GO:0035270 endocrine system development 0.0082 19 131 BP 
GO:0030865 cortical cytoskeleton organization 0.0088 5 20 BP 
GO:0048168 regulation of neuronal synaptic plasticity 0.009 9 41 BP 
GO:0045132 meiotic chromosome segregation 0.009 5 22 BP 
GO:0010951 negative regulation of endopeptidase activity 0.001 17 194 BP 
GO:0007167 enzyme linked receptor protein signalling pathway 0.001 90 928 BP 
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Category Name p value over-
representation 





GO:0035412 regulation of catenin import into nucleus 0.011 6 22 BP 
GO:0043566 structure-specific DNA binding 0.011 23 211 MF 
GO:0009651 response to salt stress 0.011 5 24 BP 
GO:0006595 polyamine metabolic process 0.011 4 17 BP 
GO:0035413 positive regulation of catenin import into nucleus 0.011 4 11 BP 
GO:0006997 nucleus organization 0.011 11 87 BP 
GO:0035066 positive regulation of histone acetylation 0.012 4 17 BP 
GO:0003779 actin binding 0.012 38 342 MF 
GO:0043542 endothelial cell migration 0.012 17 120 BP 
GO:0050321 tau-protein kinase activity 0.012 4 12 MF 
GO:0009308 amine metabolic process 0.012 19 196 BP 
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3.4.5 Candidate CpG site methylation (clozapine levels) 
Of thirty one CpG sites located within GAD1 with methylation data available, four had a 
significant association with clozapine level before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg13612847 showed a decrease in methylation (-2.101%, p=0.006), 
cg14005211 showed a decrease in methylation (-5.401%, p=0.019), cg16911423 showed a decrease 
in methylation (-1.8%, p=0.025) and cg19538089 showed a decrease in methylation (-1.316%, 
p=0.024). Across all GAD1 CpG sites, there was a mean decrease in methylation of 0.577% associated 
with an increase in clozapine level. 
Of fifteen CpG sites located within PVALB with methylation data available, one had a significant 
association with clozapine level after correction for multiple testing; cg19136704 showed an 
increase in methylation (6.358%, p= 0.5x10-4). Across all PVALB CpG sites, there was a mean 
decrease in methylation of 0.1995% associated with an increase in clozapine level. 
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Of twenty two CpG sites located within RELN with methylation data available, two had a 
significant association with clozapine level before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg27456945 showed a decrease in methylation (-1.956%, p=0.006), and 
cg19586288 showed a decrease in methylation (-3.008%, p=0.020). Across all RELN CpG sites, there 
was a mean decrease in methylation of -0.171% associated with an increase in clozapine level.  
Of fifty three CpG sites located within GRIN2A with methylation data available, six had a 
significant association with clozapine level before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg06922606 showed a decrease in methylation (-4.547%, p=0.014), 
cg27644733 showed an increase in methylation (0.9102%, p=0.017), cg01348055 showed a decrease 
in methylation (-3.007%, p=0.025), cg04933990 showed an increase in methylation (1.856%, 
p=0.031), cg00116766 showed an increase in methylation (4.332%, p=0.031) and cg16904585 
showed an increase in methylation (2.930%, p=0.012).  Across all GRIN2A CpG sites, there was a 
mean decrease in methylation of -0.1074% associated with an additional week on clozapine. 
Of thirty nine CpG sites located within GRIN2D with methylation data available, five had a 
significant association with clozapine level before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg06932616 showed a decrease in methylation (-3.447%, p=0.011), 
cg22243956 showed an increase in methylation (4.4772%, p=0.025), cg25781595 showed an 
increase in methylation (2.339%, p=0.026), cg12965344 showed a decrease in methylation (-3.72%, 
p=0.026) and cg16875863 showed a decrease in methylation (-4.179%, p=0.031). Across all GRIN2D 
CpG sites, there was a mean decrease in methylation of -0.1986% associated with an additional 
week on clozapine. 
Of thirty two CpG sites located within GRM7 with methylation data available, two had a 
significant association with clozapine level before but not after correction for multiple testing 
(0.275x10-3<p<0.05); cg24213507 showed an increase in methylation (2.665%, p=0.009), and 
cg24643102 showed an increase in methylation (2.3043%, p=0.015). Across all GRM7 CpG sites, 
there was a mean decrease in methylation of -0.1463% associated with an additional week on 
clozapine. 
3.4.6 Comparison to cross-sectional data (clozapine levels) 
First I took the top DMPs (p<0.05*10-5) from the cross-sectional dataset and identified these 
within the longitudinal dataset. There was a highly significant negative correlation between the 
regression coefficients from the longitudinal dataset and the cross-sectional data set of -0.369, p 
<0.2x10-15, df =4528. 
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I then took the top DMPs (p<0.05*10-5) from the longitudinal dataset and identified these within 
the cross-sectional dataset. There was a highly significant negative correlation between the 
regression coefficients from the longitudinal dataset and the cross-sectional data set of -0.331, p = 
0.3x10-6, df = 229.  
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3.5 Discussion: Exposure to clozapine 
To explore the effects of exposure to clozapine on DNA methylation, I have conducted mixed 
model regression analysis on 1) time exposed to clozapine within-individual as a predictor of DNA 
methylation, and 2) clozapine level within-individual as a predictor of DNA methylation. Systems 
involving signal transduction, GPCRs, AMPARs, calcium signalling at GABAergic interneurons, glucose 
homeostasis, immune function, beta-tubulin and transcription regulation are implicated.  
3.5.1 Time on clozapine 
Analysis of the association between epigenome-wide DNA methylation and time exposed to 
clozapine identified one DMP that was significant at the epigenome-wide threshold (cg23892310) 
and eighty seven other DMPs showed trends towards significance. The majority of the top ten DMPs 
show increases in methylation over time, or an initial decrease and then increases; global DNA 
methylation indicates this pattern also. Three of the top ten DMPs are located outside of genes, but 
of the seven located within genes, five have been shown to demonstrate correlations between 
methylation in blood and methylation in at least one brain region tissue, predominantly entorhinal 
cortex.  
 A high proportion of the biological systems indicated by the top ten DMPs and/or top thirty 
pathways associated with time on clozapine have been previously demonstrated to be dysfunctional 
in schizophrenia, and many have also been shown to be influenced by antipsychotics including 
clozapine.  
The top ranked DMP was located in the gene body of TBCD, which encodes a protein involved in 
the correct folding of beta-tubulin. Beta tubulin is a major cytoskeleton protein involved in neuronal 
differentiation, and a major component of axons, dendrites and dendritic spines – knock down 
studies highlight its importance for neurite density and protection against glutamate and glycine 
(Guo, Walss-Bass, & Ludueña, 2010).  Post-mortem studies of schizophrenia have found decreased 
expression of beta-tubulin in ACC and increased expression in DLPFC, and it has been suggested that 
these abnormalities disrupt normal cell division and differentiation processes (Moehle, Luduena, 
Haroutunian, Meador-Woodruff, & McCullumsmith, 2012). Some have further argued that abnormal 
expression of cytoskeletal proteins including beta-tubulin could underlie findings of reduced white 
matter in schizophrenia and abnormalities in corpus callosum communication (Sivagnanasundaram, 
Crossett, Dedova, Cordwell, & Matsumoto, 2007).  
The third ranked DMP was in CD300LB, a gene encoding an activating receptor of the 
immunoglobin super family, which is highly expressed in mast cells and monocytes/macrophages, 
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both types of leukocytes (white blood cells), and involved in cytokine secretion (Enomoto et al., 
2010).  Similarly, the third most over-represented pathway was regulation of mast cell activation, 
both indicating an effect of clozapine on DNA methylation in immune related genes. There has been 
a long history of research implicating immune dysfunction in schizophrenia, with recent formulations 
suggesting that prenatal or early experiences induce an inflammatory state which leads to later 
disruptions in dopaminergic, glutamatergic and GABAergic networks (Anders & Kinney, 2015; 
Feigensona, Kusnecovb, & Silversteina, 2014; Müller, Weidinger, Leitner, & Schwarz, 2015); these 
reviews cite evidence of associations between schizophrenia and early immunological insults, 
increased inflammatory markers such as cytokines and microglia, and autoimmune diseases.  
The literature on clozapine’s interaction with the immune system is complex. On one hand, 
studies (Hu et al., 2012) demonstrate a protective, anti-inflammatory effect of clozapine; they found 
that clozapine led to reduced microglial activation and reduced production of microglial derived 
reactive oxygen or superoxide, and protection of cortical and mesencephalic neuron-glia cultures 
from inflammation related neurodegeneration. Similarly, Song, Lin, Kenis, Bosmans, & Maes (2000) 
found an immunosuppressive effect of clozapine, with increased production of an interleukin-T 
receptor antagonist and interleukin 10 (which inhibits synthesis of cytokines). Of course, clozapine is 
also known to induce agranulocytosis, a dangerous decrease in leukocytes which indicates an 
immunosuppressive effect. On the other hand, there are studies (Hefner, Shams, Unterecker, Falter, 
& Hiemke, 2016) which find that – within individuals - increased doses of clozapine were associated 
with elevated C reactive protein, which is a non-specific marker of inflammation. Similarly, 
Fernandez-Egea et al., (2016) found that while clozapine use was associated with decreased 
numbers of HLA-DR+ regulatory T-cells and CD4+ memory T cells compared to controls, it was also 
associated with increased numbers of NK cells, naïve B cells, CXCR5+ memory T cells and classical 
monocytes.  
The tenth DMP was located within DKK2, a gene encoding a protein which regulates Wnt/beta-
catenin signalling. Wnt signalling involves signal transduction into cells via cell surface receptors; 
there are three Wnt signal transduction pathways which regulate gene transcription (canonical 
pathway), cell shape within the cytoskeleton (non-canonical planer cell polarity pathway) and 
intracellular calcium (non-canonical Wnt calcium pathway). While this DMP was not significant and is 
not indicated to show correlated methylation in blood and brain, clozapine has previously been 
demonstrated to influence Wnt signalling (Sutton, Honardoust, Mouyal, Rajakumar, & Rushlow, 
2007); upregulation of numerous proteins was found in response to clozapine exposure, including 
dishevelled-3 (replicated in vivo and in vitro) which transduces Wnt signalling for canonical and 
planer cell polarity pathways, and is associated with the D2 receptor. DKK2 has also been associated 
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with Alzheimer’s, and it has been suggested (Inestrosa, Montecinos-Oliva, & Fuenzalida, 2012) that 
Wnt signalling dysfunction underlies both these disorders, leading to neurotoxicity of amyloid in 
Alzheimer’s disease and disruption of GABAergic neurons in schizophrenia.  
Four of the top ten DMPs are located within genes involved in regulation of gene expression – 
transcription factors, histone acetyltransferase, mRNA splicing and processes involving the 
nucleobases adenine and guanine – as well as one DMP and several over-represented pathways 
indicating an involvement in regulation of protein modification.   
The most overrepresented pathway associated with time on clozapine was cation homeostasis, 
while another overrepresented pathway was ion homeostasis in general. Cations are positively 
charged ions, and ion transport is critical to action potentials and nerve impulses - mediating 
conduction across the synapse - as well as T cell activation, pancreatic beta-cell insulin release, 
cardiac function and other biological functions. Other over-represented pathways were molecular 
transducer activity and signal transducer activity; signalling cascades through cells to transmit signals 
is critical for cell communication, transcription and translation of genes, post translation protein 
changes, and cell proliferation. Overrepresentation of all these pathways may indicate that a 
consequence of clozapine exposure is modification of synaptic signalling cascades via changes in 
DNA methylation. Animal studies have previously demonstrated the effects of clozapine on signal 
transduction cascades; for example, an animal study (Browning et al., 2005) found that clozapine 
increased phosphorylation in three mitogen-activated protein kinase (MAPK) signal transduction 
pathways which mediate glutamate receptor functioning, which appeared to drive changes in 
behavioural tests of conditioned avoidance response. 
Pathway analysis specifically indicated over-representation of DMPs within G-protein coupled 
receptor activity pathways (GPCRs). GPCRs play a pivotal role in post-receptor information 
transduction; ligands (signalling molecules) bind to the GCPRs, the associated G-protein is then 
activated and the protein’s alpha subunit dissociates from other subunits, exposing the site to 
enable interaction with other molecules. There has been considerable interest in GPCR dysfunction 
in schizophrenia, as there are GPCRs in dopaminergic, serotoninergic, noradrenergic, cholinergic, 
and glutamatergic pathways, all of which have all been implicated in schizophrenia dysfunction 
(Catapano & Manji, 2007). In two 2001 studies by the same team, it was demonstrated that 
untreated patients with schizophrenia have elevated dopamine induced GPCR function and that this 
is correlated with severity of symptoms but patients treated with clozapine (or haloperidol) do not 
display this dysfunction (Avissar, Barki-Harrington, et al., 2001; Avissar, Roitman, & Schreiber, 2001). 
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This suggests that clozapine acts to reduce and normalise GPCR function, and my analysis suggests 
that this could be associated with changes in DNA methylation of relevant genes.  
Pathway analysis also specifically indicated over-representation of DMPs within the alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) selective glutamate receptor complex 
pathway. AMPA receptors (AMPARs) are the most commonly found receptor in the nervous system; 
they are ionotropic transmembrane receptors for glutamate that mediate fast synaptic transmission 
in the CNS and they are integral to long-term potentiation. Over the last couple of decades there has 
been considerable interest in modulating AMPARs as a potential treatment for schizophrenia 
(Danysz, 2002), with numerous patent applications (Ward, Pennicott, & Beswick, 2015), driven by 
post-mortem studies such as Tucholski et al., (2013) which demonstrate increased GluR4 protein 
levels and disrupted regulation and localisation of GluR2, both of which are AMPAR subunits. 
Furthermore, activating AMPARs (and the subsequent depolarisation of the postsynaptic 
membrane) is a prerequisite for activation of NMDA receptors at glutamate synapses, and inhibiting 
AMPAR desensitisation enhances dopamine response; thus abnormalities of AMPARs may result in 
altered NMDA-mediated and dopaminergic transmission, both of which have been found in 
schizophrenia (discussed more later).  
 Studies in rats have indicated that clozapine influences AMPAR function: Schmitt et al., (2003) 
found increased AMPAR binding in the striatum and frontal cortex after 21 days and in the anterior 
cingulate after six months of clozapine exposure, Meador-Woodruff, King, Damask, & Bovenkerk, 
(1996) found altered mRNA levels for AMPAR subunit genes in hippocampus and entorhinal cortex, 
and Healy and Meador-Woodruff, (1997) found altered mRNA levels for AMPAR subunit genes – 
increased GluR7 , decreased GluR3  and decreased GluR4 - in cortex and striatum.  
Pathway analysis implicated the ubiquitin protein system; this system targets proteins for 
degradation, vesicle trafficking, trafficking from the endoplasmic reticulum to plasma membrane, 
and recycling of receptors at cell membrane. Previous genetic studies have associated dysregulation 
of this system with psychosis (Bousman et al., 2010) and a post-mortem study of schizophrenia 
found reductions in protein ubiquitination and numerous associated proteins and ligases (Rubio, 
Wood, Haroutunian, & Meador-Woodruff, 2013); in the latter study, they also tested rats treated 
with haloperidol and found none of these alterations, indicating that antipsychotic treatment may 
normalise this disruption of the ubiquitin protein system.   
Pathway analysis also indicated ATPase activity. ATP, adenosine triphosphate, is a small 
molecule used and continuously recycled as a coenzyme for intracellular transfer, transporting 
chemical energy within cells for metabolism. ATP is used in signal transduction, restoration of cell 
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membrane ion gradients and transcription. A couple of bio-energetic studies have indicated that ATP 
abnormalities may be present in schizophrenia. Du et al., (2014) report abnormal storage and energy 
usage in the prefrontal cortex and a relative increase of glycolysis to ATP synthesis and suggested 
this would have implications for glutamatergic neurotransmission which is the predominant user of 
ATP. Similarly Jayakumar et al., (2010) found that antipsychotic naïve patients had high energy 
metabolism in basal ganglia (indicated by reduced PCr/ATP ratio, as PCr is converted to ATP in ATP 
consumption), which was reduced and normalised by antipsychotic treatment, with increased 
PCr/ATP ratios correlating with greater reductions in symptom severity.   
Finally, the eighth DMP was located within ELP4 which has been associated with epilepsy. This is 
intriguing as there is evidence of a bidirectional risk between epilepsy and schizophrenia (Fruchter et 
al., 2014; Wotton & Goldacre, 2012) and the literature has discussed potential common mechanism 
such as amygdala dysfunction leading to social cognition deficits in schizophrenia and mesial 
temporal lobe epilepsy (Okruszek et al., 2017), or shared glutamate dysfunction in both, with 
neuronal hyperexcitation leading to epileptic seizures and prefrontal receptor reduction involved in 
schizophrenia (Dedeurwaerdere, Boets, Janssens, Lavreysen, & Steckler, 2015). Similarly, one study 
(Vonberg & Bigdeli, 2016) found a positive association between SNPs associated with schizophrenia 
and those associated with epilepsy in GWAS data, suggesting common genetic liability. Furthermore, 
clozapine is known to induce seizures, with one study finding that 1.3% of patients on clozapine in 
the US have had seizures (Pacia & Devinsky, 1994); however, some case reports have found that 
using clozapine in patients with both epilepsy and schizophrenia has reduced seizures instead of 
increasing them as expected (Langosch & Trimble, 2002).  
One caveat to be aware of, for some of the results throughout this thesis, is that – due to the 
small sample size – some of the significant findings may be driven by outliers i.e. cpg sites where one 
individual has a particularly striking change in methylation over the study. cg05195750 is one 
example where, while there seems to be a general trend of increasing methylation, there is one 
participant in particular who may be driving the finding of significance.   
The candidate gene testing provided only weak support for an association between time 
exposed to clozapine and differential methylation at CpG sites on GAD1, GAD67, RELN, GRIN2A, 
GRIN2D, and GRM7; no associations survived correction for multiple testing. However, it may be that 
relevant changes in DNA methylation occur at CpG sites on genes involved in the broader networks 
for these genes. 
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Results from this model provide some replication of the results from previously collected cross-
sectional data, with positively correlated direction of effect for their top DMPs. However, results 
from the cross-sectional data did not provide replication of the results from this model.  
3.5.2 Clozapine level 
Analysis of the association between epigenome-wide DNA methylation and clozapine level 
identified three DMPs that were significant at the epigenome-wide threshold (cg24651966, 
cg11293029, cg13193591), and two hundred and thirty other DMPs which showed trends towards 
significance.  The majority of the top ten DMPs show decreases in methylation associated with 
higher clozapine levels, however higher global DNA methylation was associated with higher 
clozapine levels.   
One of the top ten DMPs was located outside of genes, but of the nine located within genes all 
are expressed in brain tissue to some degree, and six sites are reported to display methylation in 
blood tissue which correlates to methylation in at least one brain region tissue.   
 Again, a high proportion of the biological systems indicated by the top ten DMPs and/or top 
thirty pathways associated with clozapine level have been previously demonstrated to be 
dysfunctional in schizophrenia, and many have also been shown to be influenced by antipsychotics 
including clozapine.  
The top DMP was in BBS12, a gene associated with adipocyte differentiation and, the ninth DMP 
was in PTPRN2, a gene associated with insulin secretion. Adipose tissue plays a crucial role in 
regulating glucose homeostasis, with altered adiposity associated with insulin resistance and 
hyperglycaemia (Rosen & Spiegelman, 2006). This finding is perhaps unsurprising as clozapine is 
known for its metabolic effects and association with type 2 diabetes, discussed further in Adverse 
Reactions to Clozapine and Associated DNA Methylation Changes. Clozapine dose has previously 
been associated with fasting levels of glucose (Wysokiński & Kłoszewska, 2014), and animal studies 
suggest that clozapine stimulates insulin and glucagon secretions and blocks the typical feedback 
loop of increased glucose levels reducing glucagon secretions (Smith et al., 2014). As with the 
immune system, the challenge (particularly for future drug development) is to understand whether 
the effect of clozapine on glucose homeostasis is critical to therapeutic efficacy or a secondary effect 
with no benefit. 
BBS12 is also associated with Bardet-Biedl syndrome 12. This is a ciliopathic genetic disorder 
which causes widespread effects and is primarily characterised by obesity, retinitis pigmentosa, 
polydactyly, hypogonadism and renal failure. Interestingly, a missense mutation on a separate gene - 
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PCM1 – has been found to be associated with schizophrenia as well as Bardet-Biedl syndrome, and 
in mouse brain has been downregulated by clozapine but not haloperidol (Datta et al., 2010).  
The second DMP was located within SLC12A6, a gene that is part of the potassium-chloride 
cotransporter family; these proteins are neuron specific symporters which establish the chloride ion 
gradient by lowering intracellular chloride concentrations, critical for signal transduction which – as 
discussed above – is known to be disrupted in schizophrenia. This family of proteins specifically 
mediates synaptic inhibition and protects against excitotoxicity. PTPRN2, mentioned above, is also 
involved in regulating normal accumulation of neurotransmitters in the brain. Furthermore, the 
tenth DMP is located within C1QTNF1, a gene encoding a GPCR interacting protein, again implicating 
GPCR function.  While not statistically significant or indicated to show correlated methylation 
between brain and blood, the fifth DMP, located within SHISA9 is associated with AMPAR 
desensitisation, and the sixth DMP, located within TRIO which encodes a protein which regulates 
AMPAR synaptic function, also again implicate AMPAR function. Pathway analysis also indicated 
over-representation of DMPs within enzyme-linked receptor protein signalling pathways; enzyme-
linked receptor proteins include a number of neurotrophic factors, such as BDNF which has been 
associated with schizophrenia numerous times. Cumulatively, these results indicate an association 
between clozapine level and DNA methylation of genetic loci involved in numerous aspects of signal 
transduction.  
Pathway analysis indicated overrepresentation of DMPs in regulation of neuronal synaptic 
plasticity as well as cytoskeletal organisation and TOR signalling, which regulates cell growth in 
response to environmental cues. SHISHA9, mentioned above, regulates neuronal synaptic plasticity 
in the dentate gyrus (the section of the hippocampus where progenitors arise and new neuronal 
cells accumulate) and TRIO is also involved in development of hippocampal neurons. Focusing on the 
hippocampus, one of the few areas with continued neurogenesis into adulthood, a significant body 
of evidence from both in vivo and post mortem studies has indicated abnormalities in schizophrenia, 
from the prodromal stage on (Harrison, 2004); in particular, schizophrenia is associated with 
alterations in the organisation and functioning of neural circuits within the hippocampus, and 
connection between the hippocampus and other structures such as the prefrontal cortex. PTPRN2 is 
also specifically involved in hippocampal secretions. The hippocampus is part of the limbic system, 
interacting with numerous structures and receiving input from serotonin, noradrenaline, dopamine, 
and GABA; it plays a critical role in the consolidation of memory, which may be why hippocampal 
dysfunction has a stronger association with neuropsychological impairment than with psychotic 
symptoms (Harrison, 2004). There have been mixed findings for the effect of clozapine on 
hippocampal neurogenesis: some studies have found no effect on hippocampal volume or newly 
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dividing cells (Arango, Buchanan, Breier, MacMahon, & Carpenter, 2003; A Schmitt et al., 2003), 
some have found a short term increase in cell proliferation within the dental gyrus but no survival 
and integration of these newly generated cells (Halim, Weickert, McClintock, Weinberger, & Lipska, 
2004), while others have found an increase in post synaptic protein density and dendritic spine 
density (Critchlow et al., 2006).  
Pathway analysis also indicated regulation of endocytosis, the process of cells interacting with 
environments via control of the lipid and protein composition of the plasma membrane, which has 
been previously linked to schizophrenia; in particular, Schubert, Föcking, Prehn, & Cotter, (2012) 
proposed that dysfunction of clathrin-mediated endocytosis (along with other clathrin-dependent 
processes) could be a core pathology which explains schizophrenia-related alterations in synaptic 
function, white matter and neurodevelopment.   
Pathway analysis indicated tau-protein kinase activity; tau protein kinase is an enzyme which 
catalyses the reaction between ATP (discussed above) and tau protein and it is involved in numerous 
pathways including – among others - Wnt signalling, axon guidance and insulin signalling, all of 
which have been associated with dysfunction in schizophrenia. 
The seventh DMP is located within ENOSF1, a gene encoding antisense RNA and associated with 
gene expression regulation, the eight DMP is within SPAG5, a gene associated with regulation of 
mitotic spindles required for normal chromosome segregation (mitotic spindles are a cytoskeletal 
structure involved in cell division, which are formed of microtubules polymerised from beta-tubulin, 
discussed above), and pathway analysis indicated overrepresentation of chromosome segregation 
and histone acetylation; all indicate regulation of gene expression and chromosomal structure.  
TRIO, mentioned above, has also been associated with intellectual disability. Numerous studies 
have reported associations between schizophrenia and intellectual disability: higher rates of 
schizophrenia within the intellectual disability community (Deb, Thomas, & Bright, 2001; MORGAN & 
Al, 2008), higher rates in relatives of those with intellectual disability (Greenwood, Husted, Bomba, 
Hodgkinson, & Bassett, 2004), and de novo mutations associated with schizophrenia have 
overlapped with genes implicated in intellectual disability and vice versa, indicating a shared genetic 
aetiology (Mccarthy et al., 2014; Rees et al., 2016). Owen, Donovan, Thapar, & Craddock, (2011) 
have proposed a neurodevelopmental hypothesis of schizophrenia linking the two, in which copy 
number variants impact upon brain development and various factors influence the severity and form 
of the impairment guiding individuals towards schizophrenia and/or intellectual disability.  
The candidate gene testing provided only weak support for an association between clozapine 
level and differential methylation at CpG sites on GAD1, RELN GRIN2A, GRIN2D, and GRM7; no 
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associations survived correction for multiple testing. However, there was support for an association 
between clozapine level and a CpG site in the TSS200 promoter region of PVALB, cg19136704. This 
DMP was found to increase in methylation with increased clozapine level. This is one of the few 
positive results for candidate testing within this thesis. PVALB encodes parvalbumin, a calcium 
binding protein present in GABAergic interneurons which is essential for generating high-frequency 
cortical gamma oscillations. Increasing evidence suggests these interneurons are dysfunctional in 
schizophrenia; Stedehouder & Kushner, (2016) present a review outlining some of the findings from 
in vivo, post mortem, rodent model and genetic studies of decreased protein, transcriptional 
changes, EEG abnormalities, abnormal maturation and CNVs implicating parvalbumin interneuron 
dysfunction as the major GABAergic dysfunction in schizophrenia. Similarly Gonzalez-Burgos, Cho, & 
Lewis, (2015) present a review of evidence from clinical, basic neuroscience and post-mortem 
studies implicating parvalbumin interneuron dysfunction in schizophrenia, specifically highlighting 
their role in cognitive and perceptual functions. While clozapine has previously been shown to 
regulate gene expression in rodent models of schizophrenia, the direction of effect in my analysis 
appears to be a different direction of effect to previous reports: Aoyama et al., (2013) had reported 
that clozapine increased prefrontal mRNA expression of PVALB which would typically indicate 
reductions in methylation of promoter regions instead of an increase.  
Results from this model provide some replication of results from previously collected cross-
sectional data, with highly significant negatively correlated direction of effect for their top DMPs. 
Similarly, results from the cross-sectional data provided some replication of the results from my 
longitudinal clozapine levels analysis, with highly significant negatively correlated direction of effect 
for my top DMPs. The negative direction of effect is unexpected: it could indicate low levels of 
clozapine in the cross-sectional sample (blood may have been taken very early in clozapine titration, 
or the sample may have a bias towards patients with low levels of clozapine), or it could reflect 
differing methylation patterns over time (blood may have been taken before six weeks or after six 
months of clozapine exposure, and this may show a different relationship with clozapine level). 
3.5.3 Summary  
To summarise, of the two analyses, one epigenome-wide significant hit came from the time on 
clozapine model - cg23892310, located in the gene body of TBCD (involved in beta tubulin)- while 
three epigenome-wide significant hits came from the clozapine levels model - cg24651966 which is 
located within the gene body of BBS12 (associated with adipocyte differentiation), cg11293029 
which is located within the TSS1500 region of SLC12A6 (a neuron specific potassium chloride 
cotransporter which establishes chloride ion gradients for signal transduction), and cg13193591 
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which is located outside of any genes. The only candidate gene hit was in the clozapine levels model 
– an increase in methylation at cg19136704 in PVALB.  Also, the top regression coefficients from the 
levels model were significantly associated with previous cross-sectional data on clozapine exposure – 
whereas the time model was not associated – though this was a negative association, and it is 
unclear what this means. Overall this indicates a stronger relationship between changes in DNA 
methylation and clozapine level than time on clozapine. 
While no individual DMPs overlapped, some of the same biological systems were implicated in 
both analyses – signal transduction, especially ion function, GPCRs, AMPAR, immune function and 
regulation of gene expression and chromosomal organisation – all of which have been implicated in 
the pathology of schizophrenia, and the majority of which have been previously indicated to be 
affected by clozapine use. In the time model, the majority of top ranked DMPs showed increases in 
methylation or initial decreases then increases and this was true globally; in contrast, in the levels 
model, the majority of top ranked DMPs showed decreases in methylation, whereas globally there 
were still increases. The lack of direct overlap in individual DMPs and differing direction of 
methylation changes indicates that these analyses were measuring different variables – the analysis 
of time on clozapine is telling us about associations with the length of time exposed to clozapine 
whereas the analysis of clozapine level is telling us about associations with the amount of clozapine 
individuals are exposed to - and indeed, after baseline, clozapine level was not correlated with time 
on clozapine, so we should not necessarily expect a direct overlap.   
Of course, these are still not independent analyses and cannot act as replications of one 
another. Instead, these two analyses are intended to complement one another as different 
measures of clozapine exposure, with shared results indicating trajectories of change which are not 
associated solely with time passing but also directly associated with clozapine levels. Clozapine 
exposure appears to lead to changes in DNA methylation of genes involved in signal transduction, 
receptor function, immune function and gene regulation, which may lead to altered protein 
production and functional changes in these systems.  
However, one of the challenges in studying clozapine is that clozapine is known to have 
incredibly wide ranging effects and interactions and not all of these will be relevant to their 
therapeutic effect; some may be relevant to their undesired adverse outcomes, or some may be 
completely irrelevant. Therefore, analysis which focuses on changes which are associated with 
clinical outcomes is necessary. In the next chapter, I present my analysis on changes in DNA 
methylation associated with numerous measures of therapeutic response.  
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4  Therapeutic Response to Clozapine and Associated DNA Methylation Changes 
4.1 Background: Therapeutic response to clozapine 
Before reporting on my analysis investigating changes in DNA methylation associated with 
therapeutic response to clozapine, I will explore in greater depth previous research on clozapine 
response. First I will discuss the issue of defining response to clozapine. I will then move on to a 
review of literature on physiological changes and genetic predictors associated with clozapine 
response, based on a systematic review I co-conducted.  
4.1.1 Defining response to clozapine 
One of the first challenges encountered when studying therapeutic response to antipsychotics is 
the heterogeneity in approaches to measuring response. Two systematic literature reviews I 
conducted demonstrate this, and highlight that there are two core areas of discussion. 
Firstly, which symptoms or outcome should be measured as a measure of response? In a review 
of all studies reporting on prospective predictors of clozapine response (Appendix III) the most 
commonly used primary outcome measure was the Brief Psychiatric Rating Scale (BPRS), however 
nine other measures were also used (in order of prevalence), with different focuses on positive or 
negative symptoms: Global Assessment of Functioning Scale (GAF/GAS), Clinical Global Impression 
(CGI),  Positive and Negative Syndrome Scale (PANSS), Scale for the Assessment of Negative 
Symptoms (SANS), Scale for Assessment of Positive Symptoms (SAPS),  Bunney-Hamburg Global 
Psychosis Rating, Schedule for Affective Disorders and Schizophrenia-Lifetime (SADS-L1), a positive 
symptom subscale (BPOS), a negative symptom subscale (BNEG), and two non-specific clinical 
interviews.  
More broadly, some argue we should shift to a focus on functionality which is often prioritised 
by the patient and carers or loved ones; however, this has less established forms of measurement. It 
is unclear how this relates to symptom severity; whether there is a threshold above which 
functionality is impossible, or below which functionality is inevitable. One option is studying 
pragmatic outcomes. In a review that I conducted of studies comparing treatment-resistant and 
treatment-responsive patients (Gillespie et al., 2017) some definitions of responsiveness required 
discharge from hospital. Another option is time to discontinuation or rehospitalisation, though one 
could argue this is a negative approach predicated on the expectation of relapse rather than hopeful 
for improvement. Similarly, cognition is increasingly being recognised as critical to recovery and 
functional outcomes, but as cognitive deficits are rarely addressed with antipsychotic treatment and 
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do not abate with episodes in the way that psychotic symptoms do, there lacks an evidence base for 
defining remission via cognitive improvement.  
Secondly, should we measure change from baseline, or the passing of a threshold (which may be 
defined as remission)? Both of the above reviews found a range of approaches; a percentage 
reduction was the most common criteria for being deemed responsive, though some specified 
absolute threshold alternatively or additional (e.g. BPRS total scores ≤35). There are also decisions 
about whether to study response as a continuous variable or a categorical variable and, if a 
categorical variable, where to draw the line between who is classified a responder and who is 
classified a non-responder. For just the BPRS, the percentage change threshold for demonstrating 
response varied from 15-50%, though 20% was the most common. Opinions also differ on when 
response should be classified: the length of the clozapine trial before classifying response similarly 
varied from as low as three weeks to sixteen months.  
A review (Suzuki, Uchida, Watanabe, & Kashima, 2011) specifically focused on response to 
specific antipsychotic trials in the context of treatment-resistant schizophrenia proposed that 
treatment response should be defined “based on a CGI-Change score of ≤ 2, a ≥ 20% decrease on the 
total PANSS or Brief Psychiatric Rating Scale (BPRS) scores, and an increase of ≥ 20 points on the 
FACT-Sz or GAF.” This definition is largely based on previous studies, especially landmark ones such 
as the original one by Kane in 1988, building upon what is common to allow cross-study comparison.  
They justify their choice to stick with percentage reduction as most appropriate for treatment-
resistant patients; in contrast to first-episode patients, absolute remission is very rare and the 
percentage reduction approach allows a reasonable number of patients to be classified as 
responders which is necessary for group comparisons. Moreover, studying change from baseline 
prevents patients who are simply less symptomatic being classified as responders because they are 
close to the threshold for response and can pass this without showing a notable response to 
medication.  
They also stress the importance of considering what can be realistically expected to change 
within the chosen time frame and suggest that this is why there has been a focus on positive 
symptoms, as these are known to be more amenable to measurable, rapid change in response to 
antipsychotics. They advocate for 6-week trials, based upon evidence that improvements can be 
seen in the early stages, though note that it can take longer for a clear response to be observed and 
that this may be particularly true in refractory patients.  
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4.1.2 Physiological changes associated with response to clozapine 
Note: This section is based on a systematic review I co-conducted and which has been submitted 
for publication. See Appendix III for details on methodology.  
A number of studies have measured physiological variables and symptoms before the initiation 
of clozapine as well as after a period of clozapine treatment, allowing measurement of changes 
associated with response to clozapine, however the findings are mixed. 
A couple of studies have looked at perfusion, with Ertugrul et al., (2009) reporting that across 
patients there was an increase in right frontal/caudate perfusion ratio, but in responders to 
clozapine there was an increase in ratio bilaterally with greater increases in bilateral frontal 
perfusion. Across patients there was also increases NAA/Cr ratio in the DLPFC. However, Rodriguez 
et al., (1997) found that responders to clozapine showed decreases in perfusion not only in the 
thalamus and basal ganglia but also dorsolateral prefrontal cortex and anterior pre-frontal cortex.   
Regarding neurotransmitter metabolites, Szymanski et al., (1993) reports no significant change 
in cerebrospinal fluid measures of HVA or 5-HIAA over the length of clozapine treatment- though an 
increase in the former and decrease in the latter can be observed, and the ratio seems to be 
significant, with a greater change in the ratio over treatment associated with response to clozapine. 
However, Pickar et al., (1992) reports decreases in HVA, particularly for responders (alongside 
decreases cortisol, and increases in prolactin and noradrenaline) and Green et al., (1993) also 
reports that HVA decrease in responders (while plasma dopamine and noradrenaline increase in all 
patients during clozapine treatment).  In addition, Fleischhaker, Schulz and Remschmidt (1998) 
report increased serum serotonin and noradrenaline in all patients, and increased MHPG and 
noradrenaline in responders, and Evins et al., (1997) report increases in glutamate and aspartate 
after clozapine treatment, with the latter associated with improvements in negative symptoms. 
Ertugrul et al., (2007) report increases in monoamine oxidase B MAO-B and plasma serotonin, but 
decreases in platelet serotonin, highlighting the relevance of the tissue used to measure. However, 
many of these are small samples, with all bar one n<21. 
In summary, there are a lack of studies measuring longitudinal changes associated with 
clozapine response and those which have been conducted indicate potential longitudinal changes in 
perfusion, HVA, serotonin, MHPG, cortisol norepinephrine, glutamate, and aspartate associated with 
clozapine response but there is little consistency or replication.  
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4.1.3 Genetic variation associated with response to clozapine 
Note: This section is based on a systematic review I co-conducted and which was published after 
thesis submission and before corrections (Samanaite, Gillespie et al, 2018). See Appendix III for 
details on methodology.  
While the identification of genetic variants associated with clinical outcomes in response to 
clozapine does not directly tell us about what changes are occurring during clozapine treatment that 
are associated with clinical outcomes, they can direct us towards genomic locations and (more 
generally) biological pathways in which we might expect changes to be occurring. In particular, 
genes associated with response to clozapine are prime candidates for where we may expect to see 
differential DNA methylation, as clozapine interacts with the expression of these genes. Below 
outlines the adapted results of a systematic review I conducted in collaboration with a colleague, 
identifying all gene-association studies of clozapine response. 
The sixty-one studies identified included analysis of two-hundred-and-fifty-nine different gene 
variants. Two-hundred-and-forty-two of these were SNPs, sixteen were repeats or small 
insertion/deletions and one was a large chromosomal deletion (22q11.2). All of the identified studies 
took a candidate-gene approach, therefore suffering from the limitations described in the 
introduction to this thesis; no GWAS were identified.  
Out of the two-hundred-and-fifty-nine different genetic variants studied, thirty-seven variants 
(14%) have had significant findings, and eight of these have been replicated. Six of these eight 
replications were by an independent research group, but four of those six have also had failed 
replications. I limit comment to findings with at least one replication, as those without replication 
are at increased likelihood of being spurious findings. The details for all genetic studies, including 
those with non-significant or non-replicated findings, are provided in the appendices to the 
publication.    
Twelve SNPs within the DRD3 gene, encoding the D3 dopamine receptor, have been investigated 
in eight studies. Six studies only investigated the Ser9Gly polymorphism of rs6280 (Arranz et al., 
2000; Barlas et al., 2009; Hwang et al., 2010; Malhotra et al., 1998; Potkin et al., 2003; Scharfetter et 
al., 1999; Shaikh et al., 1996; Xu et al., 2016) but Hwang et al., (2010) also reported on eight other 
SNPs in DRD3 and Xu et al. reported on an additional three others. While two studies independently 
replicated a finding of the Gly allele of the Ser9Gly polymorphism being associated with good 
response to clozapine (Scharfetter et al., 1999; Shaikh et al., 1996), all six subsequent studies found 
non-significant results. 
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Dopamine receptors are prevalent throughout the central nervous system. They are a class of G-
protein-coupled receptors meaning their activity is mediated by G-proteins which inhibit adenylyl 
cyclase. There are five types (D1-D5), each encoded by different genes. The DRD3 gene encodes the 
D3 subtype, which is localised to limbic areas of the brain with maximum expression in the ventral 
striatum and nucleus accumbens, and associated with cognitive, emotional and endocrine functions. 
DRD3 mediates inhibitory neurotransmission and has strong affinity for both first and second 
generation antipsychotic drugs. The DRD3 gene is located on chromosome 3 and contains five exons. 
This gene can be alternative spliced resulting in multiple transcript variants encoding different 
isoforms, some of which would decay via nonsense-mediated decay. The Ser9Gly polymorphism is a 
single nucleotide polymorphism (rs6280) in exon 1 which can result in a serine-glycine substitution in 
the N terminus (codon 9) of the gene.  
Five SNPS within 5-HTR2A have been investigated in ten studies. The His allele of His452Tyr has 
been associated with good response to clozapine in four studies by two research groups (Arranz, 
Collier, Munro, & Sham, 1996; Arranz et al., 1998, 2000; Masellis et al., 1998). Two studies did not 
detect this association (Malhotra et al., 1996; Nöthen et al., 1995).  The T allele of T102C has also 
been associated with good response to clozapine in three studies by a single research group (Arranz 
et al., 1995, 2000; Sodhi et al., 1995); however, five studies by other groups have failed to replicate 
these findings (Lin et al., 1999; Malhotra et al., 1996; Masellis et al., 1998; Nöthen et al., 1995; 
Potkin et al., 2003). The G-1438A SNP has also been shown to significantly predict clozapine 
response in two studies by the same group (Arranz et al., 2000; Arranz, Munro, & Owen, 1998). 
Again, there is no independent replication, with null findings reported in the second sample analysed 
by the same research group and from an independent research group (Masellis et al., 1998). 
The 5HTR2A receptor is a subtype of the 5HT2 receptor, the main excitatory receptor subtype 
among the serotonin receptors, and is another G-protein-coupled receptor. When stimulated, the G-
protein subunits dissociate to imitate downstream effects. It enhances glutamate release, as well as 
having a complex range of interactions with the 5-HT1A, GABA, adenosine A1, AMPA, GluR2/3, 
mGlu5, and OX2 receptors. The receptor is encoded by the 5-HTR2A gene, located on chromosome 
13, which includes three exons and two intros, with four transcription initiation sites and two 
alternative promoters, with a silencer element downstream from the second promoter element. It is 
expressed widely throughout the central nervous system, particularly the prefrontal, parietal and 
somatosensory cortex. The gene has over 250 polymorphisms, many of scientific interest, including 
His452Tyr (rs6314). His452Tyr is a SNP on exon 3 of the gene which can change between a C and a T, 
resulting in a missense substitution – switching between histidine and tyrosine.  
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Four SNPS within 5-HTR3A have been studied; the only SNP which has been studied twice is 
rs1062613, but one study found that good response to clozapine was associated with the T allele 
(Rajkumar et al., 2012) while the other found that good clozapine response was associated with the 
C allele (Souza, de Luca, Meltzer, Lieberman, & Kennedy, 2010) 
Five SNPs within the 5HTT (or SLC6A4) gene have been investigated in four studies by four 
independent groups , with the only independently replicated finding for an association of the 
HTTLPR polymorphism at rs25531 with clozapine response; Kohlrausch et al., (2010) found an 
association between good response and the long allele, but M. J. Arranz et al., (2000) do not report 
the direction of effect. 
5-HTT is the sodium-dependent serotonin transporter, a monoamine transporter protein that 
transports serotonin to the presynaptic neurons from the synaptic cleft - thus terminating the action 
of serotonin - and recycles it. To function properly it requires membrane potential created by 
sodium-potassium adenosine triphosphates and therefore is dependent upon the concentration of 
potassium ion in the cytoplasm and the concentrations of sodium and chloride ions in the 
extracellular. It is encoded by the SLC6A4 gene. The 5-HTTLPR polymorphism at rs25531 is a 
degenerate repeat polymorphism within the promoter region of this gene. It is often repeated as the 
short or long variant, but it can be subdivided further, with one study identifying 14 allelic variants.  
The only other replicated finding is an association between the C allele of the C825T 
polymorphism in the G-protein-beta 3 (GNB3) gene and good clozapine response in two studies 
conducted by independent research groups (Kohlrausch et al., 2008; Müller et al., 2005). G-proteins 
intracellularly couple with most monoaminergic receptors and, upon receptor occupancy, activate to 
pass on information, integrating signals between these receptors and effector proteins which 
regulate protein activity; they are essential to converting external receptor signals into intracellular 
response. G-proteins are composed of an alpha, beta and gamma subunit, which are encoded by 
related genes, with the GNB3 gene encoding a beta subunit which regulates alpha subunits. C825T is 
a single nucleotide polymorphism in exon 10 of the GNB3 gene, and the T allele has been associated 
with a splice variant causing deletion of nucleotides in exon 9 and subsequent loss of amino acids 
within highly conserved gene units. This shorter protein is associated with increased intracellular 
signalling.  
This polymorphism has also been studied in relationship to antipsychotic induced weight gain, 
with findings that the T allele is associated with higher cholesterol in Japanese participants (Ishikawa 
et al., 2000). One meta-analysis of three published and two unpublished studies, cumulatively 
including 402 patients, found that the T allele had a trend for association with increased weight gain 
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under a fixed-effects model, but when analysed under a random-effects model to account for 
significant heterogeneity, no significant association was found, even at a trend level (Souza et al., 
2008). The five studies used samples from different ethnic populations, but stratifying by ethnicity 
did not reveal any significant associations either. They also conducted a much larger analysis of 
association with BMI in a non-psychiatric population, but similarly only found a trend under a fixed 
model, though this was in the same direction. Since then, one study of olanzapine use found an 
association with weight gain but another did not (Bishop, Ellingrod, Moline, & Miller, 2006; Park et 
al., 2009). 
Two studies have found significant gene-gene interactions (Hwang et al., 2011; Souza, Romano-
Silva, et al., 2010) and seven have found significant haplotypes (Hwang et al., 2010; Hwang et al., 
2005, 2006, 2007; Mitjans et al., 2015; Souza, et al., 2010), but none of these have been reported on 
more than once and therefore remain unreplicated.  
4.1.3.1 Summary of genetic variation associated with response to clozapine 
Despite numerous studies associating genetic polymorphisms with clozapine response there has 
been little replication in independent cohorts and from independent research groups. Those 
conducted have mainly focused on polymorphisms within genes encoding dopamine or 5-HT 
receptors, with some significant findings. Many studies also investigated SNPs in relatively small 
patient samples for genetic studies.  Of the two-hundred-and-fifty-nine polymorphisms investigated 
in relation to clozapine response a priori, replication by two or more independent research groups is 
available for the DRD3 Ser9Gly, 5HTR2A His452Tyr, 5HTT rs25531, and GNB3 C825T SNPs.  
However, findings of no association with clozapine response were also reported for DRD3, 
5HTR2A His452Tyr and no findings were replicated by more than two independent groups. This 
starkly highlights the previously mentioned issues regarding candidate gene studies. In contrast to 
analysis investigating only single variants, a combination of six polymorphisms (T102C and His452Tyr 
of HTR2A gene, G-330T/ C-244T repeat and Cys23Ser of HTR2C gene, HTTLPR of SLC6A4 gene, G-
1018A of HRH1) predicted clozapine response with the retrospective positive predictive value of 
76.7% and a sensitivity of 95% (Arranz et al., 2000) on which basis a pharmacogenetic test was 
developed, although it is no longer available. Since the majority of these studies were done, 
technology has advanced to GWAS. While this approach is beginning to be applied to identify SNPs 
contributing to response to non-clozapine antipsychotics, GWAS of clozapine response have yet 
been published. 
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4.1.4 Epigenetic variation associated with response to clozapine 
The only published study which has previously analysed epigenetic variation associated with 
response to clozapine was described above (Kinoshita et al., 2017). The methodological and 
analytical concerns raised above should again be borne in mind when interpreting these results, but 
they report finding an association between increased DNA methylation of the CREBBP (CREB binding 
protein) gene at cg05151055 and greater clinical improvement in response to clozapine, measured 
by reduction in PANSS as a continuous variable. The authors noted that CREBBP is a protein involved 
in histone acetyltransferase activity as well as stabilising protein interactions within the transcription 
complex, and pathway analysis of GWAS data has been previously associated genetic variation of 
CREBBP with schizophrenia symptoms and cognition.  
 In my analysis, as well as investigating associations with change in PANSS as a continuous 
variable, I also investigate associations with categorical classification of responders and non-
responders to clozapine, change in psychosocial functioning and quality of life, and associations with 
within-individual variations in total, positive and negative symptoms. I will now outline these 
analyses and their results.    
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4.2 Statistical method: Therapeutic response to clozapine 
To explore associations with therapeutic response to clozapine, I took two broad approaches. 
Firstly, I analysed change in clinical presentation at twelve weeks in four ways, all of which compared 
participants on measures of improvement in response to clozapine at follow up to investigate if this 
was associated with different trajectories in DNA methylation: 
1) Between-individual classification of responder or non-responder to clozapine (categorical) 
as a predictor of DNA methylation trajectories over time 
Classification of responder or non-responder: responders had a >20% decrease in their baseline 
PANSS Total score at twelve week follow-up. 
2) Between-individual variation in total symptom severity change between baseline and 
follow up (continuous) as a predictor of DNA methylation trajectories over time 
Total symptom severity change: percentage change in PANSS Total score between baseline and 
twelve week follow up was the measure of total symptom severity change. Negative percentages 
indicate improvement. 
3) Between-individual variation in psychosocial functioning change between baseline and 
follow up (continuous) as a predictor of DNA methylation trajectories over time 
Psychosocial functioning change: percentage change in PSP score between baseline and twelve week 
follow up was the measure of psychosocial functioning change. Positive percentages indicate 
improvement. 
4) Between-individual variation in quality of life change between baseline and follow up 
(continuous) as a predictor of DNA methylation trajectories over time 
Quality of life change: percentage change in GAF score between baseline and twelve week follow up 
was the measure of quality of life change. Positive percentages indicate improvement. 
 
Secondly, I analysed variation in symptom severity over the study period in three ways, all of 
which assessed whether fluctuations in symptom severity within individuals on clozapine are 
associated with differing DNA methylation:  
1) Within-individual variation in total symptom severity as a predictor of DNA methylation 
Total symptom severity: PANSS Total score was the measure of total symptom severity at all time 
points with a clinical assessment. 
Therapeutic Response to Clozapine and Associated DNA Methylation Changes 
- 125 - 
 
2) Within-individual variation in positive symptom severity as a predictor of DNA 
methylation 
Positive symptom severity: PANSS Positive score was the measure of positive symptom severity at all 
time points with a clinical assessment. 
3) Within-individual variation in negative symptom severity as a predictor of DNA 
methylation 
Negative symptom severity: PANSS Negative score was the measure of negative symptom severity at 
all time points with a clinical assessment. 
To identify DNA methylation changes associated with therapeutic response to clozapine, I 
conducted mixed model regression analyses using lmer.  
For the prediction of different methylation trajectories between individuals with different 
changes in clinical presentation between baseline and twelve weeks, the interaction between 
response group or change in total symptom severity/psychosocial functioning/quality of life and 
weeks on clozapine was used a predictor of methylation at each CpG sites. These models controlled 
for baseline age, sex, predicted cell counts (CD8T, CD4T, NK, B, granulocytes and monocytes), 
smoking at time of sample collection (yes/no), chip ID, previous medications (number of prior 
atypical antipsychotics, number of prior typical antipsychotics, number of prior benzodiazepines or 
other mood stabilisers) and current medications (number of current antipsychotics, number of 
current benzodiazepines or other mood stabilisers, number of current antidepressants), as well as 
controlling for the repeated measures from individual participants as a random effect.  
These analyses all produced a model with regression coefficients for each CpG site - representing 
the percentage change in methylation at the CpG site associated with an additional week on 
clozapine for non-responders / those with an additional improvement at twelve weeks – as well as a 
p value for the significance of this association.  
For the prediction of differential methylation within individuals due to variation in symptom 
severity across time points, symptom severity (total/positive/negative) was used as a predictor of 
methylation at each CpG site. There models controlled for baseline age, sex, predicted cell counts 
(CD8T, CD4T, NK, B, granulocytes and monocytes), smoking at time of sample collection, chip ID, 
current medications (number of antipsychotics, benzodiazepines or other mood stabilisers, 
antidepressants, hyoscine, metformin, laxatives), number of total prior antipsychotics, as well as 
controlling for the repeated measures from individual participants. 
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These analyses all produced a model with regression coefficients for each CpG site - representing 
the percentage change in methylation associated with an additional increase in symptom severity – 
as well as a p value for the significance of this association.  
For each model, I report global DNA methylation and differentially methylated positions (DMPs). 
Pathway analysis is also conducted for the between-participant categorical response model and the 
within-participant total symptom severity model. All of this is conducted as described in the previous 
chapter (Statistical method: Exposure to clozapine).  
Additionally, the categorical response model regression coefficients are used for candidate site 
testing and comparison to the cross-sectional dataset.  
Candidate CpG site methylation: Based on previous literature investigating independent 
replication of genes associated with response to clozapine (Chapter 4.1.3) and one study 
investigating genes with CpG sites associated with response to clozapine (Kinoshita et al., 2017), I 
identified five genes which have been associated with clozapine exposure: DRD3, 5HTR2A, 
5HTT/SLC6A4, GNB3 and CREBBP. In total, there were 118 CpG sites for these genes included in the 
450k assay which passed QC. To account for multiple-comparisons, the adjusted p value is 0.05/118 
= 0.000424. 
Comparison to cross-sectional data: I then compared the results of the model of categorical 
clozapine response from my longitudinal dataset to results from the previous dataset of cross-
sectional clozapine exposure, firstly to explore whether the cross-sectional model was validated by 
the longitudinal model, and then to explore whether the longitudinal model was validated by the 
cross-sectional model.  To investigate replication of findings from the cross-sectional model, I took 
all the top DMPs with a p value < 5*10-5 from the cross-sectional model and ran a correlation 
analysis on the regression coefficients from the cross-sectional model for these top DMPs and the 
regression coefficients from one of the longitudinal models for these DMPs; this was to establish if 
there was the same direction of effect for DMPs in both cohorts (i.e. if methylation was higher in the 
clozapine exposed group from the cross-sectional dataset, was there an additional increase or 
decrease in  methylation for non-responders in the longitudinal dataset). To investigate replication 
of findings from the longitudinal model of categorical clozapine response, I took all the top DMPs 
with a p value < 5*10-5 from the longitudinal model and ran a correlation analysis on the regression 
coefficients from the longitudinal model for these top DMPs and the regression coefficients from the 
cross-sectional model for these DMPs; again, this was to establish if there was the same direction of 
effect for DMPs in both cohorts (i.e. if there was an additional increase in methylation for non-
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responders in the longitudinal dataset, was methylation higher or lower in the clozapine exposed 
group from the cross-sectional dataset). 
The results for each analysis model are reported separately. First I will report the results for each 
between-participant models based on percentage change at twelve weeks - categorical classification 
of responder vs non-responder, change in total symptoms, change in psychosocial functioning, and 
then change in quality of life. Then I will report the results for each within-participant model of 
variation in symptom severity - total symptoms, positive symptoms and negative symptoms.  
 
  
Therapeutic Response to Clozapine and Associated DNA Methylation Changes 
- 128 - 
 
4.3 Results: Percentage change in response to clozapine (between-individuals) 
4.3.1 Responders vs non-responders (categorical) 
4.3.1.1 Participant characteristics 
Twelve weeks after clozapine initiation, ten participants were classified as responders to 
clozapine and twelve participants classified as non-responders. The characteristics of each group are 
compared in Table 6, with key details represented in subsequent pie charts (Figure 7): compared to 
responders, non-responders were more likely to be male, be white, have a diagnosis of paranoid 
schizophrenia, have not been previously exposed to clozapine, experience predominantly negative 
symptoms at baseline, experience drowsiness and cardiovascular symptoms, and not experience 
increased appetite/weight. Non-responders also had higher clozapine levels at twelve weeks (0.461 
vs 0.342, p=0.09), and (when baseline samples are excluded) show fairly stable high levels of 
clozapine whereas responder start with lower levels which increase over time. However, none of 
these differences were statistically significant. 
 Both groups show mean decreases in symptom severity over time, though the decreases at 
twelve weeks are smaller in non-responders and looking specifically at negative symptoms, non-
responders show no decrease while responders show large decreases (-34.295% vs -3.686% total 
symptoms p<0.0001, -36.201% vs -13.142% positive symptoms p=0.042, -26.476% vs 2.668% 
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Table 6: Characteristics of responders to clozapine vs non-responders 
  Responders Non-
Responders 
 
Age (years) Mean 38.77 36.99 p=.726 
Minimum 19.94 21.08 
Maximum 50.46 61.38 
Gender Male 7 10 p=.816 
Female 3 2 
Ethnicity White 4 6 p=.267 
Black 6 4 
Asian 0 2 
Diagnosis Schizophrenia 8 11 p=.865 
Schizoaffective 
disorder 2 1 
Months between diagnosis of 
treatment-resistance and 
clozapine start 
Mean 24.78 29.10 p=.805 
Minimum 0 0 
Maximum 100 111 
Inpatient Psychiatric 
Admissions 
Mean 4.20 2.92 p=.371 
Minimum 0 0 
Maximum 10 7 
Psychiatric Comorbidities Affective 1 1 p=.974 
Anxiety 1 1 
Substance Abuse 1 2 
None 7 8 
Prior Clozapine Exposure Yes 3 2 p=.816 
No 7 10 
Number of prior typical 
antipsychotics 
Mean 1.1 0.5 p=.08 
Minimum 0 0 
Maximum 2 1 
Number of prior atypical 
antipsychotics 
Mean 3.1 2.75 p=.599 
Minimum 1 1 
Maximum 7 4 
Number of prior mood 
stabilisers 
Mean 0.2 0.25 p=.792 
Minimum 0 0 
Maximum 1 1 
Smoker at baseline Yes 1 2 p=1 
No 9 10 
Smoker at any time-point 
during study 
Yes 3 4 p=1 
No 7 8 
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Baseline PANSS Total Mean 78.3 78.3 p=.997 
Minimum 54 55 
Maximum 105 119 
Baseline PANSS Positive Mean 20.10 19.13 p=.709 
Minimum 9 12 
Maximum 26 36 
Baseline PANSS Negative Mean 20.70 22.83 p=.531 
Minimum 9 17 
Maximum 39 30 
Predominant Baseline 
Symptoms 
Positive 5 2 p=.226 
Negative 5 10 
12w PANSS Total Mean 50.33 74.18 p=.001* 
Minimum 35 57 
Maximum 74 98 
6m PANSS Total Mean 51 69.55 p<.007* 
Minimum 37 44 
Maximum 72 97 
PANSS % Change at 12w Mean -34.30 -3.69 p<0.001* 
Minimum -53.57 -17.65 
Maximum -21.33 26.47 
PSP % Change at 12w Mean 39.33 21.33 p=.49 
Minimum -50 -47.73 
Maximum 160 162.50 
GAF % Change at 12w Mean 70.50 11.97 p<.01* 
Minimum -8.33 -25 
Maximum 185.71 29.03 
Increased appetite/weight at 
12w 
Yes 8 5 p=.167 
No 2 7 
Cardiovascular symptoms at 
12w 
Yes 1 3 p=.724 
No 9 9 
Drowsiness at 12w Yes 8 7 p=.531 
No 2 5 
Clozapine Levels at 12w Mean 0.34 0.46 p=.095 
Minimum 0.21 0.28 
Maximum 0.50 0.75 
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4.3.1.2 Global DNA methylation (Responders vs non-responders) 
Being a non-responder was associated with higher levels of global DNA methylation over time. 
For non-responders, an additional week on clozapine was associated with an average additional 
increase in global DNA methylation of 0.211x10-3 %. 50.31% of all CpG sites showed an additional 
increase in methylation associated with time exposed to clozapine for non-responders and 49.68% 
of all CpG sites showed a decrease.  
Moreover, when exploring individual time points, split by response: at baseline, mean global 
DNA methylation was 48.286% for responders and 48.284% for non-responders; at six weeks, mean 
global DNA methylation was 48.277% for responders and 48.236% for non-responders; at twelve 
weeks mean global DNA methylation was 48.292% for responders and 48.286% for non-responders; 
and at six months mean global DNA methylation was 48.294% for responders and 48.293% for non-
responders. Both groups start and end with equivalent levels of global DNA methylation and show 
the same pattern of an initial decrease and then increases, however the graph below shows the 
initial decrease is more pronounced for non-responders. 
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4.3.1.3 Differentially methylated positions (responders vs non-responders) 
Two DMPs reached the threshold for epigenome wide significance (p<1*10-7), while one 
hundred and sixty eight other DMPs were trend-level significant (p<5*10-5).  
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Table 7: Top ten DMPs associated with categorical response to clozapine classification (* indicates epigenome wide significance) 
CpG site Beta P value 
 
Mean methylation Gene Location MAPINFO Significant blood-brain 
methylation correlation 
reported? Baseline Six weeks Twelve weeks Six months 








NR: 71.23 DPP4 Body 162915902 
N 
cg18043267 0.202 x10-2 8.59E-08* 
R: 17.17 
NR: 15.58 
R: 15.67 R: 17.25 
NR: 17.27 
R: 16.93 
NR: 19.49 C10orf125 Body 135170752 
N 








NR: 68.86   199827580 
N 








NR: 81.50 ANKRD11 Body 89352529 
N 








NR: 26.94 MYEOV TSS200 69061454 
N 








NR: 12.21 ABCG1 Body 43652704 
Y – prefrontal cortex and 
entorhinal cortex 








NR: 8.62 PCDP1 TSS1500 120301779 
N 








NR: 40.49 DLG4 Body 7117160 
N 








NR: 75.85 LCN10 TSS1500 139637747 
N 









KCNK9 Body 140643009 
Y – prefrontal cortex, 
entorhinal cortex, superior 
temporal gyrus 
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The most statistically significant DMP associated with non-response to clozapine was 
cg15353603. For non-responders, each additional week exposed to clozapine was associated with an 
additional decrease in methylation at this site of 0.192% compared to responders (p=0.6x10-8). 
Uncorrected means show an average baseline methylation of 73.24% for responders and 73.82% for 
non-responders, 77.08% and 76.41% at six weeks, 74.43% and 73.49% at twelve weeks, and 74.85% 
and 71.23% at six months. In other words, responders and non-responders start off with similar 
levels of methylation but responders show an increase which tempers off but remains higher at the 
end of six months than at baseline, whereas non-responders show a smaller increase initially and 
then a decrease which means they end up with lower levels of methylation than at baseline.
 
cg15353603 is located in the gene body of DPP4, which encodes dipeptidyl peptidase 4/ cell 
surface antigen CD26. This gene is located on chromosome 2 and is expressed across numerous 
tissues including brain, with overexpression of mRNA in small intense, kidney and prostate and 
overexpression of protein in serum, pancreas, placenta, urine and saliva. Dipeptidyl Peptidase 4 is a 
type II transmembrane enzymatic glycoprotein implicated in pancreatic disease, incretin synthesis 
secretion and inactivation, glucose homeostasis, protein digestion and absorption, cardiovascular 
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disease, tumour biology, obesity and receptor binding and signalling.  It is also associated with 
immune regulation as it is essential for T-cell-receptor mediated T-cell activation and acts as a 
positive regulator of T-cell co-activation, induces T-cell proliferation, and regulates lymphocyte-
epithelial cell adhesion. DPP4 inhibitors are used for the treatment of type 2 diabetes. This CpG site 
is reported to show no correlation between methylation in blood and methylation in brain tissue. 
The second most statistically significant DMP associated with non-response to clozapine was 
cg18043267. For non-responders, each additional week exposed to clozapine was associated with an 
additional increase in methylation at this site of 0.202% compared to responders (p=0.9x10-7). 
Uncorrected means show an average baseline methylation of 17.174% for responders and 15.580% 
for non-responders, 15.670% and 15.701% at six weeks, 17.247% and 17.271% at twelve weeks, and 
16.925% and 19.488% at six months. Responders show a decrease initially and then an increase 
taking them above baseline and then a final decrease ending below initial levels of methylation, 
while non-responders start at a lower level of methylation and this increases over time ending up 
higher than responders at any time point.  
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cg18043267 is located in the gene body of C10orf125 or FUOM, which encodes fucose 
mutarotase. This gene is located on chromosome 10 and is expressed across numerous tissues 
including brain, with overexpression of mRNA in liver and kidney and overexpression of protein in 
liver and gall bladder. Fucose mutarotase is implicated in transport to the golgi and subsequent 
modification, protein metabolism, and fucose binding which is believed to play a critical role in cell-
cell adhesion and recognition processes. This CpG site is reported to show no correlation between 
methylation in blood and methylation in brain tissue. 
The sixth most statistically significant DMP associated with non-response to clozapine was 
cg01881899. For non-responders, each additional week exposed to clozapine was associated with an 
additional increase in methylation at this site of 1.267% compared to responders (p=0.9x10-6). 
Uncorrected means show an average baseline methylation of 10.257% for responders and 9.298% 
for non-responders, 10.291% and 10.099% at six weeks, 11.029% and 11.077% at twelve weeks, and 
10.812% and 12.207% at six months. Responders start off with a higher baseline methylation which 
increases and then reduces but remains above baseline, while non-responders show increase at 
each time ending with higher levels than responders. 
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cg01881899 is located with the gene body of ABCG1, which encodes ATP-binding cassette sub-
family G member 1. This gene is located on chromosome 21 and is expressed across numerous 
tissues including brain, with overexpression of mRNA in macrophages and overexpression of protein 
in adipocyte and breast. ATP-binding cassette sub-family G member 1 is a protein which transports 
various molecules – including macrophages and phospholipids - across extra and intra cellular 
membranes. This CpG site is reported to show significant weak correlation between methylation in 
blood and methylation in brain in the prefrontal cortex (r=0.239, p=0.040) and entorhinal cortex 
(r=0.26, p=0.028). 
The tenth most statistically significant DMP associated with non-response to clozapine was 
cg04408162. For non-responders, each additional week exposed to clozapine was associated with an 
additional increase in methylation at this site of 0.156% compared to responders (p=0.2x10-5). 
Uncorrected means show an average baseline methylation of 31.778% for responders and 30.735% 
for non-responders, 31.605% and 31.639% at six weeks, 31.787% and 31.985% at twelve weeks, and 
31.914% and 34.040% at six months. Responders show a higher level of methylation at baseline 
which decreases and then increases, while non-responders show an increase which ends with a 
higher level of methylation than responders at all time points.  
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cg04408162 is located in the gene body of KCNK9, which encodes potassium two pore domain 
channel subfamily K member 9 which functions as a pH-dependent potassium channel.  This gene is 
located on chromosome 8 and is expressed in numerous tissue including brain, with overexpression 
of mRNA in brain (cerebellum) and overexpression of protein in liver. Variants of this gene have been 
associated with intellectual disability. This CpG site is reported to show significant moderate 
correlation between methylation in blood and methylation in brain tissue in prefrontal (r=0.415, 
p=0.0002), entorhinal (r=0.335, p=0.004) and superior temporal gyrus (r=0.295, p=0.0101). 
4.3.1.4 Pathway analysis (responders vs non-responders) 
Pathway analysis indicated that the pathways in Table 3 were the top thirty pathways with an 
over-representation of DMPs associated with response classification.   
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Table 8 Top thirty over-represented pathways - response group 
Category Name p value over-
representation 





GO:0060080 regulation of inhibitory postsynaptic membrane potential 0.00016 5 11 BP 
GO:0010885 regulation of cholesterol storage 0.00026 5 13 BP 
GO:0010878 cholesterol storage 0.00036 5 14 BP 
GO:0032088 negative regulation of NF-kappaB transcription factor activity 0.00073 9 56 BP 
GO:1901618 organic hydroxy compound transmembrane transporter activity 0.00148 5 23 MF 
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity 0.00237 14 111 BP 
GO:1901385 regulation of voltage-gated calcium channel activity 0.00327 4 12 BP 
GO:0015370 solute: sodium symporter activity 0.00336 7 46 MF 
GO:0009220 pyrimidine ribonucleotide biosynthetic process 0.00342 4 19 BP 
GO:0015812 gamma-aminobutyric acid transport 0.00347 4 13 BP 
GO:0010884 positive regulation of lipid storage 0.00463 4 17 BP 
GO:0009218 pyrimidine ribonucleotide metabolic process 0.00482 4 21 BP 
GO:0015665 alcohol transmembrane transporter activity 0.00496 3 11 MF 
GO:0003714 transcription corepressor activity 0.00533 20 184 MF 
GO:0072528 pyrimidine-containing compound biosynthetic process 0.00583 5 32 BP 
GO:0010883 regulation of lipid storage 0.00667 6 37 BP 
GO:0031664 regulation of lipopolysaccharide-mediated signalling pathway 0.00684 4 16 BP 
GO:0043254 regulation of protein complex assembly 0.007 20 224 BP 
GO:0046131 pyrimidine ribonucleoside metabolic process 0.007 4 29 BP 
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Category Name p value over-
representation 





GO:0015294 solute: cation symporter activity 0.007 9 77 MF 
GO:0015293 symporter activity 0.007 12 124 MF 
GO:0003084 positive regulation of systemic arterial blood pressure 0.008 3 13 BP 
GO:0000109 nucleotide-excision repair complex 0.008 3 11 CC 
GO:0030832 regulation of actin filament length 0.0095 12 114 BP 
GO:0019915 lipid storage 0.0099 7 56 BP 
GO:0006221 pyrimidine nucleotide biosynthetic process 0.0101 4 24 BP 
GO:0032984 macromolecular complex disassembly 0.0102 16 196 BP 
GO:0031663 lipopolysaccharide-mediated signalling pathway 0.0102 6 43 BP 
GO:0055094 response to lipoprotein particle 0.0106 3 10 BP 
GO:0051059 NF-kappaB binding 0.0107 4 24 MF 
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4.3.1.5 Candidate CpG site methylation (responders vs non-responders) 
Of eleven CpG sites located within DRD3 with methylation data available, two had a significant 
association with clozapine response before but not after correction for multiple testing (0.424x10-
3<p<0.05) - cg04333485 (0.129%, p=0.002) and cg25836326 showed an additional increase in 
methylation for non-responders (0.122%, p=0.002). Across all DRD3 CpG sites, there was a mean 
additional increase in methylation of 0.0291% associated with non-response.  
Of twenty five CpG sites located within 5HTR2A with methylation data available, one had a 
significant association with clozapine response before but not after correction for multiple testing 
(0.424x10-3<p<0.05) - cg12367389 showed an additional decrease in methylation for non-responders 
(-0.056%, p=0.007). Across all 5HTR2A CpG sites, there was a mean additional decrease in 
methylation of -0.00248% associated with non-response.  
Of fifteen CpG sites located within 5HTT with methylation data available, two had a significant 
association with clozapine response before but not after correction for multiple testing (0.424x10-
3<p<0.05) - cg06841846 showed an additional decrease in methylation (-0.124%, p=0.476x10-3) and 
cg22584138 showed an additional increase in methylation for non-responders (0.150%, p=0.019). 
Across all 5HTT CpG sites, there was a mean additional increase in methylation of 0.0106% 
associated with non-response.  
Of twelve CpG sites located within GNB3 with methylation data available, no CpG sites had a 
significant association with clozapine response. Across all GNB3 CpG sites, there was a mean 
additional increase in methylation of 0.0122% associated with non-response.  
Of fifty five CpG sites located within CREBBP with methylation data available, three had a 
significant association with clozapine response before but not after correction for multiple testing 
(0.424x10-3<p<0.05) - cg05898629 showed an additional decrease in methylation (-0.039%, p=0.001), 
cg08506924 showed an additional increase in methylation (0.0613%, p=0.023) and cg04432137 
showed an additional increase in methylation for non-responders (0.0582%, p=0.028). Across all 
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4.3.1.6 Comparison to cross-sectional data (responders vs non-responders) 
First I took the top DMPs (p<0.05*10-5) from the cross-sectional dataset and identified these 
within the longitudinal dataset. There was a highly significant moderate positive correlation between 
the regression coefficients from the longitudinal dataset and the cross-sectional data set of 0. 610, 
p<2.2e-16, df =4561.  
 
I then took the top DMPs (p<0.05*10-5) from the longitudinal dataset and identified these within 
the cross-sectional dataset. There was a highly significant strong positive correlation between the 
regression coefficients from the longitudinal dataset and the cross-sectional data set of 0.737, p = 
2.2e-16, df = 165.  
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4.3.2 Change in total symptom severity (continuous) 
4.3.2.1 Participant characteristics 
All participants had a score for percentage change in total symptom severity at twelve weeks so 
all twenty two participants and eighty five samples were included. Greater reductions in total 
symptom severity were correlated with greater improvements in quality of life (-0.620, df=19, 
p=0.003)  and with greater improvements in psychosocial functioning (though this was not 
significant, -0.33 df=18 p=0.16), and improvements in psychosocial functioning and quality of life 
were correlated with one another (0.6, df=18, p=0.0052). 
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4.3.2.2 Global DNA methylation (change in total symptom severity %) 
Participants with greater reductions in total symptom severity showed greater reductions in 
global DNA methylation over time. Each additional decrease in symptom severity at twelve weeks 
was associated with an additional decrease in global DNA methylation over time of -0.00103%. 
49.50% of all CpG sites showed an increase in methylation associated with greater reductions, and 
50.50% showed a decrease.  
4.3.2.3 Differentially methylated positions (change in total symptom severity %) 
Two DMPs reached the threshold for epigenome wide significance (p<1*10-7), while one 
hundred and eighty eight other DMPs were trend-level significant (p<5*10-5) .
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Table 9: Top ten DMPs associated with change in total symptom severity (continuous) (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO Significant blood-brain methylation correlation 
reported? 
cg10015974 0.245x10-2 3.15E-09*   199827580 N 
cg15353603 
-0.190 




2 1.70E-07 TRIM31 Body 30079536 












2 2.66E-07 PDCD2L Body 34895882 
Y – prefrontal cortex 
cg22112035 
0.179 x10-
2 4.10E-07 ANO1 Body 70002414 
N 
cg06275059 0.86 x10-3 7.96E-07 PCDP1 TSS1500 120301779 N 
cg03528137 0.40 x10-3 9.38E-07   111589969 N 
cg10020520 
0.116 x10-
2 9.64E-07 SETD1A Body 30976186 
N 
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The most statistically significant DMP associated with reduction in total symptom severity at 
twelve weeks was cg10015974. Having an additional reduction in total symptom severity was 
associated with an additional decrease in methylation over time of -0.245% (p=0.3x10-8).  
cg10015974 is located on chromosome 1, outside of any characterised genes. This CpG site is 
reported to show no correlation between methylation in blood and methylation in brain tissue. 
The second most statistically significant DMP associated with reduction in total symptom 
severity at twelve weeks was cg15353603. Having an additional reduction in total symptom severity 
was associated with an additional increase in methylation over time of 0.19% (p=0.3x10-7).  
cg15353603 is described above – it is located within the gene body of DPP4.  
The third most statistically significant DMP associated with reduction in total symptom 
severity at twelve weeks was cg07829465. Having an additional reduction in total symptom severity 
was associated with an additional decrease in methylation over time of -0.172% (p=0.2x10-6).  
cg07829465 is located within the gene body of TRIM31, which encodes tripartite motif-
containing protein 31. This gene is located on chromosome 6 and is expressed across numerous 
tissue including brain, with overexpression of mRNA in colon, bladder, small intense and stomach 
and overexpression of protein in adipocyte. Tripartite motif-containing protein 31 functions as an E3 
ubiquitin-protein ligase, involved in regulation of cell growth, interferon gamma signalling, ligase 
activity and the innate immune system. This CpG site is reported to show a significant moderate 
correlation between methylation in blood and methylation in prefrontal cortex (r=0.336, p=0.0035), 
entorhinal cortex (r=0.43, p=0.0002), and superior temporal gyrus (r=0.346, p=0.0023).  
The sixth most statistically significant DMP associated with reduction in total symptom 
severity at twelve weeks was cg10006515. Having an additional reduction in total symptom severity 
was associated with an additional decrease in methylation over time of -0.12% (p=0.3x10-6).  
cg10006515 is located within the gene body of PDCD2L, which encodes programmed cell death 2 
like. This gene is located on chromosome 19 and is expressed across numerous tissues including 
brain, with overexpression of protein in ovary, bone marrow and breast. Programmed cell death 2 
like is involved in transcriptional regulation and cell cycle progression. This CpG site is reported to 
show a significant weak correlation between methylation in blood and methylation in prefrontal 
cortex (r=0.28, p=0.0155), with a trend for negative correlation in cerebellum (r=-0.211, p =0.078). 
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4.3.3 Change in psychosocial functioning (continuous) 
4.3.3.1 Participant characteristics 
Two participants did not have a score for percentage change in psychosocial functioning at 
twelve weeks so the twenty remaining participants and their seventy eight samples were included in 
the below analysis. 
4.3.3.2 Global DNA methylation (change in psychosocial functioning %) 
Participants with greater improvements in psychosocial functioning showed increased global 
DNA methylation over time. Each additional increase in psychosocial functioning at twelve weeks 
was associated with an average additional increase in global DNA methylation over time of 
0.00103%. 48.88% of all CpG sites showed a decrease in methylation associated with greater 
improvements, and 51.12% showed an increase.  
4.3.3.3 Differentially methylated positions (change in psychosocial functioning %) 
One DMP was epigenome wide significant (p<1*10-7), and one hundred and twenty two other 
DMPs were trend-level significant (p<*10-5). 
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Table 10: Top ten DMPs associated with change in psychosocial functioning (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO Significant blood-brain methylation correlation 
reported? 
cg05195750 0.103x10-2 3.55E-08* ELP4;IMMP1L Body;TSS1500 31531557 Y – entorhinal cortex and prefrontal cortex 
cg20676542 0.31 x10-3 5.06E-07 TRIM25 TSS200 54991456 N 
cg15113009 
0.192 x10-
2 5.50E-07 PKNOX2 Body 125297719 
Y – superior temporal gyrus 
cg22867608 
-0.115 
x10-2 7.20E-07 EGR2 Body 64573356 
Y – prefrontal cortex, entorhinal cortex, superior 
temporal gyrus and cerebellum 
cg09595020 
0.143 x10-




2 1.08E-06 OLFM2 Body 10022659 
Y – entorhinal cortex 
cg07572579 -0.76 x10-3 1.69E-06   68116058 N 
cg21215820 
-0.175 




2 1.98E-06 UGP2 Body;5'UTR 64069583 
Y – entorhinal cortex 
cg20951539 
0.148 x10-
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The most statistically significant DMP associated with improvement in psychosocial 
functioning at twelve weeks was cg05195750. Having an additional improvement in psychosocial 
functioning was associated with an additional increase in methylation over time of 0.103% 
(p=0.4x10-7).  
cg05195750 is described above – it is located within the gene body of ELP4. 
The third most statistically significant DMP associated with improvement in psychosocial 
functioning at twelve weeks was cg15113009. Having an additional improvement in psychosocial 
functioning was associated with an additional increase in methylation over time of 0.192% 
(p=0.6x10-6).  
cg15113009 is located within the gene body of PKNOX2, which encodes homeobox protein 
PREP-2. This gene is located on chromosome 11 and is expressed in numerous tissues including 
brain, with overexpression of mRNA in cortex and overexpression of protein in liver. Homeobox 
protein PREP-2 is a sequence-specific transcription factor which plays a key role in cell proliferation, 
differentiation and death, and has also been associated with substance dependence. This CpG site is 
reported to show a significant negative correlation between methylation in blood and methylation in 
superior temporal gyrus (r=-0.243, p=0.035). 
The fourth most statistically significant DMP associated with improvement in psychosocial 
functioning at twelve weeks was cg22867608. Having an additional improvement in psychosocial 
functioning was associated with an additional decrease in methylation over time of 0.115% 
(p=0.7x10-6).  
cg22867608 is located within the gene body of EGR2, which encodes early growth response 2. 
This gene is located on chromosome 10 and is expressed in numerous tissues including brain, with 
overexpression of mRNA in tibial nerve. Early growth response 2 is a transcription factor which binds 
to two specific DNA sites located in the promoter region of HOXA4 and is associated with charcot-
marie tooth disease which is a congenital disorder of hypo-myelination. This CpG site is reported to 
shown significant moderation correlations between methylation in blood and methylation in 
prefrontal cortex (r=0.495, p=7.47e-06), entorhinal cortex (r=0.371, p=0.0014), superior temporal 
gyrus (r=0.329, p=0.0039), and cerebellum (r=0.368, p=0.0016).  
The sixth most statistically significant DMP associated with improvement in psychosocial 
functioning at twelve weeks was cg07950397. Having an additional improvement in psychosocial 
functioning was associated with an additional increase in methylation over time of 0.105% 
(p=0.1x10-5).  
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cg07950397 is located within the gene body of OLFM2, which encodes olfactomedin 2. This gene 
is located on chromosome 19 and is expressed across numerous tissue including brain, with 
overexpression of mRNA in brain (putamen, amygdala and nucleus accumbens) and overexpression 
of protein in vitreous humour and serum. Olfactomedin 2 is a protein involved in transforming 
growth factor beta and AMPAR complex organisation. This CpG site is reported to show a significant 
weak correlation between methylation in blood and methylation in entorhinal cortex (r=0.308, 
p=0.0091).  
The ninth most statistically significant DMP associated with improvement in psychosocial 
functioning at twelve weeks was cg14150252. Having an additional improvement in psychosocial 
functioning was associated with an additional increase in methylation over time of 0.321% 
(p=0.2x10-5).  
cg14150252 is located within the gene body of UGP2, a gene which encodes UDP-glucose 
pyrophosphorylase 2. This gene is located on chromosome 2 and is expressed in numerous tissues 
including brain, with overexpression of mRNA in skeletal muscle and overexpression of protein in 
liver. UDP-glucose pyrophosphorylase 2 is an enzyme involved in carbohydrate conversions of 
glucose. This CpG site is reported to demonstrate a trend towards negative correlation between 
methylation in blood and methylation in entorhinal cortex (r=-0.218, p=0.0677). 
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4.3.4 Change in quality of life (continuous) 
4.3.4.1 Participant characteristics 
One participant did not have a score for percentage change in psychosocial functioning at twelve 
weeks so the twenty one remaining participants and their eighty two samples were included in the 
below analysis. 
4.3.4.2 Global DNA methylation (change in quality of life %) 
Participants with greater improvements in quality of life showed increased global DNA 
methylation over time. Each additional increase in quality of life at twelve weeks was associated 
with an average additional increase in global DNA methylation of 0.000898%. 48.99% of all CpG sites 
showed a decrease in methylation associated with greater improvements, and 51.01% showed an 
increase.  
4.3.4.3 Differentially methylated positions (change in quality of life %) 
One DMP reached the threshold for epigenome wide significance (p<1*10-7) and one hundred 
and forty eight DMPs were trend-level significant (p<5*10-5). 
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Table 11: Top ten DMPs associated with change in quality of life (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO Significant blood-brain methylation correlation 
reported? 
cg14150252 0.408x10-2 5.94E-08* UGP2 Body;5'UTR 64069583 Y – entorhinal cortex 
cg11641222 
0.185 x10-




2 1.94E-07 SLC9A3 Body 497639 




2 2.38E-07 ELP4;IMMP1L Body;TSS1500 31531557 
Y – entorhinal cortex and  superior temporal gyrus 
cg07829465 
0.166 x10-
2 3.39E-07 TRIM31 Body 30079536 




2 4.52E-07 BTRC Body 103245907 




2 5.30E-07 EHF TSS1500 34642463 
Y – prefrontal cortex, entorhinal cortex, superior 
temporal gyrus and cerebellum 
cg00182202 
-0.157 
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The most statistically significant DMP associated with improvement in quality of life at twelve 
weeks was cg14150252. Having an additional improvement in quality of life was associated with an 
additional increase in methylation over time of 0.408% (p=0.6x10-7).  
cg14150252 is described above - it is located within the gene body of UGP2.  
The third most statistically significant DMP associated with improvement in quality of life at 
twelve weeks was cg00190355. Having an additional improvement in quality of life was associated 
with an additional increase in methylation over time of 0.301% (p=0.2x10-6).  
cg00190355 is located within the gene body of SLC9A3, which encodes solute carrier family 9 
member A3. This gene is located on chromosome 5 and is expressed across numerous tissues 
including brain, with overexpression of mRNA in colon, kidney and stomach and overexpression of 
protein in fetal gut, kidney and urine. Solute carrier family 9 member A3 is involved in sodium ion 
transportation, signal transduction and pH regulation. This CpG site is reported to show significant 
weak correlation between methylation in blood and methylation in prefrontal cortex (r=0.264, 
p=0.023), entorhinal cortex (r=0.366, p=0.0017), and superior temporal gyrus (r=0.262, p=0.023).  
The fourth most statistically significant DMP associated with improvement in quality of life at 
twelve weeks was cg05195750. Having an additional improvement in quality of life was associated 
with an additional increase in methylation over time of 0.108% (p=0.2x10-6).  
cg05195750 is described above – it is located within the gene body of ELP4.  
The fifth most statistically significant DMP associated with improvement in quality of life at 
twelve weeks was cg07829465. Having an additional improvement in quality of life was associated 
with an additional increase in methylation over time of 0.166% (p=0.3x10-6).  
cg07829465 is described above - it is located within the gene body of TRIM31. 
The sixth most statistically significant DMP associated with improvement in quality of life at 
twelve weeks was cg11970204. Having an additional improvement in quality of life was associated 
with an additional increase in methylation over time of 0.191% (p=0.5x10-6).  
cg11970204 is located within the gene body of BTRC, which encodes beta-transducin repeat 
containing E3 ubiquitin protein ligase. This gene is located on chromosome 10 and is expressed 
across numerous tissues including brain, with overexpression of protein in peripheral blood 
mononuclear cells and pancreatic juice. Beta-transducin repeat containing E3 ubiquitin protein ligase 
is involved in phosphorylation-dependent ubiquitination, IL-1 signalling, and ligase activity by 
targeting cells for degradation. This CpG site is reported to show significant weak correlations 
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between methylation in blood and methylation in prefrontal cortex (r=0.306, p=0.008), entorhinal 
cortex (0.253, p=0.033), and superior temporal gyrus (r=0.309, p=0.007).  
The seventh most statistically significant DMP associated with improvement in quality of life 
at twelve weeks was cg13084525. Having an additional improvement in quality of life was 
associated with an additional increase in methylation over time of 0.213% (p=0.5x10-6).  
cg13084525 is located within the TSS1500 promoter region of EHF, which encodes ETS 
homologous factor. This gene is located on chromosome 11 and is expressed across numerous 
tissues including brain, with overexpression of mRNA in oesophagus, salivary gland and vagina and 
overexpression of protein in salivary gland and skin. ETS homologous factor is a transcriptional 
repressor involved in epithelial-specific expression. This CpG site is reported to show significant 
moderation correlations between methylation in blood and methylation in prefrontal cortex 
(r=0.432, p=0.0001) and entorhinal cortex (0.457, p=6.18e-05), and weak correlations between 
methylation in blood and methylation in superior temporal gyrus (r=0.254, p=0.028) and cerebellum 
(r=0.238, p=0.046). 
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4.4 Results: Symptom severity (within individuals) 
4.4.1 Participant characteristics 
Twenty five of the samples did not have corresponding symptom severity score; twenty three of 
these because these were six/eight week samples when no clinical assessments were done. The 
remaining sixty samples from all twenty two participants were included in the following analysis.  
4.4.2 Total symptom severity 
4.4.2.1 Global DNA methylation (total symptom severity) 
Higher within-individual total symptom severity at any time point was associated with higher 
global DNA methylation. An increase in symptom severity was associated with an average increase in 
global DNA methylation of 0.0005%; however, 51.79% of all CpG sites showed a decrease in 
methylation associated with total symptom severity, and 48.20% showed an increase.  
4.4.2.2 Differentially methylated positions (total symptom severity) 
Five DMPs reached the threshold for epigenome wide significance (p<1*10-7), while four 
hundred and fifty three other DMPs were trend-level significant (p<5*10-5). 
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Table 12: Top ten DMPs associated with within-individual variation in total symptom severity (* indicates epigenome wide significance) 








2 1.92E-08* GLRA1 TSS1500 151305528 
Y – entorhinal cortex, superior temporal gyrus 
cg26129353 
-0.153 
x10-2 6.30E-08* ATP8B1 Body 55316927 
Y – prefrontal cortex 
cg17651451 
-0.145 




2 8.38E-08* NEFM TSS1500;oneExon 24771466 
Y – entorhinal cortex 
cg03765206 0.85 x10-3 1.07E-07 NAV2 Body 19429376 N 
cg22359217 -0.21 x10-3 1.93E-07 FBXO4 Body 41925772 N 
cg08127293 -0.26 x10-3 2.21E-07   14379328 N 
cg00496462 
-0.128 
x10-2 2.74E-07   93577610 
Y – entorhinal cortex 
cg08160619 -0.69 x10-3 3.16E-07 CORO1A 5'UTR 30195318 Y – prefrontal cortex 
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The most statistically significant DMP associated with total symptom severity was cg02890365. 
Each within-individual increase in total symptom severity was associated with a decrease in 
methylation of 0.152% (p=0.7x10-8). Using uncorrected means there was a negative correlation of -
0.354 between total symptom severity and methylation at any time point across all samples. 
 
cg02890365 is located within the body of TUFT1, which encodes for tuftelin. This gene is located 
on chromosome 1 and is expressed in numerous tissues including brain, with overexpression of 
mRNA in skin and overexpression of protein in skin and cervix. Tuftelin is an acidic phosphorylated 
glycoprotein found in tooth enamel, which is also implicated in neurotrophin nerve growth factor 
mediated neuronal differentiation. This CpG site is reported to show no correlation between 
methylation in blood and methylation in brain tissue. 
The second most statistically significant DMP associated with total symptom severity was 
cg23158483. Each within-individual increase in total symptom severity was associated with an 
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increase in methylation of 0.229% (p=0.2x10-7). Using uncorrected means there was a correlation of 
0.515 between total symptom severity and methylation at any time point across all samples.  
 
cg23158483 is located within the TSS1500 promoter region of GLRA1, which encodes the glycine 
receptor subunit alpha-1. This gene is located on chromosome 5 and is expressed in numerous tissue 
including brain, with overexpression of mRNA in brain (hypothalamus, substantia nigra and spinal 
cord) and overexpression of protein in retina; this gene has also been associated with startle disease. 
The glycine receptor subunit alpha-1 is an inhibitory glycine receptor, one of the most widely 
distributed inhibitory receptors in the central nervous system key for mediating neurotransmission 
through postsynaptic inhibition. This CpG site is reported to show a significant weak correlation 
between methylation in blood and methylation in entorhinal cortex(r=0.331, p=0.005) and superior 
temporal gyrus (r=0.246, p=0.033), with a trend for correlation (r=0.211, p=0.072) at the prefrontal 
cortex. 
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The third most statistically significant DMP associated with total symptom severity was 
cg26129353. Each within-individual increase in total symptom severity was associated with a 
decrease in methylation of 0.153% (p=0.6x10-7). Using uncorrected means there was a correlation of 
-0.180 between total symptom severity and methylation at any time point across all samples. 
 
cg26129353 is located within the gene body of ATP8B1, which encodes ATPase phospholipid 
transporting 8B1. This gene is located on chromosome 18 and is expressed in numerous tissues 
including brain, with overexpression of mRNA in colon and overexpression of protein in nasal 
epithelium and amniocyte. ATPase phospholipid transporting 8B1 is part of a family of proteins 
which transport phosphatidylserine and phosphatidylethanolamine from one side of a bilayer to 
another, and it is implicated in nucleotide binding and ion channel transport. This CpG site is 
reported to show a significant weak correlation between methylation in blood and methylation in 
prefrontal cortex (r=-0.274, p=0.018). 
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The fourth most statistically significant DMP associated with total symptom severity was 
cg17651451. Each within-individual increase in total symptom severity was associated with a 
decrease in methylation of 0.145% (p=0.8x10-7). Using uncorrected means there was a correlation of 
-0.0003 between total symptom severity and methylation at any time point across all samples. 
 
cg17651451 is located within the gene body of ADAMTS2, which encodes ADAM 
metallopeptidase with thrombospondin type 1. This gene is located on chromosome 5 and is 
expressed in numerous tissues including brain, but with low levels of mRNA expression in brain, high 
levels in skin, bone, tendon and aorta and overexpression of protein in amniocyte and bone marrow 
stem cell. ADAM metallopeptidase with thrombospondin type 1 has a role in collagen biosynthesis 
and peptidase activity. This CpG site is reported to show no correlation between methylation in 
blood and methylation in brain tissue. 
The fifth most statistically significant DMP associated with total symptom severity was 
cg23290344. Each within-individual increase in total symptom severity was associated with an 
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increase in methylation of 0.1904% (p=0.8x10-7). Using uncorrected means there was a correlation of 
0.286 between total symptom severity and methylation at any time point across all samples. 
 
 
cg23290344 is located within the TSS1500 promoter region of NEFM, which encodes 
neurofilament medium. This gene is located on chromosome 8 and is expressed in numerous tissues 
including brain, with overexpression of mRNA in brain (frontal cortex, cortex, anterior cingulate 
cortex, hippocampus, substantia nigra) and overexpression of protein in spinal cord, frontal cortex 
and brain.  Neurofilament medium functionally maintains neuronal calibre and is implicated in 
intracellular transport to axons and dendrites. This CpG site is reported to show significant weak 
correlation between methylation in blood and methylation in entorhinal cortex (r=0.316, p=0.007). 
The ninth most statistically significant DMP associated with total symptom severity was 
cg00496462. Each within-individual increase in total symptom severity was associated with a 
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decrease in methylation of 0.128% (p=0.3x10-6). Using uncorrected means there was a correlation of 
-0.211 between total symptom severity and methylation at any time point across all samples.  
 
cg00496462 is located on chromosome 7, outside of any characterised genes. This CpG site is 
reported to show no significant correlation between methylation in blood and methylation in brain 
tissue, except for a trend in entorhinal cortex (r=0.222, p=0.063). 
The tenth most statistically significant DMP associated with total symptom severity was 
cg08160619. Each within-individual increase in total symptom severity was associated with a 
decrease in methylation of 0.069% (p=0.3x10-6). Using uncorrected means there was a correlation of 
-0.248 between total symptom severity and methylation at any time point across all samples.  
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cg08160619 is located within the 5’UTR region of CORO1A, encodes coronin 1A. This gene is 
located on chromosome 16 and is expressed in numerous tissues including brain, with 
overexpression of mRNA in whole blood and spleen and overexpression of protein in lymph node, 
NK cells and T lymphocytes; variants of this gene have been associated with immunodeficiency. 
Coronin 1A, a member of the WD repeat protein family, is implicated in numerous cellular processes 
including signal transduction, gene regulation, and poly(A) RNA binding. This CpG site is reported to 
show significant weak correlations between methylation in blood and methylation in prefrontal 
cortex (r=0.253, p=0.0296) with a trend in superior temporal gyrus (r=0.208, p=0.073). 
4.4.2.3 Pathway analysis (total symptom severity) 
Pathway analysis indicated that the pathways in Table 13 were the top thirty pathways with an 
over-representation of DMPs associated with total symptom severity.  
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Table 13: Top thirty over-represented pathways - total symptom severity 
Category Name p value over-
representation 





GO:0007156 homophilic cell adhesion 5.30E-07 50 130 BP 
GO:0098609 NA 9.08E-06 53 178 BP 
GO:0000902 cell morphogenesis 0.00063 163 1022 BP 
GO:0021761 limbic system development 0.00070 20 73 BP 
GO:0010876 lipid localization 0.00093 42 264 BP 
GO:0005509 calcium ion binding 0.00106 101 629 MF 
GO:0030030 cell projection organization 0.00107 158 1005 BP 
GO:0032989 cellular component morphogenesis 0.00146 167 1090 BP 
GO:0032990 cell part morphogenesis 0.00182 123 728 BP 
GO:0045956 positive regulation of calcium ion-dependent exocytosis 0.00194 7 14 BP 
GO:0048858 cell projection morphogenesis 0.00205 121 711 BP 
GO:0000904 cell morphogenesis involved in differentiation 0.00251 127 742 BP 
GO:0043330 response to exogenous dsRNA 0.00282 7 28 BP 
GO:0017158 regulation of calcium ion-dependent exocytosis 0.00324 10 30 BP 
GO:0022412 cellular process involved in reproduction in multicellular organism 0.00342 35 225 BP 
GO:0006869 lipid transport 0.00342 36 233 BP 
GO:0021766 hippocampus development 0.00346 14 51 BP 
GO:0031175 neuron projection development 0.00348 124 731 BP 
GO:0022610 biological adhesion 0.00358 150 992 BP 
GO:0004629 phospholipase C activity 0.00360 8 30 MF 
GO:0045921 positive regulation of exocytosis 0.00389 11 41 BP 
GO:0007155 cell adhesion 0.00418 149 989 BP 
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Category Name p value over-
representation 





GO:0048013 ephrin receptor signalling pathway 0.00503 10 32 BP 
GO:0015020 glucuronosyltransferase activity 0.00510 8 27 MF 
GO:0002922 positive regulation of humoral immune response 0.00542 4 10 BP 
GO:0007409 axonogenesis 0.00597 91 500 BP 
GO:0061564 axon development 0.00604 93 517 BP 
GO:0007411 axon guidance 0.00633 67 351 BP 
GO:0097485 neuron projection guidance 0.00633 67 351 BP 
GO:0034389 lipid particle organization 0.00635 5 14 BP 
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4.4.3 Positive symptom severity 
4.4.3.1 Global DNA methylation (positive symptom severity) 
Higher within-individual positive symptom severity at any time point was associated with higher 
global DNA methylation. An increase in positive symptom severity was associated with an average 
increase in global DNA methylation of 0.00023%; however, 50.96% of all CpG sites showed a 
decrease in methylation associated with positive symptom severity, and 49.04% showed an increase.  
4.4.3.2 Differentially methylated positions (positive symptom severity) 
 
Three DMPs reached the threshold for epigenome wide significance (p<1*10-7), and two 
hundred and thirty four DMPs were trend-level significant (p<5*10-5).  
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Table 14: Top ten DMPs associated with within-individual variation in positive symptom severity (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO Significant blood-brain methylation correlation 
reported? 
cg03661817 0.298x10-2 2.42E-08* KIFC3 Body;1stExon;5'UTR 57831745 Y – prefrontal cortex and superior temporal gyrus 
cg02759966 0.305 x10-2 3.24E-08*   29139086 N 
cg08283882 0.134 x10-2 9.63E-08* EBF2 Body 25901017 N 
cg26620021 -0.298 x10-2 1.29E-07 MIR641;AKT2 TSS1500;5'UTR 40788926 Y - cerebellum 
cg17790273 0.482 x10-2 1.71E-07 SPAG9 3'UTR 49040709 N 
cg16926712 0.270 x10-2 2.02E-07 INTS9 Body 28657193 
Y – prefrontal cortex, entorhinal cortex, superior 
temporal gyrus and cerebellum 
cg26724545 0.395 x10-2 2.39E-07 C5orf58 1stExon;5'UTR 169659950 N 
cg10298215 0.269 x10-2 2.42E-07 HLA-DQB2 Body 32730046 Y – superior temporal gyrus  
cg22673724 0.184 x10-2 3.66E-07 ATL3 TSS1500 63439590 Y – entorhinal cortex 
cg10561983 0.312 x10-2 3.71E-07   23454432 N 
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The most statistically significant DMP associated with positive symptom severity was 
cg03661817. Each within-individual increase in positive symptom severity was associated with an 
increase in methylation of 0.298% (p=0.2x10-7). Using uncorrected means there was a correlation of 
0.0772 between positive symptom severity and methylation at any time point across all samples. 
 
cg03661817 is located within the gene body of KIFC3, which encodes kinesin family member C3.  
This gene is located on chromosome 16 and is expressed across numerous tissues including brain, 
with overexpression of protein in monocytes, peripheral blood mononuclear cells, testis and 
adipocyte. Kinesin family member C3 is a microtubule motor which plays a role in the formation, 
maintenance and remodelling of bipolar mitotic spindle. This CpG site is reported to show significant 
moderate correlations between methylation in blood and methylation in prefrontal cortex (r=0.294, 
p=0.011) and superior temporal gyrus (r=0.282, r=0.014). 
The second most statistically significant DMP associated with positive symptom severity was 
cg02759966. Each within-individual increase in positive symptom severity was associated with an 
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increase in methylation of 0.304% (p=0.3x10-7). Using uncorrected means there was a correlation of 
0.0227 between positive symptom severity and methylation at any time point across all samples. 
 
cg02759966 is located on chromosome 16, outside of any characterised genes. This CpG site is 
reported to show no correlation between methylation in blood and methylation in brain tissue. 
The third most statistically significant DMP associated with positive symptom severity was 
cg08283882. Each within-individual increase in positive symptom severity was associated with an 
increase in methylation of 0.134% (p=0.096x10-7). Using uncorrected means there was a correlation 
of 0.5210 between positive symptom severity and methylation at any time point across all samples.  
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cg08283882 is located within the body of EBF2, a gene which encodes early b-cell factor 2. This 
gene is located on chromosome 8 and is expressed across numerous tissues including brain, with 
overexpression of mRNA in tibial nerve and adipose tissue and overexpression of protein in 
pancreas, salivary gland and oral epithelium. Early b-cell factor 2 is a non-basic helix-loop-helix 
transcription factor implicated in developmental processes such as osteoblast differentiation. This 
CpG site is reported to show no correlation between methylation in blood and methylation in brain 
tissue. 
The fourth most statistically significant DMP associated with positive symptom severity was 
cg26620021. Each within-individual increase in positive symptom severity was associated with a 
decrease in methylation of 0.298% (p=0.1x10-6). Using uncorrected means there was a correlation of 
-0.1283 between positive symptom severity and methylation at any time point across all samples.  
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cg26620021 is located within the TSS1500 promoter region of MIR641, which encodes microRNA 
641, involved in post-transcriptional regulation of gene expression. This gene is located on 
chromosome 19 and is expressed across numerous tissues including brain. This CpG site is reported 
to show a significant negative correlation between methylation in blood and methylation in 
cerebellum (r=-0.316, p=0.007). 
The sixth most statistically significant DMP associated with positive symptom severity was 
cg16926712. Each within-individual increase in positive symptom severity was associated with an 
increase in methylation of 0.27% (p=0.2x10-6). Using uncorrected means there was a correlation of 
0.4073 between positive symptom severity and methylation at any time point across all samples.  
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cg16926712 is located within the gene body of INTS9, which encodes integrator complex subunit 
9. This gene is located on chromosome 8 and is expressed across numerous tissues including brain, 
with overexpression of protein in heart, placenta, breast and monocytes. Integrator complex subunit 
9 binds to the C-terminal domain of RNA polymerase II and is therefore involved in gene expression 
and translational regulation. This CpG site is reported to show significant strong correlations 
between methylation in blood and methylation in prefrontal cortex (r=0.698, p=4.69e-12), 
entorhinal cortex r=0.562, p=3.34e-07), superior temporal gyrus (r=0.688 p=9.39e-12) and 
cerebellum (r=0.759, p=1.64e-14). 
The eighth most statistically significant DMP associated with positive symptom severity was 
cg10298215. Each within-individual increase in positive symptom severity was associated with an 
increase in methylation of 0.269% (p=0.2x10-6). Using uncorrected means there was a correlation of 
0.2094 between positive symptom severity and methylation at any time point across all samples.  
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cg10298215 is located within the body of HLA-DQB2, which encodes major histocompatibility 
complex, class II, DQ beta 2. This gene is located on chromosome 6 and is expressed in numerous 
tissues including brain, with overexpression of mRNA in skin and overexpression of protein in NK 
cells; variants of this gene have been associated with two sleep disorders: Kleine-Levin syndrome 
and recurrent hypersomnia. Major histocompatibility complex, class II, DQ beta 2 is involved in the 
immune system; it presents peptides derived from extracellular proteins, and is implicated in 
interferon gamma signalling. This CpG site is reported to show significant weak correlations between 
methylation in blood and methylation in superior temporal gyrus (r=0.26 p=0.024) with a trend for a 
significant correlation with entorhinal cortex r=0.231, p=0.053). 
The ninth most statistically significant DMP associated with positive symptom severity was 
cg22673724. Each within-individual increase in positive symptom severity was associated with an 
increase in methylation of 0.184% (p=0.4x10-6). Using uncorrected means there was a correlation of 
0.285 between positive symptom severity and methylation at any time point across all samples.  
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cg22673724 is located within the TSS1500 promoter region of ATL3, which encodes atlastin 
GTPase 3. This gene is located on chromosome 11 and is expressed across numerous tissues 
including brain, with overexpression of mRNA central nervous system and dorsal root ganglia 
neurons; variants have been associated with neuropathy. Atlastin GTPase 3 is involved in formation 
of endoplasmic reticulum tubules network. This CpG site is reported to show a significant weak 
correlation between methylation in blood and methylation in entorhinal cortex r=0.269, p=0.023). 
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4.4.4 Negative symptom severity 
4.4.4.1 Global DNA methylation (negative symptom severity) 
Higher within-individual negative symptom severity at any time point was associated with higher 
global DNA methylation. An increase in negative symptom severity was associated with an average 
increase in global DNA methylation of 0.00207%. 51.44% of all CpG sites showed a decrease in 
methylation associated with negative symptom severity, and 48.56% showed an increase.  
4.4.4.2 Differentially methylated positions (negative symptom severity) 
Fourteen DMPs reached the threshold for epigenome wide significance (p<1*10-7), and seven 
hundred and thirty six DMPs were trend-level significant (p<5*10-5).  
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Table 15: Top ten DMPs associated with within-individual variation in negative symptom severity (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO Significant blood-brain methylation correlation 
reported? 
cg00293996 0.266x10-2 2.98E-09* CLDN14 5'UTR;TSS1500 37915391 N 
cg21288861 
-0.174 
x10-2 8.80E-09* ITGB3 TSS200 45331061 




x10-2 1.11E-08* ADAMTS8 Body 130297149 
Y – entorhinal cortex 
cg27116770 
0.199 x10-
2 1.17E-08* TRIM54 1stExon 27505755 
N 
cg01371207 -0.78 x10-3 1.87E-08* PFDN6;WDR46 TSS200 33257335 N 
cg03321142 
0.393 x10-
2 2.04E-08* IGSF9 Body 159899640 
Y – prefrontal cortex and superior temporal gyrus  
cg08682625 
0.232 x10-




x10-2 3.31E-08* SLAIN1 TSS1500 78271894 
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The most statistically significant DMP associated with negative symptom severity was 
cg00293996. Each within-individual increase in negative symptom severity was associated with an 
increase in methylation of 0.265% (p=0.3x10-8). Using uncorrected means there was a correlation of 
0.313 between negative symptom severity and methylation at any time point across all samples.
 
cg00293996 is located within the 5’UTR region of CLDN14, which encodes claudin 14. This gene 
is located on chromosome 21 and is expressed in numerous tissues including brain, with 
overexpression of mRNA in liver and overexpression of protein in urine. Claudin 14 is an integral 
membrane protein and component of tight junction strands, and defects can cause deafness. This 
CpG site is reported to show no significant correlation between methylation in blood and 
methylation in brain tissue, but a trend towards significant correlation between blood and 
cerebellum (r=0.224, p=0.0598). 
The second most statistically significant DMP associated with negative symptom severity was 
cg21288861. Each within-individual increase in negative symptom severity was associated with a 
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decrease in methylation of 0.174% (p=0.9x10-8). Using uncorrected means there was a correlation of 
-0.556 between negative symptom severity and methylation at any time point across all samples. 
 
cg21288861 is located within the TSS200 promoter region of ITGB3 which encodes integrin beta 
chain beta 3. This gene is located on chromosome 17 and is expressed in numerous tissues including 
brain, with overexpression of mRNA in artery and colon and overexpression of protein in platelets, 
peripheral blood mononuclear cells and neutrophils. Integrin beta chain beta 3 is an integral cell-
surface protein involved in cell adhesion and cell-surface mediated signalling. This CpG site is 
reported to show significant moderate correlations between methylation in blood and methylation 
in entorhinal cortex (r=0.392, p=0.0007), superior temporal gyrus (r=0.407, p=0.0003) and 
cerebellum (r=0.341, p=0.0036). 
The third most statistically significant DMP associated with negative symptom severity was 
cg02518691. Each within-individual increase in negative symptom severity was associated with a 
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decrease in methylation of 0.545% (p=0.1x10-7). Using uncorrected means there was a correlation of 
-0.280 between negative symptom severity and methylation at any time point across all samples.  
 
cg02518691 is located within the gene body of ADAMTS8, a gene which encodes ADAM 
metallopeptidase with thrombospondin type 1 motif 8. This gene is located on chromosome 11 and 
is expressed across numerous tissues including brain, with overexpression of mRNA in lung and 
artery and overexpression of protein in heart. ADAM metallopeptidase with thrombospondin type 1 
motif 8 is an enzyme involved in heparin binding and integrin binding. This CpG site is reported to 
show a significant moderate correlation between methylation in blood and methylation in 
entorhinal cortex (r=0.323, p=0.006), with a trend towards significance at the prefrontal cortex 
(r=0.22, p=0.060). 
The fourth most statistically significant DMP associated with negative symptom severity was 
cg27116770. Each within-individual increase in negative symptom severity was associated with an 
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increase in methylation of 0.199% (p=0.1x10-7). Using uncorrected means there was a correlation of 
0.365 between negative symptom severity and methylation at any time point across all samples.  
 
cg27116770 is located within the 1st exon of TRIM54, which encodes tripartite motif containing 
54. This gene is located on chromosome 2 and is expressed across numerous tissues including brain, 
with overexpression of mRNA in skeletal muscle and heart, and overexpression of protein in heart. 
Tripartite motif containing 54 has been implicated in signal transducer activity and microtubule 
binding. This CpG site is reported to show no correlation between methylation in blood and 
methylation in brain tissue. 
The fifth most statistically significant DMP associated with negative symptom severity was 
cg01371207. Each within-individual increase in negative symptom severity was associated with a 
decrease in methylation of 0.078% (p=0.2x10-7). Using uncorrected means there was a correlation of 
-0.500 between negative symptom severity and methylation at any time point across all samples.  
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cg01371207 is located within the TSS200 promoter region of PFDN6, which encodes prefoldin 
subunit 6. This gene is located on chromosome 6 and is expressed in numerous tissues including 
brain, with overexpression of protein in fetal brain and peripheral blood mononuclear cells. 
Prefoldin subunit 6 is implicated in unfolded protein binding, chaperone binding, and tubulin folding. 
This CpG site is reported to show no correlation between methylation in blood and methylation in 
brain tissue. 
The sixth most statistically significant DMP associated with negative symptom severity was 
cg03321142. Each within-individual increase in negative symptom severity was associated with an 
increase in methylation of 0.393% (p=0.2x10-7). Using uncorrected means there was a correlation of 
0.521 between negative symptom severity and methylation at any time point across all samples.  
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cg03321142 is located within the body of IGSF9, which encodes immunoglobulin superfamily 
member 9. This gene is located on chromosome 1 and is expressed in numerous tissues including 
brain, with overexpression of mRNA in liver, skin, and colon and overexpression of protein in breast. 
Immunoglobulin superfamily member 9 is implicated in cell-cell adhesion, dendrite outgrowth and 
synapse maturation. This CpG site is reported to show significant weak correlations between 
methylation in blood and methylation in blood and prefrontal cortex (r=0.3, p=0.009) and superior 
temporal gyrus (r=0.24, p=0.038). 
The seventh most statistically significant DMP associated with negative symptom severity was 
cg08682625. Each within-individual increase in negative symptom severity was associated with an 
increase in methylation of 0.232% (p=0.3x10-7). Using uncorrected means there was a correlation of 
0.125 between negative symptom severity and methylation at any time point across all samples.  
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cg08682625 is located within the gene body of LOC727677, a gene which encodes miscRNA and 
is located on chromosome 8 but is otherwise uncharacterised; variants have been associated with 
colorectal and prostate cancer. This CpG site is reported to show no correlation between 
methylation in blood and methylation in brain tissue. 
The eighth most statistically significant DMP associated with negative symptom severity was 
cg14660007. Each within-individual increase in negative symptom severity was associated with a 
decrease in methylation of 0.199% (p=0.3x10-7). Using uncorrected means there was a correlation of 
-0.389 between negative symptom severity and methylation at any time point across all samples.  
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cg14660007 is located within the TSS1500 promoter region of SLAIN1, which encodes SLAIN 
motif family member 1. This gene is located on chromosome 13 and is expressed across numerous 
tissue including brain, with overexpression of mRNA in brain (spinal cord, substantia nigra and 
hippocampus) and overexpression of protein in monocytes and lung. This CpG site is reported to 
show significant weak correlations between methylation in blood and methylation in prefrontal 
cortex (r=0.231, p=0.048), entorhinal cortex (r=0.303, p=0.010) and cerebellum (r=0.393, p=0.0007). 
The ninth most statistically significant DMP associated with negative symptom severity was 
cg19060383. Each within-individual increase in negative symptom severity was associated with a 
decrease in methylation of 0.374% (p=0.3x10-7). Using uncorrected means there was a correlation of 
-0.396 between negative symptom severity and methylation at any time point across all samples.  
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cg19060383 is located within the body of NPHS1, which encodes renal glomerulus-specific cell 
adhesion receptor. This gene is located on chromosome 19 and is expressed across numerous 
tissues including brain, with overexpression of mRNA in kidney and pancreas and overexpression of 
protein in plasma, urine and peripheral blood mononuclear cells. Renal glomerulus-specific cell 
adhesion receptor is an immunoglobin cell adhesion molecule involved in the filtration barrier in the 
kidney. This CpG site is reported to show no correlation between methylation in blood and 
methylation in brain tissue. 
The tenth most statistically significant DMP associated with negative symptom severity was 
cg05797770. Each within-individual increase in negative symptom severity was associated with a 
decrease in methylation of 0.309% (p=0.5x10-7). Using uncorrected means there was a correlation of 
-0.202 between negative symptom severity and methylation at any time point across all samples.  
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cg05797770 is located within the gene body of EPHA2, which encodes ephrin type-A receptor 2. 
This gene is located on chromosome 1 and is expressed in numerous tissues including brain, with 
overexpression of mRNA in oesophagus and overexpression of protein in amniocyte and adrenal. 
Ephrin type-A receptor 2 is a receptor involved in mediating development of the nervous system and 
implicated in G-protein couple receptors, protein tyrosine kinase activity and transferase activity 
This CpG site is reported to show no correlation between methylation in blood and methylation in 
brain tissue. 
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4.5 Discussion: Therapeutic response to clozapine 
To explore the effects of clozapine on DNA methylation associated with therapeutic response, I 
took three key analysis approaches. Firstly, multi-level model analyses exploring between-individual 
variation in the change between baseline and twelve weeks as predictors of DNA methylation 
trajectories over time, with a model of categorical classification of responder or non-responder and 
then secondly three models of continuous percentage change in total symptom severity, 
psychosocial functional and quality of life.  Then, multi-level model analysis of within-individual 
variation in symptom severity (total, negative and positive) was used as a predictor of variation in 
DNA methylation. Systems involving signal transduction, NMDARs, glycine receptors, calcium 
signalling, neuronal development, cell adhesion, glucose homeostasis, immune function, 
microtubules and transcription regulation are implicated.  
4.5.1 Responders vs non-responders 
Analysis of the association between epigenome-wide DNA methylation and categorical response 
classification identified two DMPs that were significant at the epigenome-wide threshold 
(cg15353603 and cg18043267) and one hundred and sixty eight other DMPs which showed trends 
towards significance. Global DNA methylation levels suggest both groups start and end with 
equivalent levels of global DNA methylation and show the same pattern of an initial decrease and 
then increase, but non-responders show a more pronounced initial decrease. One of the top ten 
differentially methylated sites is located outside of genes, but of the nine located within genes six 
are expressed in brain tissue to some degree, and one is reported to display methylation in blood 
tissue which correlates to methylation in at least one brain region tissue.   
Again, a high proportion of the biological systems indicated by the top ten DMPs and/or top 
thirty pathways associated with categorical response classification have been previously 
demonstrated to be dysfunctional in schizophrenia, and many have also been shown to be 
influenced by antipsychotics including clozapine. 
Several of the overrepresented pathways and the first, seventh, eighth, ninth and tenth DMPs 
are located within genes (respectively: DPP4, PCDP1, DLG4, LCN10 and KCNK9) which are associated 
with different aspects of signal transduction – receptor binding and signalling, ion channels and 
potassium channels, ligand transportation, regulation of voltage-gated calcium channel activity, 
calmodulin binding, cation symporter activity and cell-cell adhesion – some of which have already 
been previously discussed in the context of schizophrenia and clozapine.  
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Calmodulin is a calcium modulated protein which acts in the calcium signal transduction 
pathway by modifying interactions with target proteins; this can involve binding to target proteins, 
many of which cannot bind to calcium themselves so use calmodulin as a calcium sensor and signal 
transducer. Clozapine, among other antipsychotics, has been shown to increase calmodulin proteins 
and mRNA levels in an amphetamine model of schizophrenia (Rushlow, Seah, Sutton, Bjelica, & 
Rajakumar, 2009). Calmodulin mediates inflammation, metabolism, and immune response, as well 
as increasing the sensitivity of AMPARs through phosphorylation, all of which are discussed 
elsewhere in this thesis in the context of clozapine and schizophrenia.  More broadly, dysfunction of 
calcium signalling has been long been implicated in schizophrenia. One review (Lidow, 2003) 
proposes calcium signalling as a unifying molecular pathology in schizophrenia: calcium is involved in 
regulation of dopamine synaptic uptake, is regulated by dopamine receptors, can inhibit NMDAR via 
regulation of NMDA voltage gated calcium channels, is required for myelination-associated proteins, 
and is required for proper formation of synaptic contacts, dendritic trees, cell death, and neuronal 
migration and all of these processes have been found to be disrupted in schizophrenia.  Another 
(Berridge, 2014) has further linked calcium signalling to the NMDAR dysfunction theory of 
schizophrenia, as there appears to be decreased entry of calcium through NMDARs and repetitive 
calcium signalling of NMDARs is involved in maintaining GABAergic inhibitory interneurons. Genetic 
studies support these theories, with post-mortem gene expression data, GWAS and polygenic risk 
scores all implicating calcium related processes such as voltage gated calcium channels (Hertzberg, 
Katsel, Roussos, Haroutunian, & Domany, 2015; Purcell et al., 2014; Ripke et al., 2014) An epigenetic 
study of mQTLs associated with both differential methylation and gene expression specifically 
identified an association between schizophrenia risk and a SNP which regulates calcium homeostasis 
(van Eijk et al., 2015). Clozapine has been shown to normalise disrupted calcium systems in DISC1 
knockout models (Park et al., 2015) and inhibit the current in calcium channels, facilitating influx and 
altering cells excitability and firing properties through action on calcium channels (Choi & Rhim, 
2010).  
Potassium channels are the most common type of ion channel, conducting potassium ions 
rapidly and selectively down the electrochemical gradient in excitable neuronal cells. They shape 
action potentials and regulate secretion of hormones. Mice knock out models without genes 
encoding a voltage-dependent potassium channel subunit show reduced proteins and behavioural 
and pharmacological abnormalities similar to the schizophrenia phenotype, some of which were 
normalised by clozapine (Peltola et al., 2016). Similarly, Duncan, Chetcuti and Schofield, (2008) 
found clozapine (among other antipsychotics) downregulated genes involved in potassium channel 
subunit expression.  
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Cell adhesion molecules are critical to neuronal development – including synapse formation, 
neural connectivity and axonal/dendrite growth – and they have been specifically implicated in 
previous schizophrenia research (Jones & Murray, 1991). Early studies reported decreased 
expression of embryonic neural cell adhesion molecules in post mortem hippocampal samples of 
schizophrenia patients (Barbeau et al., 1995) and more recent genetic studies indicate associations 
between schizophrenia and genes regulating cell adhesion molecules: pathway analysis of the 
International Schizophrenia Consortium data found that only genes associated with cell adhesion 
molecules survived correction for multiple testing (Corvin et al., 2010), and other studies have 
commented on novel risk loci associated with cell adhesion (Collier, Eastwood, Malki, & Mokrab, 
2016; Ripke et al., 2014). Furthermore, Kinoshita et al., (2017) reported that DMPs associated with 
clozapine use in humans were enriched for cell-adhesion genes and animal studies have found that 
clozapine elevates the level of spectrins (which associate with neural cell adhesion molecules) 
(Kedracka-Krok et al., 2015), suggesting this is a process clozapine targets, and my analysis indicates 
this may be linked to clozapine response. 
The eight ranked DMP is located within DLG4, a gene involved in NMDAR function and the ratio 
of excitatory to inhibitory synapses in hippocampal neurons. While this result was not statistically 
significant or at a site where correlation between methylation in brain and blood is indicated, it is of 
interest because of the considerable literature on NMDAR involvement in schizophrenia. NMDARs 
are ionotropic glutamate receptors, which are activated when glutamate and glycine bind to them 
and allow positively charged ions to flow through the cell membrane, and which NMDA selectively 
binds to. They are important for postsynaptic mediation of activity dependent synaptic plasticity and 
memory. Olney, Newcomer and Farber (1999) proposed the NMDAR hypofunction model of 
schizophrenia, partly based on early studies showing that NMDA channel blockers produced positive, 
negative and cognitive symptoms of schizophrenia in healthy controls (Krystal Karper, et al., 1994). 
Ketamine or PCP has since been used to model NMDAR hypofunction, which appears to increase 
glutamate levels in the short term but reduce levels in the long term, with upregulation of NMDA 
transporters. This leads to a schizophrenia-like phenotype: hyperactive subcortical dopamine and 
hypoactive prefrontal dopamine, reduced GABA synthesis enzyme levels, and neurotoxic effects 
(Jentsch & Roth, 1999). Evidence since then has further supported the hypothesis of NMDAR 
hypofunction in schizophrenia, with post-mortem samples and animal studies indicating 
hypofunction (Balu & Coyle, 2015) and genetic studies indicating disruption in NMDAR and 
glutamatergic transmission pathways (Allen et al., 2008; Ripke et al., 2014). There has been some 
suggestion that glutamatergic dysfunction is particularly true or exclusively true in treatment-
resistant patients, especially clozapine-responsive patients (Gillespie et al., 2017; Goldstein, 
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Anderson, Pillai, Kydd, & Russell, 2015), while dopaminergic abnormalities are predominant in 
patients responsive to non-clozapine antipsychotics. This may explain why trials of glutamatergic 
drugs have found no overall effects, but substantial differences between sites (Buchanan et al., 
2007).  
Interestingly, clozapine has been shown to be much more effective in alleviating symptoms in 
PCP models of schizophrenia than haloperidol (Jentsch & Roth, 1999), perhaps due to partial 
agonism of glycine-sites on NMDAR (Schwieler, Engberg, & Erhardt, 2004), enhanced activation of 
NMDAR through both increased release of D-serine and glutamate by glia (Tanahashi, Yamamura, 
Nakagawa, Motomura, & Okada, 2012) and antagonistic effects on glutamate causing NMDAR 
upregulation (Veerman, Schulte, Begemann, Engelsbel, & de Haan, 2014).  
DLG4 has previously found to be hypermethylated in schizophrenia, in a sample of patients 
either on clozapine or risperidone (Liao et al., 2014); in my analysis, responders started with a higher 
baseline level of methylation and ended up showing increases in methylation (increase, decrease, 
increase) while non-responders showed significant decreases (increase first).   
Pathway analysis indicated overrepresentation of DMPs involved in regulation of GABA 
transport. GABA is the most common inhibitory neurotransmitter in the CNS and a reduced level of 
mRNA encoding GAD67 (which regulates GABA synthesis, dependent upon the amount of excitatory 
activity received by GABA neurons) in the DLPFC is “one of the most replicated observations in post-
mortem studies of schizophrenia”, alongside evidence for increased uptake of GABA due to 
decreased GABA transporters (Lewis & Sweet, 2009). Dysfunction of parvalbumin, a calcium binding 
protein involved in GABAergic interneuron signalling, was discussed in the previous chapter as I 
found methylation of a DMP in PVALB to be associated with clozapine levels. GABAergic dysfunction 
may be due to NMDAR hypofunction on GABAergic interneurons; this leads to a defective ability to 
respond to glutamate, with increased glutamate release exciting inhibitory interneurons to release 
GABA, which in turn increases production of NMDAR antagonists leading to a reduction in NMDAR 
function and further increased glutamate release i.e. a defective feedback loop. Genetic studies of 
schizophrenia have implicated associations with genes in GABA pathways, suggesting a genetic basis 
for this dysfunction (Collier et al., 2016). Furthermore, Ohno-Shosaku et al., (2011) found that, in 
cultured hippocampal neurons, clozapine depressed inhibitory transmission and post synaptic 
potentials, by antagonising postsynaptic GABA receptors and inhibiting presynaptic calcium and 
sodium channels.  
The top DMP was within DPP4, a gene involved in regulation of immune function via T-cell 
receptors. The relationship between schizophrenia and clozapine and immune function was 
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discussed above, but T cells specifically interact with MHC molecules (also called HLA complex) 
which are receptors that aid identification of antigens. Debnath, (2015) specifically singles out 
altered T cell function in schizophrenia, as T cells can infiltrate the brain and dopamine can modulate 
the proliferation, trafficking and function of T cells, MHC pathways have been implicated in 
schizophrenia by some of the largest genetic studies to date (Ripke et al., 2014), and clozapine 
appears to regulate T cell levels (Chen et al., 2011; Fernandez-Egea et al., 2016; Steiner et al., 2010). 
DPP4 is also associated with glucose homeostasis, which as discussed above, has been 
implicated in schizophrenia and clozapine; similarly, the sixth DMP was within ABCG1, a gene 
associated with ATP transportation, and the tenth DMP was within a gene associated with 
intellectual disability, KCNK9.   
The candidate gene testing provided only weak support for an association between classification 
as non-responder to clozapine and differential methylation at CpG sites on DRD3, 5HTT, 5HTR2A and 
CREBBP; no associations survived correction for multiple testing.  
Results from this model provide some replication of results from previously collected cross-
sectional data, with significant positively correlated direction of effect for their top DMPs. Similarly, 
results from the cross-sectional data provided replication of results from my longitudinal clozapine 
levels analysis, with significant positively correlated direction of effect for my top DMPs. As a 
positive correlation indicates a common direction of effect associated with non-response in the 
current sample, this could indicate high levels of non-response in the cross-sectional sample or again 
it could reflect differing methylation patterns over time (blood may have been taken before six 
weeks or after six months of clozapine exposure, and this may show a different relationship with 
response to clozapine). 
As in the previous chapter, some of the significant DMPs appear to be driven by outliers, and this 
should be considered when drawing conclusions. For example, methylation at both cg18043267 (the 
second most significant DMP) and cg04408162 (the tenth most significant DMP) rose sharply in one 
non-responder towards the end of the study, whereas for the rest of the sample the differences in 
methylation are much subtler. It may be that these CpG site were of significance for the clinical 
response in these individuals or, perhaps more likely, they may be spurious findings and thus should 
be treated with caution. They are presented here in this exploratory analysis but future work looking 
to replicate and find common patterns across groups must consider how to tackle outliers.  
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4.5.2 Change in total symptoms (continuous)  
Analysis of the association between epigenome-wide DNA methylation and change in total 
symptom severity identified two DMPs that were significant at the epigenome-wide threshold 
(cg10015974 and cg15353603), and one hundred and eighty eight other DMPs which showed trends 
towards significance. The majority of the top ten DMPs show additional increases in methylation 
associated with increased percentage reduction and global DNA methylation indicates this pattern 
also. Two of the top ten DMPs are located outside of genes, but of the eight located within genes 
seven are expressed in brain tissue to some degree, and three sites are reported to display 
methylation in blood tissue which correlates to methylation in at least one brain region tissue. 
Again, a high proportion of the biological systems indicated by the top ten DMPs and/or top 
thirty pathways associated with change in total symptom severity have been previously 
demonstrated to be dysfunctional in schizophrenia, and many have also been shown to be 
influenced by antipsychotics including clozapine. One gene in particular – SETD1A – has been 
previously associated with schizophrenia. 
Two of the top DMPs for continuous change in symptom severity were also within the top ten 
DMPs for categorical response classification, unsurprisingly as these analysed the same variables but 
in categorical and continuous forms: cg15353603 in DPP4 and cg06275059 in PCDP1, genes 
implicated in glucose homeostasis, receptor binding, immune activation via T cells, and calmodulin 
binding.  Similarly, the seventh DMP was in ANO1, a gene associated with calcium chloride channel 
activity – while this does not directly overlap with the categorical response results, both implicate an 
effect on calcium signalling which – as discussed above – is thought to be disrupted in schizophrenia 
and potentially normalised by clozapine.  
ANO1 is also associated with glucose regulation, which was discussed in Chapter 3 as this system 
was implicated in results for clozapine levels.  
The tenth ranked DMP was within SETD1A. While this CpG site was not statistically significant 
and is not indicated to have correlated methylation between blood and brain, SETD1A is a gene 
which has specifically been associated with schizophrenia and so is of particular interest. SETD1A 
encodes a subunit of a histone methyltransferase protein complex, which mediates methylation of 
histone 3 at Lysine 4 (H3K4), a marker of active gene transcription. An association between 
schizophrenia and loss-of-function variants of SETD1A was first identified by an exome sequencing of 
231 parent and proband trios (Takata et al., 2014), and this was confirmed by a study of over 4,000 
schizophrenia cases (Singh et al., 2016) 
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Histone methylation processes are strongly associated with psychiatric disorders, including 
schizophrenia – as identified by pathway analysis of mega-analyse of genomic data - (Consortium, 
2015), and H3K4 tri-methylation appears involved in neurodevelopment, and regulation of neuronal 
signalling - specifically GABAergic, glutamatergic and dopaminergic signalling (Dincer et al., 2015). 
Clozapine inducing an upregulation in H3K4 tri-methylation of GAD1 was one of the key findings by 
Huang et al., (2007), and this effect may come about through disruption of regulatory genes like 
SETD1A.  
The third DMP was in TRIM31, a gene associated with immune function via interferon gamma 
signalling. The general association between the immune system and both schizophrenia and 
clozapine is described above; interferon signalling specifically involves a type of cytokine made and 
released by host cells in response to pathogens, causing nearby cells to heighten defences. This 
includes upregulating antigen presentation by increasing MHC expression, leading to fever and other 
flu-like symptoms. Interferon gamma is a type II class interferon produced predominantly by T cells 
and is critical for innate and adaptive immunity, with immune-stimulatory and immunomodulatory 
effects and the ability to alter transcription of up to 30 genes. It is one of the cytokines which Song 
et al, (2000) found to increase in response to clozapine. 
TRIM31 is also involved in ubiquitin proteins and ligase activity, both systems discussed in 
Chapter 3, associated with time on clozapine.  
4.5.3 Change in psychosocial functioning 
Analysis of the association between epigenome-wide DNA methylation and change in 
psychosocial functioning identified one DMP that was significant at the epigenome-wide threshold 
(cg05195750) and one hundred and twenty two other DMPs showed trends towards significance. 
The majority of the top ten DMPs show additional increases in methylation associated with greater 
improvements in psychosocial functioning and global DNA methylation shows the same pattern. One 
of the top ten DMPs is located outside of any genes, but of the nine located within genes all are 
expressed in brain tissue to some degree, and four sites are reported to display methylation in blood 
tissue which correlates to methylation in at least one brain region tissue. 
Again, a high proportion of the biological systems indicated by the top ten DMPs and/or top 
thirty pathways associated with change in psychosocial functioning have been previously 
demonstrated to be dysfunctional in schizophrenia, and many have also been shown to be 
influenced by antipsychotics including clozapine.  
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The first DMP in ELP4, a histone acetyltransferase associated with chromatin organisation and 
risk of epilepsy, was also in the top ten DMPs associated with time on clozapine and is discussed in 
Chapter 3.  Similarly, the fifth DMP was in IQCE, a gene associated with GPCRs and the sixth DMP 
was in OLFM2, a gene associated with AMPAR organisation: both of these are systems which were 
implicated in exposure to clozapine analysis and their dysfunction in schizophrenia was discussed in 
Chapter 3 also. 
The second DMP was in TRIM25, a gene associated with interferon signalling and the seventh 
DMP was in CLEC10A, a gene associated with inflammation. While the DMP in CLEC10A was not 
statistically significant or in a location indicated to show correlated methylation between blood and 
brain, it is not only associated with inflammation but carbohydrate binding (the ninth DMP in UGP2 
is associated with carbohydrate conversion) and with cell adhesion, a process implicated by studies 
of genetic risk for schizophrenia. The third DMP is in PKNOX, a gene associated with cell 
proliferation. Changes in methylation of genes involved in systems of immune function, abnormal 
cell development, glucose homeostasis and cell adhesion were all implicated by analysis of change in 
total symptom severity and are discussed above also.  
PKNOX is also associated with substance dependence. A prospective population based study 
using Danish registers found that substance abuse was associated with an six fold increased risk of 
schizophrenia, with risk especially high for cannabis and alcohol and significant effects even after 15 
years (Nielsen, Toftdahl, Nordentoft, & Hjorthøj, 2017). Similarly, a review (Thoma & Daum, 2013) 
reports that around half of patients with schizophrenia have comorbid substance dependence, 
particularly men with early onset. This review outlines numerous explanations: diathesis-stress 
model, in which drug use triggers genetic risk; cumulative risk factor model, in which poor cognitive 
abilities and low functioning lead to drug use; self-medication hypothesis, in which patients abuse 
drugs in an attempt to alleviate symptoms; affect regulation model, in which personality traits such 
as impulsivity and maladaptive coping mechanisms lead to drug use; altered reward processing 
hypothesis, in which patients overvalue the positive consequences of drugs; or the developmental 
dysfunction hypothesis, in which developmental deficits lead to a predisposition for both. 
Interestingly, studies of polygenic risk have found that the polygenic risk score for schizophrenia is 
associated with substance abuse disorders suggesting common genetic risk (Hartz et al., 2017). Some 
studies have reported that clozapine may be particularly efficacious for substance abuse, with a 
systematic review reporting that clozapine was superior in all existing comparison studies 
(Machielsen & de Haan, 2009); they suggest this may be due to its profile of low D2 receptor 
occupancy, high dissociation rate and a high D1/D2 receptor ratio. Mesholam-Gately, Gibson, 
Seidman, & Green (2014) suggest that clozapine may ameliorate dysfunction of the brain reward 
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circuit, demonstrating that patients on clozapine show broader and stronger responses to rewarding 
stimuli. Interestingly, some studies report that patients with a history of substance abuse are better 
responders to clozapine treatment, even if they are equivalent in other characteristics and clinical 
severity at baseline (Buckley, Thompson, Way, & Meltzer, 1994; Kelly, Gale, & Conley, 2003) 
The fourth ranked DMP was in EGR2, a gene associated with disorders of hypo-myelination. 
Hypo-myelination has been frequently reported in schizophrenia (Carter, 2007), a recent review 
highlights myelination abnormalities as a key etiological mechanism of schizophrenia present from 
onset (Stedehouder & Kushner, 2016) and animal studies support that hypo-myelination is 
associated with schizophrenia like behaviours (e.g. impaired PPI) (Ishimoto et al., 2017) . A review 
(Corfas, Roy, & Buxbaum, 2004) suggests that hypo-myelination leads to reduced or irregular neural 
transmission (perhaps an adaptation of the brain, altering synaptic release or expression of 
receptors and other molecules), which then leads to dysfunctional perception and emotional 
processing, and/or that hypo-myelination may “unmask” other dysfunction in brain structure or 
connectivity. A review of genetic and neuroimaging studies reports that genes regulating 
myelination and oligodendrocyte function appear dysregulated in schizophrenia, and that density 
and distribution of oligodendrocytes in PFC appears altered along with reduced myelin content (Woo 
& Crowell, 2005), and recent pathway analysis of genetic data  Duncan et al., (2014) implicates the 
glia-oligodendrocyte pathway in schizophrenia . Maas, Vallès and Martens, (2017) suggested that 
hypo-myelination may be caused by oxidative stress (triggered by genetic and environmental 
factors) impairing signal transduction processes for oligodendrocytes, necessary for the adolescent 
PFC myelination process. In comparison to haloperidol, clozapine has been found to enhance 
oligodendrocyte glucose metabolism, improving the energy supply and myelin lipid synthesis, 
leading to greater white matter integrity (Steiner et al., 2014)   
TRIM25, PKNOX, and EGR2 are also all genes for transcription factors, again highlighting the 
potential role of clozapine in regulating gene expression indirectly through methylation of genes 
which regulate transcription.  
4.5.4 Change in quality of life 
Analysis of the association between epigenome-wide DNA methylation and change in quality of 
life identified one DMP (cg14150252) that was significant at the epigenome-wide threshold and one 
hundred and forty eight DMPs showing trends towards significance. The majority of the top ten 
DMPs showed additional increases in methylation associated with increased changes in quality of life 
and global DNA methylation shows this association also. One of the top ten DMPs is located outside 
of genes, but of the nine located within genes all are expressed in brain tissue to some degree, and 
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six are reported to display methylation in blood tissue which correlates to methylation in at least 
one brain region tissue. 
Again, a high proportion of the biological systems indicated by the top ten DMPs and/or top 
thirty pathways associated with change in quality of life have been previously demonstrated to be 
dysfunctional in schizophrenia, and many have also been shown to be influenced by antipsychotics 
including clozapine.  
Three of the DMPs have been within the top ten DMPs of other analysis (cg14150252 in UGP2 
associated with psychosocial functioning, cg05195750 in ELP4 associated with psychosocial 
functioning and time, and cg07829465 in TRIM31 associated with response classification). 
Furthermore, many of the individual DMPs and over-represented pathways implicate systems also 
implicated in previous analysis. The third DMP was in SLC9A3, a gene associated with sodium ion 
transport and signal transduction. The sixth DMP was in BTRC, a gene associated with ubiquitination 
and ligase activity. The seventh DMP was in EHF, a transcription repressor. The eight DMP was in 
SRL, a gene associated with calcium transport. Changes in methylation of genes involved in signal 
transduction, ubiquitination, ligase activity, regulation of transcription and calcium transport were 
all systems implicated by analysis of time exposed to clozapine and change in total symptom severity 
and are discussed above also. However, there were some novel systems implicated as well.  
BTRC is also associated with immune function and specifically interleukin (IL) signalling; 
interleukins are a group of thirty six cytokines first expressed by leukocytes, which the immune 
system relies upon for various forms of regulation, inhibiting or increasing production of other 
cytokines or lymphocytes. A meta-analysis of IL10 polymorphisms (IL10 inhibits synthesis of a 
number of cytokines) found an association with schizophrenia (Gao, Li, Chang, & Wang, 2014), and 
clozapine has been shown to increase IL10 (Ajami et al., 2014) ; clozapine has also been shown to 
inhibit neutrophil migration via IL8 (Capannolo et al., 2015), and both increase IL6 (B cell stimulatory 
factor) in healthy controls (Song et al., 2000) but decrease IL6 in macrophage cell cultures 
(Kracmarova & Pohanka, 2014). 
4.5.5 Total symptom severity 
Analysis of the association between epigenome-wide DNA methylation and total symptom 
severity identified five DMPs that were significant at the epigenome-wide threshold (cg02890365, 
cg23158483, cg26129353, cg17651451 and cg23290344) and four hundred and fifty three other 
DMPs showing trends towards significance. The majority of the top ten DMPs showed decreases in 
methylation associated with total severity, however global DNA methylation showed an increase. 
Two of the top ten differentially methylated sites are located outside of genes, but of the eight 
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located within genes seven are expressed in brain tissue to some degree, and four sites are reported 
to display methylation in blood tissue which correlates to methylation in at least one brain region 
tissue. 
 The first and fifth ranked DMP are within TUFT1 and NEFM, genes implicated in  neuronal 
differentiation and neuronal calibre (diameter, degree of myelination) and pathway analysis also 
indicated overrepresentation of DMPs in neuron project development and guidance, and 
axonogenesis and axon development and guidance specifically, and highlighted development in the 
limbic system and hippocampus. Furthermore, analysis indicated above that DMPs on genes 
involved in neuronal plasticity were associated with clozapine level. 
Abnormalities in neuronal development processes have long been implicated in schizophrenia, 
with an early review (Jones & Murray, 1991) highlighting not only structural abnormalities but 
potential defects in cell proliferation, migration, connectivity, axonal growth, myelination and 
neuronal density. Post-mortem studies (Lewis & Sweet, 2009) indicate increased neuronal density 
due to reductions in axon terminals and dendritic spines, lowered gene expression for proteins 
present in axon terminals, dendritic length and spine density, and suggest there may be exaggerated 
synaptic pruning during adolescence or deficits which adolescent synaptic pruning reveals.  
DISC1 knock out studies have resulted in neurons have aberrant development and 
dispositioning, enhanced excitability and accelerated formation, suggesting this gene (long 
associated with schizophrenia) regulates progress of neuronal integration (Duan et al., 2007); DISC1 
appears to exert its affect via numerous protein interaction partners involved in neuronal migration, 
neural progenitor proliferation, neuron signalling and synaptic function (Bradshaw & Porteous, 
2012). Interestingly, clozapine has been shown to reverse DISC-1 induced disruption of systems 
which regulate of axonal growth (Park et al., 2015). 
A number of studies have observed neurons developed from human induced pluripotent stem 
cells of patients with schizophrenia, and found a wide range of abnormalities: diminished neuronal 
connectivity and decreased neurite numbers, as well as decreased glutamate receptor expression 
and altered expression of Wnt signalling pathways (Brennand et al., 2011) (both discussed above); 
cytoskeletal remodelling, aberrant migration, increased oxidative stress, and dysfunctional neuronal 
maturation and cell adhesion gene expression (Brennand et al., 2015); differential expressed genes, 
copy number variants and differential methylation, with differential expression pathways (validated 
by post mortem study) indicating genes associated with neurodevelopment (Maschietto et al., 
2015); and dopaminergic cells showing an impaired ability to differentiate and glutamatergic cells 
unable to mature, and disruption of mitochondrial connectivity, responsiveness and structure (which 
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modulates morphogenesis and plasticity of spines and synapses) related to both (Robicsek et al., 
2013). It is worth noting that a) many of these studies involve very small sample sizes and therefore 
may not reflect schizophrenia as a whole and b) cultured cells are more likely to have genomic 
instability and mutations, but there appears to be consistent implication of abnormal neuronal 
development in stem cells taken from schizophrenia patients. 
Some (Selemon & Zecevic, 2015) have suggested that prenatal maternal exposure or genetic 
liability limits early gestational cell proliferation, and then stress from adverse social situations in 
adolescence increases dopamine stimulation of meso-cortical pathways and leads to exaggerated 
synaptic pruning, and the combination of these two hits leads to schizophrenia; this is partly based 
on animal models showing that limiting early gestational cell proliferation can lead to schizophrenia-
like behaviour, and dopamine hyper stimulation decreases pyramidal cell spine density and induces 
cognitive changes. These abnormalities may underlie dysfunction in signal transduction; or they may 
be caused by signalling dysfunction. 
The third DMP is within ATP8B1, a gene involved in ion channel transport, NEFM1 is involved in 
intracellular transport to axons and dendrites, and the tenth DMP is within CORO1A, involved in 
signal transduction generally. Additionally, pathway analysis also indicated overrepresentation of 
DMPs in genes involved in calcium ion binding and cell adhesion; cell adhesion specifically was the 
most over-represented pathway in this analysis and one of the most statistically significant across all 
analysis in this thesis.  Different aspects of signal transduction have been implicated in all of the 
analyses, and have been discussed previously.  
The second ranked DMP is within the promoter region of GLRA1, which encodes a subunit of the 
glycine receptor. Glycine receptors are ionotropic receptors which produce fast responses when 
chloride current enters the neuron and induces hyperpolarisation; they are one of the most widely 
distributed inhibitory receptors, but there are also extra-synaptic excitatory glycine receptors which 
control migration of interneurons via activation of voltage-gated calcium channels, and some co-
localise with GABA-A receptors on some hippocampal neurons. They are activated by a range of 
simple amino acids including glycine (biosynthesised from serine) but also b-alanine and taurine. The 
glycine system interacts with the glutamate system, as glycine is a required co-agonist for NMDARs 
and levels of occupancy and reuptake modulate calcium dependent neuronal excitation. A review of 
recent genetic studies highlighted noteworthy loci associated with schizophrenia which included 
SLC32A1, involved in glycine transport and localised to inhibitory terminals of glycinergic neurons, 
and NLGN4X which is localised to glycinergic post-synapses and regulates the number of glycine 
receptors (Collier et al., 2016). Yamamori et al., (2014) found that d-serine (from which L-serine is 
Therapeutic Response to Clozapine and Associated DNA Methylation Changes 
- 216 - 
 
synthesised) and D/L serine ratios are lower in schizophrenia patients, and the ratio increases and 
normalises as symptoms improve and with clozapine treatment. 
A meta-analysis of clinical trials in schizophrenia found that glycine and d-serine particularly 
improve negative symptoms (Tuominen, Tiihonen, & Wahlbeck, 2005), and d-serine has been found 
to improve all PANSS measures in treatment-resistant schizophrenia as an adjunct to risperidone or 
olanzapine, with a third of patients becoming responders to antipsychotics (>20% reduction in BPRS) 
(Heresco-Levy et al., 2005) . D-cycloserine has also been shown to improve negative symptoms and 
memory consolidation (Goff et al., 2008), and D alanine has been shown to significantly improve CGI 
and PANSS scores (Tsai, Yang, Chang, & Chong, 2006), both as adjuncts. Tuominen et al. (2005) note 
that trials tend to show no improvement when glycine agonists are adjuncts to clozapine e.g. (Evins, 
Fitzgerald, Wine, Rosselli, & Goff, 2000), and suggest this is because clozapine is already working via 
this mechanism of action, a suggestion also made by others (Harvey & Yee, 2013; Tsai et al., 1999) 
who found no effect of serine on symptoms in clozapine treated patients and say that this is 
consistent with clozapine already activating the NMDA glycine receptor. The idea that clozapine may 
be an NMDAR glycine receptor agent is supported by animal studies which find that clozapine has 
similar effects to d-serine and glycine transporter inhibitors in restoring disrupted prepulse and 
latent inhibition (Lipina, Labrie, Weiner, & Roder, 2005). 
GLRA1 has also been associated with startle disease, an exaggerated startle response. Deficits in 
pre-pulse inhibition (in which a weaker pre-stimulus inhibits reaction to subsequent stronger stimuli) 
have been widely replicated in schizophrenia, with a recent review suggesting that underlying 
schizophrenia pathology is a cognitive, motor and sensory gating impairment (an inability to filter 
out redundant or unnecessary stimuli) (Swerdlow, Braff, & Geyer, 2016). This review also noted that 
intact PPI appears to be a good predictor of response, suggesting that deficits may be particularly 
relevant for treatment-resistant patients. Interestingly, in animal models, clozapine has been shown 
to reverse PPI deficits induced by dopamine agonists (Swerdlow & Geyer, 1993) or PCP (Bakshi, 
Swerdlow, & Geyer, 1994), with the later study demonstrating that this effect could not be 
attributed solely to antagonism of D1, D2 or 5-HT2 receptors.   
The tenth ranked DMP is located within  CORO1A, a gene involved in immune function. The 
fourth ranked DMP is within ADAMTS2, a gene associated with collagen biosynthesis. The third DMP 
is located within ATP8B1, a gene involved in nucleotides, and CORO1A is involved in gene regulation. 
Changes in methylation of genes involved in immune function, , collagen biosynthesis and gene 
regulation were all systems implicated by analysis of time exposed to clozapine and change in total 
symptom severity or psychosocial function and are discussed above. 
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4.5.6 Positive symptom severity 
Analysis of the association between epigenome-wide DNA methylation and PANSS positive 
severity identified three DMPs that were significant at the epigenome-wide threshold (cg03661817, 
cg02759966 and cg08283882) and two hundred and thirty four other DMPs showing trends towards 
significance. The majority of the top ten DMPs and global DNA methylation showed increases in 
methylation associated with higher positive symptom severity. Two of the top ten DMPs are located 
outside of genes, but of the eight located within genes seven are expressed in brain tissue to some 
degree, and four sites are reported to display methylation in blood tissue which correlates to 
methylation in at least one brain region tissue. As previously noted for other analyses, some of the 
significant DMPs may be driven by outliers – this is most evident in the second DMP for this analysis, 
cg02759966, in which one individuals methylation levels are starkly different from the rest of the 
sample. 
The first ranked DMP is within KIFC3, a gene associated with microtubule and bipolar mitotic 
spindles, necessary for chromosomal segregation; my analysis indicated DMPs involved with beta-
tubulin and microtubule function were also associated with exposure to clozapine, as described 
above.  
The eight ranked DMP is within HLA-DQB2, a gene associated with sleep disorders. Many 
psychiatric disorders include sleep disturbances, but early reviews of evidence suggested that 
disturbances were especially pronounced in schizophrenia (Benca, Obermeyer, Thisted, & Gillin, 
1992) and more recent reviews confirm that sleep disturbances are common in schizophrenia 
patients, even from prodromal stages (Cohrs, 2008): this seems to come in the form of reduced 
sleep efficiency and total sleep time, and increased sleep latency (time to fall asleep), as well as 
potential differences in REM and slow wave sleep. The latter review noted that clozapine specifically 
appears to normalise these disturbances, and while this could be explained as a secondary effect of 
symptom reduction, the same direction of effect is seen in healthy controls suggesting a direct 
effect.  
The ninth ranked DMP is within ATL3, a gene associated with endoplasmic reticulum tubules – 
these are tubules within the network of intracellular membranes which synthesise and export 
proteins and membrane lipids. One of this network’s many functions is to regulate intracellular 
calcium homeostasis which, as discussed above, is disrupted in schizophrenia and affected by 
clozapine. It also interacts with the ubiquitin system, again, discussed above in context of disruption 
in schizophrenia. ATL3 has also been associated with neuropathy - nerve disorders of sensory, motor 
or autonomic systems. There is limited research linking this to schizophrenia, but (Neale, Olszewski, 
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Gehl, Wroblewska, & Bzdega, 2005) discusses a common disruption of N-acetyl-aspartyl-glutamate 
in models of both neuropathic pain and schizophrenia, with NAAG peptidase inhibitors modulating 
both models.  
HLA-DQB2 is involved in immune function, in particular interferon gamma signalling, as part of 
the MHC. The third, fourth, and sixth ranked DMPs are within EBF2, MIR641 and INTS9, which are 
implicated in transcription regulation, micro RNA and RNA polymerase function. Both immune 
function and regulation of gene expression are systems which have been implicated by analysis of 
DMPS associated with exposure to clozapine and change in symptom severity, and have been 
discussed above.  
4.5.7 Negative symptom severity 
Analysis of the association between epigenome-wide DNA methylation and negative symptom 
severity identified fourteen DMPs that were significant at the epigenome-wide threshold 
(cg00293996, cg21288861, cg02518691, cg271166770, cg01371207, cg03321142, cg08682625, 
cg14660007, cg19060383, cg05797770, cg17502527, cg00919806, cg05340048 and cg10594105) as 
well as seven hundred and thirty six other DMPs which showed trends towards significance, making 
this the analysis with the most statistically significant results within this thesis. The majority of the 
top ten DMPs showed decreases in methylation associated with negative symptom severity but 
global DNA methylation showed an increase. None of the top ten DMPs are located outside of 
genes, and of the ten located within genes nine are expressed in brain tissue to some degree, and 
four sites are reported to display methylation in blood tissue which correlates to methylation in at 
least one brain region tissue. 
These sites implicate pathways including synapse maturation, dendrite outgrowth, G-protein 
couple receptors, kinase activity, cell adhesion, cell-surface mediation signalling, signal transducer 
activity, RNA, microtubule binding, heparin binding, integrin binding, chaperone binding, tubule 
folding, kidney filtration. They have also been associated with deafness and colorectal and prostate 
cancer. 
The first ranked DMP is within CLDN14, a gene which has been associated with deafness. Early 
studies (Cooper, 1976) drew a link between schizophrenia and deafness, noting that samples of 
older patients with paranoid psychosis have a particularly high proportion who are hard of hearing, 
and suggesting that this may lead to social isolation or dysfunction with subsequent psychological 
impact, or that predisposed individuals with hearing impairments may misperceive auditory stimuli 
and develop subsequent inappropriate associations. Minimal research has been done in recent 
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years, but one review (S Leucht et al., 2007) found two studies investigating an association between 
schizophrenia and ear disease or hearing loss, both of which reported positive findings.  
The sixth and tenth ranked DMP are within IGSF9 and EPHA2, two genes associated with synapse 
maturation, dendrite outgrowth and the development of the nervous system, some of which was 
discussed above in the context of schizophrenia and clozapine. Research has specifically investigated 
dendritic growth in schizophrenia; dendrites integrate synaptic inputs (up to 100,000) and determine 
the production of action potentials, and dendritic spines increase the ability to isolate signal 
specificity.  They change in response to neural activity and long term potentiation and affect the 
communication and processing of cells.  Combining PGC genetic data and proteomic data of 
schizophrenia samples has indicated disruptions in dendritic spine development (Pers et al., 2016), 
supporting previous models linking DISC1 to dendritic development (Duan et al., 2007; Kim et al., 
2012) and one review of post-mortem studies which indicated that reduced density of dendritic 
spines was one of the most consistent findings in schizophrenia e.g. (Konopaske, Lange, Coyle, & FM, 
2014), with some suggestion of reduced dendritic arborisation as well (Moyer, Shelton, & Sweet, 
2015). This appears to be significant in schizophrenia as accelerated reduction in grey matter during 
adolescence is one of the predictors for transition to psychosis. Alterations in dendritic growth may 
be due to the disruption in schizophrenia of microtubules, calcium channel signalling and/or 
myelination discussed above. Critchlow et al., (2006) report that in cultures of rat hippocampal 
neurons clozapine increased primary dendritic spine density by 59%, whereas haloperidol led to 
reduced density. Similarly, Barros et al., (2009) report that clozapine was able to reverse dendritic 
spine deficits and associated behavioural deficits in gene knock out studies of ErbB2/B4-mediated 
NRG1 signalling. In contrast, Jaehne et al., (2015) found that clozapine was unable to reverse 
dendritic spine deficits in 14-3-3 knock out mice, but suggests that the cause of dendritic spine loss 
may be crucial to clozapine’s abilities to reverse this.   
EPHA2 is also associated with GPCRs and kinase activity, IGSF9 is associated with cell adhesion, 
and the second and fourth DMPs are within ITGB3 and TRIM54 which are genes associated with cell 
adhesion and signal transduction; all of these processes have been implicated and discussed above.  
ITGB3 and ADAMTS8, in which the third ranked DMP is located, are both genes associated with 
integrin binding. Integrins are produced by a wide variety of cells and play a role in cell adhesion and 
signal transduction primarily for extracellular matrix components. Integrins form cell adhesion 
complexes with other proteins to regulate kinase signalling and circulating leukocytes have cell 
membrane integrins which maintain their inactivity until inflammatory response is required.  
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The ninth ranked DMP is within NPHS1, a gene associated with kidney filtration via 
immunoglobin cell adhesion molecules. Kidneys filter blood to make urine and regulate water, 
waste, nitrogen, ion concentrations, hormones, acid-base balance and blood pressure.   
The seventh ranked DMP is within LOC727677, a gene associated with colorectal and prostate 
cancer. One review has reported increased rates in schizophrenia, particularly associated with 
antipsychotic use (Seeman, 2010); however, the majority of individual studies report decreased rates 
of most cancers including colorectal or prostate cancer (Dalton et al., 2006; Howard et al., 2010; 
Lichtermann, Ekelund, Pukkala, Tanskanen, & Lönnqvist, 2001; Mortensen, 1994). 
TRIM54, PFDN6 – in which the fifth DMP is located - and LOC727677 are all genes associated 
with different aspects of gene and protein expression: miscRNA, microtubule binding and folding, 
and chaperone binding (proteins assisting primarily in protein folding and assembly).  
4.5.8 Summary 
To summarise, two DMPs were epigenome-wide significant for an association with responder 
status - cg15353603 which is located within DPP4 (regulates glucose homeostasis and immune 
function) and cg18043267 which is located within C10orf125 (involved in cell-cell adhesion). The 
former was also epigenome-wide significant for an association with percentage change in symptom 
severity, unsurprisingly, as was cg10015974. Only one DMP was epigenome-wide significant for an 
association with percentage change in psychosocial functioning - cg05195750 in ELP4 (a histone 
acetyltransferase complex)– and one DMP was significantly associated with percentage change in 
quality of life –cg14150252 which is located within UGP2 (involved in carbohydrate conversion). 
None of the candidate genes for response were found to have significant DMPs in the categorical 
response model; however, the top regression coefficients associated with response status were 
significantly associated with previous cross-sectional data on clozapine exposure, providing a form of 
replication and some supporting evidence that the associations found are relevant to the 
therapeutic efficacy of clozapine and not spurious findings. Also, as might be expected some of the 
models produced the same DMPs. The categorical and continuous version of percentage change in 
PANSS both identified the same CpG sites in DPP4 and PCDP1, unsurprisingly as these were looking 
at the same variable coded differently. Similarly, but more interestingly, the models of change in 
quality of life and psychosocial function – overlapping and correlated constructs but based on 
distinct measures – both identified the same CpG sites in ELP4 and UGP2 within their top ten 
significant DMPs.  
Each of the analysis exploring symptom severity (total, positive or negative) found epigenome-
wide significant DMPs. Five were associated with total symptoms - cg02890365 in TUFT1 (involved in 
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neuronal differentiation), cg23158483 in GLRA1 (encoding a glycine receptor subunit), cg26129353 
in ATP8B1 (involved in ion channel transport), cg17651451 in ADAMTS2 (involved in collagen 
biosynthesis) and cg23290344 in NEFM (involved in neuronal calibre and transport between axons 
and dendrites). Three were associated with positive symptoms - cg03661817 in KIFC3 (involved in 
bipolar mitotic spindles), cg02759966, and cg08283882 in EBF2 (a transcription factor) – and 
fourteen were associated with negative symptoms, making negative symptoms the strongest 
predictor of differential methylation of any variable studied in this thesis – the top ten were 
cg00293996 in CLDN14 (associated with deafness), cg21288861 in ITGB3 (involved in cell adhesion), 
cg02518691 in ADAMTS8 (involved in integrin binding), cg271166770 in TRIM54 (involved in signal 
transduction and microtubules), cg01371207 in PFDN6 (involved in tubulin folding), cg03321142 in 
IGSF9 (involved in cell adhesion and dendritic and synaptic development), cg08682625 in 
LOC727677, cg14660007 in SLAIN1, cg19060383 in NPHS1 (involved in cell adhesion and kidney 
filtration) and cg05797770 in EPHA2 (involved in GPCR function). The majority of DMPs were 
expressed in brain, and just under half have evidence for correlation between methylation in blood 
and brain. It is worth bearing in mind that the categorical response model and percentage change 
models are significantly less powered analyses because these compare between individuals, whereas 
the measures of symptom severity are exploring variation within individuals and therefore control 
for many more confounding variables related to individual differences.   
Again, while these models are exploring related variables, we can look at systems indicated by 
differing methodological approaches to find those most likely to reflect changes associated with a 
symptomatic response to clozapine. 
Both categorical and continuous measures of between-individual change in overall symptoms in 
response to clozapine indicate differential methylation in genes associated with receptor signalling 
and function, ion channels (in particular calcium channels), neuronal precursors, immune function, 
glucose homeostasis, and regulation of gene expression; within-individual variation of symptoms at 
any time point also indicate differential methylation genes associated with all of these except 
glucose homeostasis. Similarly, between-participant variation in percentage change in overall 
symptoms, psychosocial functioning and quality of life all indicated differential methylation in genes 
associated with receptor signalling function, calcium channels, immune function, glucose 
homeostasis and regulation of gene expression. Positive symptoms appear to be associated with 
differential methylation of genes indicated in signal transduction, ion channels, immune function 
and transcription regulation, while negative symptoms appear to be associated with signal 
transduction, receptor function, neuronal development and transcription regulation. Positive and 
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negative symptoms are quite different phenomenon, so it is to be expected that there would be 
deviation between the DMPs and systems implicated.  
While this analysis allows us to identify differential methylation associated with therapeutic 
response and therefore likely to indicate regions associated with mechanisms of clinical interest, the 
causal relationship is still uncertain; these changes in DNA methylation may be the cause of 
symptomatic change, or may simply reflect the processes of symptomatic change.  
Looking back at the previous chapter, models of exposure to clozapine and models of 
therapeutic response to clozapine both overlap in indicating differential methylation at loci involved 
in signal transduction, ion channels (especially calcium), GPCRs, glutamatergic function, 
microtubules or beta tubulin, and regulation of gene expression, as well as immune function and 
glucose homeostasis; as this analysis associates the latter two with response to clozapine, this 
suggest the effect on these systems may be critical to the  therapeutic efficacy of clozapine and not 
just associated with adverse reactions. 
 The next chapter will present my analysis on adverse reactions during clozapine treatment.  
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5 Adverse Reactions to Clozapine and Associated DNA Methylation Changes  
5.1 Background: Adverse reactions to clozapine 
In this section I will first outline research on the prevalence of adverse reactions and implications 
for patients, and then review existing research on potential mechanisms underlying adverse 
reactions, which is predominantly genetic.  
Aside from the well-known but relatively rare cases of agranulocytosis, there are many more 
common adverse reactions of clozapine which also put patients at high risk. Patients with severe 
mental illness, including schizophrenia, have increased mortality rate and reduced life expectancy, 
with cardiovascular disease one of the leading causes of death, partly driven by increased rates of 
metabolic syndrome and associated obesity, glucose intolerance and hypertension. Weight gain and 
metabolic syndrome hold the potential for developing diabetes or cardiac problems, both of which 
increase the risk of a range of negative outcomes. In 2004, the American Diabetes Association 
highlighted the clinical significance of long-term antipsychotic use increasing risk for obesity related 
problems, which seems to be a particularly high risk for African-American patients (Blin & Micallef, 
2001).  
Various reviews (Nasrallah & Newcomer, 2004) highlight the increased risk posed by clozapine. 
Along with olanzapine, clozapine has been reported as the second-generation-antipsychotic known 
to be most highly associated with weight gain (Pramyothin & Khaodhiar, 2010). Lamberti, Bellnier 
and Schwarzkopf (1992) found that half of patients on clozapine have metabolic adverse reactions, a 
significantly higher proportion than those in a matched comparison group within the healthy 
population. One naturalistic study of 307 patients found no increased risk for clozapine patients of 
any metabolic measures (body mass index, type 2 diabetes, hypertension, dyslipidaemia, or obesity) 
(Kelly et al., 2014). However, Allison et al., (1999) did a comprehensive review and meta-analysis of 
81 studies investigating antipsychotic associated weight gain, and while most were associated with 
weight gain, clozapine was associated with the greatest weigh gain over a ten week period of 
treatment, with an average gain of 4.45 kg which is a clinically meaningful gain with associated risks. 
There are also adverse reactions such as constipation which appear mundane but can have 
severe consequences, including death, and are not systematically monitored despite their 
prevalence. There are numerous adverse reactions with less risk to life but still significant impact on 
quality of life. Many of these are at best inconvenient but at worst contribute to humiliation and 
stigma (Hodge & Jespersen, 2008) and impact on self-esteem. For example, hyper-salivation is one of 
the most common adverse reactions and this is very visible and easily recognisable as an adverse 
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reaction of antipsychotics; this inhibits privacy and is generally disruptive to confidence in social 
situations.  Adverse reactions such as these can cause a lack of medication adherence, potentially 
leading to relapse; approximately 20% of patients prescribed clozapine discontinue due to adverse 
reactions, with a larger group of patients showing covert partial adherence (Young, Bowers, & 
Mazure, 1998).   
Some of the most commonly reported adverse reactions, both by manufacturers and patients, 
are daytime drowsiness or sedation, dizziness or postural hypotension, tachycardia, myoclonus, 
hyper-salivation, anticholinergic effects including dry mouth and blurred vision, nausea, vomiting, 
gastric reflux or heartburn, constipation, nocturnal enuresis, polyuria, polydipsia, weight gain and 
sexual dysfunction. These have been reported to remain throughout the duration of treatment, with 
Yusufi et al., (2007) finding that 77% of patients on chronic treatment (at least three months but 
median of 30 months) had at least one moderate or severe adverse reaction, 19% reporting one or 
more severe adverse reactions, and every patient reporting at least one adverse reaction. The 
majority of adverse reactions (649/766 reported) were not reported when patients were asked an 
open question, only in response to systematic assessment, creating concern about untreated 
adverse reactions; this was especially true for adverse reactions which patients might feel 
embarrassed to report such as sexual dysfunction.  
However, there is a problem of under-prescription; Meltzer (2012) highlights that fewer than 5% 
of American patients with schizophrenia are treated with clozapine, which is less than a fifth of those 
who meet the criteria indicated for prescription. This may be driven by concerns about adverse 
reactions, but two large epidemiological studies have found clozapine to have the lowest mortality 
rate of any antipsychotic drug, a finding which is driven largely due to its significant reduction in 
suicide risk. In a study across all patients of Finland admitted to psychiatric care, found clozapine was 
associated with the lowest mortality risk, and this risk was significantly lower than for all other 
antipsychotics (Tiihonen et al., 2009)– potential explanations given were more intensive monitoring, 
increased effectiveness, increased treatment compliance and subsequent improved lifestyle. There 
were no differences in terms of death due to ischemic heart disease, despite known increases in 
cardiovascular adverse reactions. These results are surprising considering that there is a selection 
bias working against this finding – clozapine is reserved for the most unwell, most suicidal, most 
risky patients. Also, in an Australian observational cohort study of 355 patients, older age of 
commencement on clozapine was associated with increased risk of adverse reactions suggesting we 
should not allow concern about adverse reactions to delay prescription of clozapine as this only 
heightens the risk (Hyde et al., 2015). However, the Tiihonen study has been criticised (De Hert, 
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Correll, & Cohen, 2010) for incomplete reporting and various analytical choices which could explain 
these findings, and cautions against dismissing the risks associated with clozapine.  
Despite the disagreement in the literature about the level of risk relative to other antipsychotics 
and relative to overall benefit, the prevalence of a range of distressing adverse reactions cannot be 
denied and patient concerns cannot be dismissed. A meta-analysis (de Silva et al., 2016) found that 
metformin was most effective in preventing antipsychotic induced weight gain in first episode 
patients, compared to reducing weight in chronic patients who have already gained significant 
amount of weight and likely developed insulin resistance, highlighting the importance of early 
intervention and identification of patients at risk. Understanding of these adverse reactions, their 
mechanisms, who is most at risk and how we may be able to prevent or alleviate them, is therefore 
necessary.  
5.1.1 Mechanisms of adverse reactions to clozapine 
Most literature regarding predictors of antipsychotic-induced adverse reactions has focused on 
antipsychotic-induced weight gain and genetic variants. There has been a particular focus on 
studying the association between the 5-HTR2C receptor and antipsychotic-associated weight gain. 
Rodent studies highlight its importance in the regulation of food intake in rodents (mice with the 
HTR2C gene knocked out show chronic hyperphagia and develop obesity and hyperinsulinemia) 
(Butler & Cone, 2001). Polymorphisms such as C-759T (rs3813929), in the promoter region, have 
been associated with late-onset diabetes and obesity in non-psychiatric populations, as well as 
consistently associated with antipsychotic induced weight gain (Zhang & Malhotra, 2013); ten out of 
17 studies reporting on the association between this SNP and antipsychotic induced weight gain 
found the C allele was associated with more weight gain, especially clozapine and olanzapine, and 
this is confirmed by a meta-analysis reporting that the C allele was associated with over double risk 
of gaining at least 7% of baseline body weight (clinically significant weight gain) (De Luca, Mueller, de 
Bartolomeis, & Kennedy, 2007). However, this cannot be the full explanation as a range of 
antipsychotics with similar moderate 5-HTR2C binding affinity are associated with variable risk of 
metabolic adverse reactions, and ziprasidone has very minimal metabolic adverse reactions despite 
having the most potent binding.  
Unsurprisingly, leptin genes have also been implicated, as leptin is a hormone - released by 
subcutaneous adipocytes and transported to the hypothalamus - which plays a critical role in 
regulating food intake and homeostasis. Genetic variants have been associated with obesity 
elsewhere and studies have associated the functional leptin promoter 2458G/A with antipsychotic 
induced weight gain, with one finding the polymorphism account for 9% of variation in weight gain 
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(Zhang et al., 2007). Studies find increased levels of leptin in the blood of patients on antipsychotics 
but observed changes in glucose and lipid metabolism induced by antipsychotics are believed to 
occur independently of the weight gain (Panariello, Polsinelli, Borlido, Monda, & De Luca, 2012): 
they occur before the onset of weight gain instead of a consequence afterwards, and the effect sizes 
between the two patterns of disturbance do not always correlate. 
As previously discussed, candidate-gene studies are severely limited. Brandl et al., (2015) 
performed a GWAS for antipsychotic induced weight gain in a subsample of participants from the 
CATIE study, but did not find any SNPs which reached genome-wide significance. One of the variants 
with suggestive significance, rs9346455 – which is located 6.6 kb upstream of the opioid growth 
factor receptor-like 1 gene (OGFRL1) on chromosome 6 -, was replicated in a separate sample for 
association with antipsychotic induced weight gain though, and in both the minor G-allele was 
associated with higher weight gain. However, the functional relevance of this polymorphism is 
currently unclear.  
 Other investigations specifically for clozapine have focused on genetic polymorphisms of 
CYP1A2, the cytochrome P450 enzyme which is the main metaboliser of clozapine and may affect 
clozapine clearance and plasma levels; allelic variation has been associated with tardive dyskinesia, 
and mRNA levels have been associated with adverse reactions in general. In one of the larger studies 
of 237 long term clozapine users (Viikki et al., 2014), the TT genotype of polymorphisms -1545 
(rs2470890) was associated with significantly more severe adverse reactions during clozapine 
treatment. The sub-analysis did not find significant effects for individual adverse reaction types, but 
the pattern was similar across all seven types of adverse reactions studies. 
A review (Shams & Müller, 2014) concludes that the genetic variants with the most consistently 
replicated findings are in the melanocortin 4 receptor (MC4R), the serotonin 2C receptor (5HT2C), 
leptin, neuropeptide Y (NPY) and cannabinoid receptor 1 (CNR1) genes.  
Studies have implicated methylation in metabolic syndrome experienced by patients treated 
with antipsychotics; for example, Lott et al., (2013) found COMT promoter region methylation, 
physical activity and metabolic syndrome were significantly associated in Val158Met patients, with 
genotype and physical activity both playing a role in epigenetic modulation of COMT with apparent 
implications for metabolic syndrome.  
One suggestion (Scigliano & Ronchetti, 2013) for the mechanism of antipsychotic induced 
metabolic effects is that blocking peripheral dopamine receptors increases sympathetic activity, 
leading to disturbances in autonomic function. Concurrently, the blocking of peripheral muscarinic 
receptors reduces vagal parasympathetic activity. High levels of adrenaline and noradrenaline 
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oppose the anabolic effects of insulin, promoting glycogen transformation to glucose, inhibiting 
insulin release and inducing hyperglycaemia, as well as reducing glucose uptake by muscle and 
adipose tissue promoting insulin resistance, and stimulating adipose lipolysis promoting release of 
glycerol, free fatty acids, leptin, adiponectin and pro-inflammatory cytokines. Similarly, cortisol 
increases insulin resistance, promotes abdominal fat accumulation and stimulates intake of 
carbohydrates and fat. There are widespread peripheral dopamine receptors, present in heart, 
kidneys, live, pancreas etc. When activated, D2 like receptors inhibit noradrenaline release and 
adrenaline secretion, indirectly inhibiting sympathetic tone; and when there is intense sympathetic 
stimulation, dopamine is released alongside noradrenaline and adrenaline, modulating sympathetic 
discharge. Antipsychotic blockade of D2 receptors therefore is likely to remove inhibition of 
sympathetic tone and prevent the modulation of sympathetic activity. Support for the hypothesis 
that hyperglycaemia is caused by increased sympathetic nervous system activity comes from animal 
research demonstrating that hyperglycaemia following acute antipsychotic administration is blocked 
by an adrenoceptor antagonist. If it was simply D2 receptor blockade causing metabolic adverse 
reactions, the most potent D2 blockers would be most strongly associated with these adverse 
reactions. An explanation for why clozapine and olanzapine are most strongly associated, despite 
less potent antagonism, is that a) they may already be blocking adrenergic receptors, preventing the 
effect of increased availability of adrenergic neurotransmitters, and b) they bind at cholinergic M3 
receptors where parasympathetic activity would act to counterbalance the increased sympathetic 
activity.  
Since the early days of chlorpromazine there has also been a suggestion that the patients who 
benefit most from treatment are also those who show the most weight gain and metabolic adverse 
reactions, and while this remains an area of interest this has yet to be unequivocally proven 
(Sharma, Rao, & Venkatasubramanian, 2014). 
To further our understanding into these unwanted consequences of clozapine use, I will now 
present my analysis of DNA methylation trajectories associated with having or not having clozapine-
induced increased appetite/weight, drowsiness and cardiovascular symptoms; the latter two have 
been minimally researched across all research fields, with no existing epigenetic research in humans 
to the best of my knowledge.  
 
5.2 Statistical method: Adverse reactions to clozapine 
To explore associations with adverse reactions to clozapine, I compared whether experiencing 
an adverse reaction or not after twelve weeks of clozapine use was associated with different 
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trajectories of DNA methylation. I analyse the following three adverse reactions – with symptom 
clusters of the most frequently reported adverse reactions - as predictors: 
1) Between-individual classification of experiencing increased appetite/weight (categorical) 
as a predictor of DNA methylation trajectories over time 
Increased appetite/weight: experiencing increased appetite/weight was defined as self-report of 
increased appetite or weight gain more than once in the last week, when assessed at twelve week 
follow up.  
2) Between-individual classification of experiencing drowsiness (categorical) as a predictor of 
DNA methylation trajectories over time 
Drowsiness: experiencing drowsiness was defined as self-report of feeling sleepy during the day time 
or “drugged like a zombie” more than once in the last week, when assessed at twelve week follow 
up.  
3) Between-individual classification of experiencing cardiovascular symptoms (categorical) 
as a predictor of DNA methylation trajectories over time 
Cardiovascular symptoms: experiencing cardiovascular symptoms was defined as self-report of 
feeling chest pain or irregular/fast heart beating more than once in the last week, when assessed at 
twelve week follow up. 
To identify DNA methylation changes associated with adverse reactions to clozapine, I again 
conducted mixed model regression analyses using lmer.  
For the prediction of different methylation trajectories between individuals with or without each 
adverse reaction, the interaction between adverse reaction group (experience vs do not experience) 
and weeks on clozapine was used a predictor of methylation at each CpG sites. These models 
controlled for baseline age, sex, predicted cell counts (CD8T, CD4T, NK, B, granulocytes and 
monocytes), smoking at time of sample collection (yes/no), chip ID, previous medications (number of 
prior atypical antipsychotics, number of prior typical antipsychotics, number of prior 
benzodiazepines or other mood stabilisers) and current medications (number of current 
antipsychotics, number of current benzodiazepines or other mood stabilisers, number of current 
antidepressants), as well as controlling for the repeated measures from individual participants as a 
random effect.  
These analyses all produced a model with regression coefficients for each CpG site - representing 
the percentage change in methylation at the CpG site associated with an additional week on 
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clozapine for those not experiencing the adverse reaction – as well as a p value for the significance 
of this association.  
For each model, I report global DNA methylation, differentially methylated positions (DMPs) and 
pathway analysis results. All of this is conducted as described in previous chapters (Statistical 
method: Exposure to clozapine).  
Additionally, the regression coefficients of each model are used for candidate site testing. 
Candidate CpG site methylation: Based on previous literature on the genetics of clozapine 
adverse reactions (Shams & Müller, 2014; Viikki et al., 2014), I identified five genes which have been 
associated with adverse reactions: MC4R, 5HT2C, NPY, and CNR1 and CYP1A2.  In total, there were 
87 CpG sites for these genes included in the 450k assay which passed QC. The first four genes have 
exclusively been identified in relationship to weight gain or other metabolic symptoms so were only 
tested in the increased appetite/weight model. The last gene, CYP1A2, has been associated with 
numerous adverse reactions so was tested in all models. There were seven CpG sites included in the 
450k assay which passed QC.  
To account for multiple-comparisons in the increased appetite/weight model, the adjusted p 
value is 0.05/87 = 0.000575. To account for multiple-comparisons in the drowsiness and 
cardiovascular symptoms models, the adjusted p value is 0.05/7 = 0.00714. 
The results for each analysis model are reported separately. First I will report results for 
increased appetite/weight, then drowsiness, then cardiovascular symptoms. 
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5.3 Results: Increased appetite/weight  
5.3.1 Participant characteristics (increased appetite/weight)  
Twelve weeks after clozapine initiation, thirteen participants were experiencing increased 
appetite/weight as an adverse reaction to clozapine and nine were not. The characteristics of each 
group are compared in Table 16, with key details represented in subsequent pie-charts ( ): compared 
to those who did not experience increased appetite/weight, those who did experience increased 
appetite/weight were more likely to be black, have comorbidities (especially substance abuse), have 
not been previously exposed to clozapine, be a responder to clozapine, and experience drowsiness. 
At twelve weeks, those who experienced increased appetite/weight had greater reductions in total 
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Table 16: Characteristics of participants with and without increased appetite/weight at 12 weeks 





Age (years) Mean 36.42 39.78 p=0.55 
Minimum 19.94 21.08 
Maximum 50.99 61.38 
Gender Male 10 7 p=1 
Female 3 2 
Ethnicity White 5 5 p=0.637 
Black 7 3 
Asian 1 1 
Diagnosis Schizophrenia 11 8 p=1 
Schizoaffective 






Mean 27.90 26.11 p=0.92 
Minimum 0 1 
Maximum 111 100 
Inpatient Psychiatric 
Admissions 
Mean 4.08 2.67 p=0.27 
Minimum 0 0 
Maximum 10 7 
Psychiatric 
Comorbidities 
Affective 2 0 p=0.21 
Anxiety 1 1 
Substance Abuse 3 0 
None 7 8 
Prior Clozapine 
Exposure 
Yes 4 1 p=0.57 
No 9 8 
Number of prior 
typical 
antipsychotics 
Mean 0.85 0.67 p=0.59 
Minimum 0 0 
Maximum 2 2 
Number of prior 
atypical 
antipsychotics 
Mean 3.15 2.56 p=0.32 
Minimum 1 1 
Maximum 7 4 
Number of prior 
mood stabilisers 
Mean 0.23 0.22 p=0.97 
Minimum 0 0 
Maximum 1 1 
Smoker at baseline Yes 2 1 p=1 
No 11 8 
Yes 4 3 p=1 
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Smoker at any time-
point during study 
 No 9 6 
Baseline PANSS 
Total 
Mean 76.46 81 p=0.58 
Minimum 55 54 
Maximum 105 119 
Baseline PANSS 
Positive 
Mean 19.88 19.11 p=0.80 
Minimum 12 9 
Maximum 26 36 
Baseline PANSS 
Negative 
Mean 21.15 22.89 p=0.61 
Minimum 11 9 
Maximum 30 39 
Predominant 
Baseline Symptoms 
Positive 4 3 p=1 
Negative 9 6 
12w PANSS Total Mean 56.82 71.56 p=0.07 
Minimum 35 38 
Maximum 76 98 
6m PANSS Total Mean 58.92 64.63 p=0.53 
Minimum 43 37 
Mean 77 97 
PANSS % Change at 
12w 
Mean -22.34 -10.76 p=0.18 
Minimum -53.57 -31.03 
Maximum 21.82 26.47 
PSP % Change at 
12w 
Mean 12.27 57.43 p=0.13 
Minimum -50 -14.29 
Maximum 57.14 162.5 
GAF % Change at 
12w 
Mean 39.28 40.60 p=0.96 
Minimum -10 -25 
Maximum 102.86 185.71 
Responder at 12w Yes 8 2 p=0.17 
No 5 7 
Cardiovascular 
symptoms at 12w 
Yes 2 2 p=1 
No 11 7 
Drowsiness at 12w Yes 11 4 p=0.13 
No 2 5 
Clozapine Levels at 
12w 
Mean 0.36 0.46 p=0.17 
Minimum 0.21 0.28 
Maximum 0.59 0.75 
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Figure 8: Pie charts comparing key demographics for those with and without increased 
appetite/weight 
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5.3.2 Global DNA methylation (increased appetite/weight) 
Not experiencing increased appetite/weight was associated with global demethylation over 
time. For those without increased appetite/weight, an additional week on clozapine was associated 
with an average additional decrease in global DNA methylation of 0.00114%. 50.49% of all CpG sites 
showed an additional increase in methylation associated with time exposed to clozapine if not 
experiencing increased appetite/weight and 49.51% of all CpG sites showed a decrease.  
Moreover, when exploring individual time points, split by adverse reaction: at baseline, mean 
global DNA methylation was 48.316% for those with increased appetite/weight and 48.240% for 
those without; at six weeks, 48.258% for those with and 48.250% for those without; at twelve 
weeks, 48.334% for those with s and 48.233% for those without; and at six months, 48.328% for 
those with and 48.242% for those without. Those who experience increased appetite/weight show 
higher starting level of global DNA methylation which decreases, increases and then decreases but 
remains higher than baseline; while those who do not experience these adverse reactions start with 
     No increased appetite/weight      Increased appetite/weight 
increased appetite/weight 
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lower levels which increase, decrease and increase and end similar to baseline and lower than those 
who do experience the adverse reactions.  
 
5.3.3 Differentially methylated positions (increased appetite/weight) 
Three DMPs reached the threshold for epigenome wide significance (p<1*10-7) and two hundred 







Clozapine-associated increased appetite/weight 
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Table 17: Top ten DMPs associated with increased appetite/weight (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO 
cg10966876 0.195x10-2 6.03E-09* TWIST2 TSS1500 239755461 
ch.6.163729680F 0.74 x10-3 4.81E-08*   163809690 
cg21097199 
0.180 x10-
2 5.99E-08* POLQ; 1stExon;5'UTR 121264819 
cg08314457 
0.268 x10-
2 1.51E-07   77507534 
cg07957953 0.85 x10-3 1.78E-07 GGT7 TSS1500 33460865 
cg20296524 -0.56 x10-3 6.07E-07 TARBP1 1stExon 234614614 
cg25151834 
-0.182 
x10-2 7.31E-07 UNKL Body 1449528 
cg19155552 
-0.284 
x10-2 7.49E-07 TMEM116 3'UTR 112369383 
cg21167587 
-0.735 
x10-2 7.51E-07 RNF38 5'UTR;Body 36397390 
cg09241703 
0.245 x10-
2 7.56E-07 FOXN3 Body  
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The most statistically significant DMP associated with not experiencing increased 
appetite/weight was cg10966876. For those who did not experience increased appetite/weight, 
each additional week exposed to clozapine was associated with an additional increase in 
methylation at this site of 0.195% compared to those who did (p=0.6x10-8). For those who 
experienced increased appetite/weight, uncorrected means show an average baseline methylation 
of 10.303%, 9.869% at six weeks, 9.275% at twelve weeks, and 9.548% at six months. For those who 
did not experience increased appetite/weight, uncorrected means show an average baseline 
methylation of 9.182%, 10.365% at six weeks, 10.216 % at twelve weeks, and 12.227 % at six 
months.  Those who experience increased appetite/weight show a decrease over time with an 
increase towards the end of the study period but remain below baseline, while those who do not 
start at a lower level at baseline but show an increase, slight decrease and then large increase 
ending at levels higher than both groups at any other point. 
 
cg10966876 is located in the TSS1500 promoter region of TWIST2, which encodes twist family 
BHLH transcription factor 2. This gene is located on chromosome 2 and expressed across numerous 
No increased appetite/weight 
Increased appetite/weight 
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tissues with overexpression of mRNA in cervix and secreting glandular tissue and overexpression of 
protein in serum. Twist family BHLH transcription factor 2 is involved in transcription regulation, 
repression of pro-inflammatory cytokine expression, glycogen storage and energy metabolism. 
The second most statistically significant DMP associated with not experiencing increased 
appetite/weight was located at ch.6.163729680F. For those who did not experience increased 
appetite/weight, each additional week exposed to clozapine was associated with an additional 
increase in methylation at this site of 0.0743% compared to those who did (p=0.5x10-7). For those 
who experienced increased appetite/weight, uncorrected means show an average baseline 
methylation of 4.525%, 4.304% at six weeks, 4.456 % at twelve weeks, and 4.486% at six months. For 
those who did not experience increased appetite/weight, uncorrected means show an average 
baseline methylation of 3.975%, 4.462% at six weeks, 4.712% at twelve weeks, and 5.515 % at six 
months.  Those who experience increased appetite/weight show an initial decrease then increase 
but remain lower than baseline, while those who do not start at a lower baseline level and increase 
over time. 
 
No increased appetite/weight 
Increased appetite/weight 
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This CpG site is located on chromosome 6 but is otherwise uncharacterised.  
 The third most statistically significant DMP associated with not experiencing increased 
appetite/weight was cg21097199. For those who did not experience increased appetite/weight, 
each additional week exposed to clozapine was associated with an additional increase in 
methylation at this site of 0.1801% compared to those who did (p=0.6x10-7). For those who 
experienced increased appetite/weight, uncorrected means show an average baseline methylation 
of 9.564%, 10.229% at six weeks, 8.689% at twelve weeks, and 10.351% at six months. For those 
who did not experience increased appetite/weight, uncorrected means show an average baseline 
methylation of 9.990%, 10.575% at six weeks, 11.867% at twelve weeks, and 13.178% at six months.  
Those who experience increased appetite/weight show an initial increase, then decrease, then 
increase and end higher than baseline, while those who do not show increases at each time point. 
 
cg21097199 is located in the 1st exon of POLQ, which encodes DNA polymerase theta – this 
protein repairs double-strand breaks in DNA. This gene is located on chromosome 3 and expressed 
No increased appetite/weight 
Increased appetite/weight 
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across numerous tissues, with overexpression of mRNA in oesophagus and testis and overexpression 
of protein in fetal testis and brain.  
5.3.4 Pathway analysis (increased appetite/weight) 
Pathway analysis indicated that the pathways in Table 18 were the top thirty pathways with an 
over-representation of DMPs associated with increased appetite/weight.  
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Table 18: Top thirty over-represented pathways - increased appetite/weight 
Category Name p value over-
representation 





GO:0043555 regulation of translation in response to stress 0.00102 5 13 BP 
GO:0032386 regulation of intracellular transport 0.00141 40 356 BP 
GO:0033157 regulation of intracellular protein transport 0.00151 25 195 BP 
GO:0042992 negative regulation of transcription factor import into nucleus 0.00275 8 36 BP 
GO:0046823 negative regulation of nucleocytoplasmic transport 0.00275 11 60 BP 
GO:0042308 negative regulation of protein import into nucleus 0.00313 10 51 BP 
GO:0046822 regulation of nucleocytoplasmic transport 0.00344 22 168 BP 
GO:0051224 negative regulation of protein transport 0.00375 16 109 BP 
GO:0033572 transferrin transport 0.00417 7 33 BP 
GO:0042306 regulation of protein import into nucleus 0.00483 18 133 BP 
GO:0019722 calcium-mediated signalling 0.00554 15 98 BP 
GO:0035107 appendage morphogenesis 0.00557 24 139 BP 
GO:0035108 limb morphogenesis 0.00557 24 139 BP 
GO:0015682 ferric iron transport 0.00578 7 35 BP 
GO:0072512 trivalent inorganic cation transport 0.00578 7 35 BP 
GO:0007004 telomere maintenance via telomerase 0.00583 5 16 BP 
GO:0048713 regulation of oligodendrocyte differentiation 0.00586 7 25 BP 
GO:0034504 protein localization to nucleus 0.00685 23 180 BP 
GO:0043588 skin development 0.00752 36 324 BP 
GO:0050431 transforming growth factor beta binding 0.00771 5 16 MF 
GO:0048706 embryonic skeletal system development 0.00773 21 123 BP 
GO:0090317 negative regulation of intracellular protein transport 0.00791 11 71 BP 
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Category Name p value over-
representation 





GO:0048483 autonomic nervous system development 0.00823 10 42 BP 
GO:1900180 regulation of protein localization to nucleus 0.00837 19 146 BP 
GO:0021604 cranial nerve structural organization 0.00878 4 10 BP 
GO:0006730 one-carbon metabolic process 0.00883 6 30 BP 
GO:0007338 single fertilization 0.00916 12 102 BP 
GO:0048736 appendage development 0.00938 25 157 BP 
GO:0060173 limb development 0.00938 25 157 BP 
GO:0051223 regulation of protein transport 0.00954 34 338 BP 
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5.3.5 Candidate CpG site methylation (increased appetite/weight) 
Of six CpG sites located within MC4R with methylation data available, none had a significant 
association with increased appetite/weight before or after correction for multiple testing. Across all 
MC4R CpG sites, there was a mean additional increase in methylation of 0.0123% associated with 
each additional week on clozapine for those who experience increased appetite/weight. 
Of twenty five CpG sites located within 5HT2C with methylation data available, four had a 
significant association with increased appetite/weight before but not after correction for multiple 
testing – cg25885716 showed an additional decrease in methylation (-0.137%, p=0.028), cg05100479 
showed an additional increase in methylation (0.0516%, p=0.031), cg18153989 showed a decrease in 
methylation (-0.211%, p=0.039), and cg10997274 showed a decrease in methylation (-0.097%, 
p=0.015). Across all 5HT2C CpG sites, there was a mean additional decrease in methylation of 
0.0251% associated with each additional week on clozapine for those who experience increased 
appetite/weight. 
Of eighteen sites located within NPY with methylation data available, one had a significant 
association with increased appetite/weight after correction for multiple testing (p<0.575x10-3) – 
cg11653966 showed an additional increase in methylation for those who did not experience 
increased appetite/weight (0.1802%, p=0.0002). Six others had a significant association with 
increased appetite/weight before but not after correction for multiple testing (0.000575<p<0.05). 
cg16964348 showed an additional decrease in methylation (-0.096%, p=0.002), cg18106668 showed 
an additional increase in methylation (0.0579%, p=0.002), cg00355281 showed an additional 
decrease in methylation (-0.072%, p=0.023), cg24885417 showed an additional decrease in 
methylation (-0.062%, p=0.020), cg15929698 showed an additional decrease in methylation (-0.062, 
p=0.0409) and cg21097881 showed an additional decrease in methylation (-0.066%, p=0.028). 
Across all NPY CpG sites, there was a mean additional decrease in methylation of -0.0213% 
associated with each additional week on clozapine for those who experience increased 
appetite/weight. 
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Of twenty six sites located within CNR1 with methylation data available, two had a significant 
association with increased appetite/weight before but not after correction for multiple testing 
(0.575x10-3<p<0.05). cg03300581 showed an additional decrease in methylation (-0.04%, p=0.005) 
and cg02498983 showed an additional increase in methylation (0.0642%, p=0.042). Across all CNR1 
CpG sites, there was a mean additional decrease in methylation of -0.002312% associated with each 
additional week on clozapine for those who experience increased appetite/weight. 
Of seven sites located within CYP1A2 with methylation data available, none had a significant 
association with increased appetite/weight before or after correction for multiple testing. Across all 
CYP1A2 CpG sites, there was a mean additional increase in methylation of 0.00047%.  
No increased appetite/weight 
Increased appetite/weight 
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5.4 Results: Drowsiness  
5.4.1 Participant characteristics (drowsiness) 
Twelve weeks after clozapine initiation, fifteen participants were experiencing drowsiness as an 
adverse reaction to clozapine and seven were not. The characteristics of each group are compared in 
Table 19, with key details represented in subsequent pie-charts (Error! Reference source not 
found.): compared to those who did not experience drowsiness, those who did experience 
drowsiness were more likely to be male, black, have no comorbidities, have previous exposure to 
clozapine, have predominantly negative symptoms at baseline, be a responder to clozapine, and 
experience increased appetite/weight. At twelve weeks, those who experienced drowsiness had 
lower clozapine levels. However, none of these differences were statistically significant except 
gender (X=4.348, p=0.037), a variable which was controlled for in analysis. 
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Table 19: Characteristics of participants with and without drowsiness at 12 weeks 
  Drowsiness No drowsiness  
Age (years) Mean 36.87 39.80 p=0.58 
Minimum 19.94 21.08 
Maximum 61.38 52.52 
Gender Male 14 3 p=0.04* 
Female 1 4 
Ethnicity White 6 4 p=0.533 
Black 8 2 
Asian 1 1 
Diagnosis Paranoid 
Schizophrenia 13 6 
p=1 






Mean 29.75 22.43 p=0.69 
Minimum 1 0 
Maximum 111 100 
Inpatient Psychiatric 
Admissions 
Mean 3.80 2.86 p=0.40 
Minimum 0 1 
Maximum 10 5 
Psychiatric 
Comorbidities 
Affective 1 1 p=0.85 
Anxiety 1 1 
Substance Abuse 2 1 
None 11 4 
Prior Clozapine 
Exposure 
Yes 4 1 p=0.92 
No 11 6 
Number of prior 
typical 
antipsychotics 
Mean 0.87 0.57 p=0.33 
Minimum 0 0 
Maximum 2 1 
Number of prior 
atypical 
antipsychotics 
Mean 2.87 3 p=0.81 
Minimum 1 2 
Maximum 7 4 
Number of prior 
mood stabilisers 
Mean 0.2 0.29 p=0.7 
Minimum 0 0 
Maximum 1 1 
Smoker at baseline Yes 3 0 p=0.54 
No 12 7 
Smoker at any time-
point during study 
Yes 5 2 p=1 
No 10 5 
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Mean 77.73 79.57 p=0.85 
Minimum 55 54 
Maximum 105 119 
Baseline PANSS 
Positive 
Mean 18.77 21.29 p=0.43 
Minimum 9 15 
Maximum 26 36 
Baseline PANSS 
Negative 
Mean 22.73 20 p=0.41 
Minimum 11 9 
Maximum 39 30 
Predominant 
Baseline Symptoms 
Positive 4 3 p=0.79 
Negative 11 4 
12w PANSS Total Mean 61.31 67.43 p=0.54 
Minimum 35 38 
Maximum 79 98 
6m PANSS Total Mean 58.93 66.50 p=0.49 
Minimum 38 37 
Maximum 80 97 
PANSS % Change at 
12w 
Mean -18.61 -15.44 p=0.74 
Minimum -53.57 -39.39 
Maximum 21.82 26.47 
PSP % Change at 
12w 
Mean 26.77 38.64 p=0.71 
Minimum -50 -14.29 
Maximum 160 162.5 
GAF % Change at 
12w 
Mean 46.40 26.73 p=0.35 
Minimum -10 -25 
Maximum 185.71 95.12 
Responder at 12w Yes 8 2 p=0.53 
No 7 5 
Cardiovascular 
symptoms at 12w 
Yes 3 1 p=1 




Yes 11 2 p=0.13 
No 4 5 
Clozapine Levels at 
12w 
Mean 0.37 0.51 p=0.16 
Minimum 0.21 0.25 
Maximum 0.59 0.75 
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Figure 9: Pie-charts of characteristics in those with and without drowsiness       
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5.4.2 Global DNA methylation (drowsiness) 
Not experiencing drowsiness was associated with global demethylation. For those without 
drowsiness, an additional week on clozapine was associated with an average additional decrease in 
global DNA methylation of 0.00075%. But 51.01% of all CpG sites showed an additional increase in 
methylation associated with time exposed to clozapine if not experiencing drowsiness and 48.99% of 
all CpG sites showed a decrease.  
However, when exploring individual time points, split by response: at baseline, mean global DNA 
methylation was 48.285% for those with drowsiness and 48.285% for those without; at six weeks, 
48.240% for those with and 48.284% for those without; at twelve weeks 48.292% for those with and 
48.282% for those without; and at six months 48.295% for those with and 48.291% for those 
without. Both groups show the same starting level of global DNA methylation and end at a slightly 
higher level, but those who experience drowsiness show an initial decrease and then an increase 
beyond those who do not.  
Adverse Reactions to Clozapine and Associated DNA Methylation Changes 
- 271 - 
 
  
5.4.3 Differentially methylated positions (drowsiness) 
 
 Two DMPs reached the threshold for epigenome wide significance (p<1*10-7) and one hundred 
and eight nine DMPs were trend-level significant (p<5*10-5). 
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Table 20: Top ten DMPs associated with drowsiness (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO 
cg12155676 
0.161x10-
2 3.67E-08*   11970561 
cg21399492 0.27 x10-2 9.65E-08*   48055701 
cg06228491 
-0.305 
x10-2 4.17E-07   1578330 
cg10864791 0.9 x10-3 4.38E-07 EFHA1 TSS200 22178445 
cg01406247 
-0.21 x10-
2 4.95E-07   34611274 
cg21097199 
0.189 
x10-2 5.67E-07 POLQ 1stExon;5'UTR 121264819 
cg27299846 
-0.151 
x10-2 5.84E-07 MAST3 Body 18235489 
cg02348449 
0.178 
x10-2 9.83E-07 ZSCAN18 TSS1500 58630429 
cg16402835 
-0.212 
x10-2 9.98E-07 PTPN14 3'UTR 214531223 
cg23606925 
0.227 
x10-2 1.04E-06   102471597 
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The most statistically significant DMP associated with not experiencing drowsiness was 
cg12155676. For those who did not experience drowsiness, each additional week exposed to 
clozapine was associated with an additional increase in methylation at this site of 0.161% compared 
to those who did (p=0.4x10-7). For those who experienced drowsiness, uncorrected means show an 
average baseline methylation of 9.853%, 9.34% at six weeks, 8.878% at twelve weeks, and 9.194% at 
six months. For those who did not experience drowsiness, uncorrected means show an average 
baseline methylation of 9.124%, 8.963% at six weeks, 9.854% at twelve weeks, and 11.296% at six 
months. Those who experienced drowsiness showed decreases then an increase but remained lower 
than baseline, whereas those who did not started at a lower baseline level and showed a decrease 
but then increase and ended higher than baseline. 
 
cg12155676 is located on chromosome 2 outside of a characterised gene.  
The second most statistically significant DMP associated with not experiencing drowsiness was 
cg21399492. For those who did not experience drowsiness, each additional week exposed to 
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clozapine was associated with an additional increase in methylation at this site of 0.27% compared 
to those who did (p=0.97x10-7). For those who experienced drowsiness, uncorrected means show an 
average baseline methylation of 75.871%, 76.545% at six weeks, 76.133% at twelve weeks, and 
77.182% at six months. For those who did not experience drowsiness, uncorrected means show an 
average baseline methylation of 72.780%, 73.063% at six weeks, 76.063% at twelve weeks, and 
77.968% at six months.  Those who experienced drowsiness showed an increase, decrease and then 
increase ending higher than baseline, whereas those who did started at a lower baseline level but 
increase at each time point ending higher than any time point for either group. 
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5.4.4 Pathway analysis (drowsiness) 
Pathway analysis indicated that the pathways in Table 21 were the top thirty pathways with an 
over-representation of DMPs associated with drowsiness.  
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Table 21: Top thirty over-represented pathways - drowsiness 
Category Name p value over-
representation 





GO:00+C3+A2:A2:F21 lamellipodium 0.0004 21 135 CC 
GO:0016887 axoneme 0.0023 9 61 CC 
GO:0032648 ciliary cytoplasm 0.0023 9 61 CC 
GO:0032608 neural tube development 0.0032 20 151 BP 
GO:0098552 regulation of protein export from nucleus 0.0043 5 23 BP 
GO:2001222 amino sugar metabolic process 0.006 6 36 BP 
GO:0032312 neural tube closure 0.0068 13 82 BP 
GO:0033158 tube closure 0.0072 13 83 BP 
GO:0010875 regulation of smoothened signalling pathway 0.0076 10 63 BP 
GO:0061630 cell projection cytoplasm 0.0082 9 73 CC 
GO:0007127 antioxidant activity 0.0090 8 62 MF 
GO:0032728 primary neural tube formation 0.0093 13 87 BP 
GO:0042623 protein homooligomerization 0.0112 20 234 BP 
GO:0006163 glucosamine-containing compound metabolic process 0.0112 4 23 BP 
GO:0009203 cochlea morphogenesis 0.0114 5 21 BP 
GO:0009207 defence response to fungus 0.0125 3 21 BP 
GO:0009146 N-acetylglucosamine metabolic process 0.0134 3 14 BP 
GO:0030660 secretion 0.0136 61 856 BP 
GO:0009143 secretion by cell 0.0136 55 749 BP 
GO:0007131 positive regulation of protein export from nucleus 0.0152 3 11 BP 
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Category Name p value over-
representation 





GO:0035825 neuroblast proliferation 0.0159 8 51 BP 
GO:0006152 smoothened signalling pathway 0.0160 13 112 BP 
GO:0046130 phosphate ion homeostasis 0.0167 3 11 BP 
GO:0046128 trivalent inorganic anion homeostasis 0.0167 3 11 BP 
GO:0042454 filopodium membrane 0.0169 4 16 CC 
GO:0009150 recycling endosome membrane 0.0171 5 35 CC 
GO:0042278 neural tube formation 0.0174 13 99 BP 
GO:0032373 intraciliary transport particle B 0.0180 3 15 CC 
GO:0032376 beta-catenin binding 0.0180 9 58 MF 
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5.4.5 Candidate CpG site methylation (drowsiness) 
Of seven sites located within CYP1A2 with methylation data available, two had a significant 
association with drowsiness before but not after correction for multiple testing: cg24182584 was 
associated with an additional decrease (-0.037%, p=0.042) and cg14503537 was associated with an 
increase for those who did not experience drowsiness (0.1002%, p=0.0474). Across all CYP1A2 CpG 
sites, there was a mean additional increase in methylation of 0.00769%. 
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5.5 Results: Cardiovascular symptoms 
5.5.1 Participant characteristics (cardiovascular symptoms) 
Twelve weeks after clozapine initiation, four participants were experiencing cardiovascular 
symptoms as an adverse reaction to clozapine and seven were not. The characteristics of each group 
are compared in Table 22, with key details represented in subsequent pie charts (Figure 10): 
compared to those who did not experience cardiovascular symptoms, those who did experience 
cardiovascular symptoms were more likely to be male, smoke, have prior exposure to clozapine, 
have predominantly negative symptoms at baseline, experience drowsiness and increased 
appetite/weight as well, and be a non-responder to clozapine. At twelve weeks, those who 
experienced cardiovascular symptoms had lower levels of clozapine and had lower reductions in 
symptom severity (two of four had shown increases in symptoms). However, none of these 
differences were statistically significant. The only significant difference was that those who 
experienced cardiovascular symptoms had taken a great number of prior atypical antipsychotic 
medications (t=-2.387, p=0.03), a variable which was controlled for in analysis. 
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Table 22: Characteristics of participants with and without cardiovascular symptoms at 12 weeks 





Age (years) Mean 38.06 37.74 p=0.95 
Minimum 26.76 19.94 
Maximum 45.30 61.38 
Gender Male 4 13 p=0.59 
Female 0 5 
Ethnicity White 2 8 p=0.783 
Black 2 8 
Asian 0 2 
Diagnosis Paranoid 
Schizophrenia 3 15 
p=1 






Mean 58.33 21.19 p=0.36 
Minimum 1 0 
Maximum 111 100 
Inpatient Psychiatric 
Admissions 
Mean 5.75 3 p=0.22 
Minimum 2 0 
Maximum 10 10 
Psychiatric 
Comorbidities 
Affective 0 2 p=0.71 
Anxiety 0 2 
Substance Abuse 1 2 
None 3 12 
Prior Clozapine 
Exposure 
Yes 2 3 p=0.44 
No 2 15 
Number of prior 
typical 
antipsychotics 
Mean 1 0.72 p=0.56 
Minimum 0 0 
Maximum 2 2 
Number of prior 
atypical 
antipsychotics 
Mean 3.75 2.72 p=0.03* 
Minimum 3 1 
Maximum 4 7 
Number of prior 
mood stabilisers 
Mean 0.25 0.22 p=0.92 
Minimum 0 0 
Maximum 1 1 
Smoker at baseline Yes 2 1 p=0.12 
No 2 17 
Yes 3 4 p=0.15 
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Smoker at any time-
point during study 
 No 1 14 
Baseline PANSS 
Total 
Mean 74.25 79.22 p=0.62 
Minimum 55 54 
Maximum 94 119 
Baseline PANSS 
Positive 
Mean 18.25 19.86 p=0.63 
Minimum 12 9 
Maximum 25 36 
Baseline PANSS 
Negative 
Mean 22.25 21.78 p=0.84 
Minimum 20 9 
Maximum 26 39 
Predominant 
Baseline Symptoms 
Positive 0 7 p=0.36 
Negative 4 11 
12w PANSS Total Mean 77.33 61 p=0.07 
Minimum 67 35 
Maximum 86 98 
6m PANSS Total Mean 71 58.75 p=0.12 
Minimum 60 37 
Mean 77.33 97 
PANSS % Change at 
12w 
Mean 1.83 -21.92 p=0.17 
Minimum -25 -53.57 
Maximum 26.47 4.11 
PSP % Change at 
12w 
Mean 11.34 35.08 p=0.44 
Minimum -47.73 -50 
Maximum 57.14 162.50 
GAF % Change at 
12w 
Mean 22.56 43.91 p=0.51 
Minimum -25 -8.33 
Maximum 96.67 185.71 
Responder at 12w Yes 1 9 p=0.72 




Yes 2 11 p=1 
No 2 7 
Drowsiness at 12w Yes 3 12 p=1 
No 1 6 
Clozapine Levels at 
12w 
Mean 0.315 0.43 p=.09 
Minimum 0.28 0.21 
Maximum 0.35 0.75 
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 Figure 10: Pie charts comparing key demographics for those with and without cardiovascular 
symptoms 
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5.5.2 Global DNA methylation (cardiovascular symptoms) 
Not experiencing cardiovascular symptom was associated with increased global DNA 
methylation over time. For those without cardiovascular symptoms, an additional week on clozapine 
was associated with an average additional increase in global DNA methylation of 0.00035%. 51.30% 
of all CpG sites showed an additional increase in methylation associated with time exposed to 
clozapine if not experiencing cardiovascular symptoms and 48.70% of all CpG sites showed a 
decrease.  
 However, when exploring individual time points, split by response: at baseline, mean global 
DNA methylation was 48.218% for those with cardiovascular symptoms and 48.300% for those 
without; at six weeks, 48.240% for those with and 48.257% for those without; at twelve weeks 
48.259% for those with and 48.294% for those without; and at six months 48.301% for those with 
and 48.292% for those without. Those who experience cardiovascular symptoms show lower starting 
level of global DNA methylation which gradually increase; while those who do not experience these 
adverse reactions start with higher levels which decrease then increase and end similar to baseline 
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5.5.3 Differentially methylated positions (cardiovascular symptoms) 
No DMPs reached the threshold for epigenome wide significance (p<1*10-7) but eighty two 
DMPs were trend-level significant (p<5*10-5). 
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Table 23: Top ten DMPs associated with cardiovascular symptoms (* indicates epigenome wide significance) 
CpG site Beta P value Gene Location MAPINFO 
cg12590655 0.85x10-3 1.95E-07   164340525 
cg12026992 
0.155 x10-
2 5.37E-07   90004011 
cg07374403 -0.48 x10-3 6.65E-07 ATPAF1 TSS200 47134188 
cg00692277 0.83 x10-3 1.28E-06   3230847 
cg23892310 
-0.132 
x10-2 2.19E-06 TBCD Body 80816702 
cg15404971 
-0.218 
x10-2 2.82E-06   7392579 
cg06846719 
0.203 x10-
2 3.11E-06 FAM60A 5'UTR 31475291 
cg18978540 
-0.187 
x10-2 3.85E-06 SMAD9 5'UTR 37493431 
cg14596987 
-0.121 
x10-2 4.15E-06 PTCH1; 5'UTR;Body 98249189 
cg15718289 0.87 x10-3 4.49E-06 HOXC4;HOXC5;HOXC6 5'UTR;Body;1stExon 54410671 
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5.5.4 Pathway analysis (cardiovascular symptoms) 
Pathway analysis indicated that the pathways in Table 24 were the top thirty pathways with an 
over-representation of DMPs associated with cardiovascular symptoms.  
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Table 24 Top thirty over-represented pathways - cardiovascular symptoms 
Category Name p value over-
representation 





GO:0009897 external side of plasma membrane 0.00199 11 203 CC 
GO:0016887 ATPase activity 0.00221 19 352 MF 
GO:0032648 regulation of interferon-beta production 0.00235 4 31 BP 
GO:0032608 interferon-beta production 0.00292 4 33 BP 
GO:0098552 side of membrane 0.00391 14 275 CC 
GO:2001222 regulation of neuron migration 0.00410 4 23 BP 
GO:0032312 regulation of ARF GTPase activity 0.00417 5 25 BP 
GO:0033158 regulation of protein import into nucleus 0.00430 3 16 BP 
GO:0010875 positive regulation of cholesterol efflux 0.00503 3 13 BP 
GO:0061630 NA 0.00508 3 15 MF 
GO:0007127 meiosis I 0.00510 6 70 BP 
GO:0032728 positive regulation of interferon-beta production 0.00520 3 21 BP 
GO:0042623 ATPase activity 0.00520 14 243 MF 
GO:0006163 purine nucleotide metabolic process 0.00525 51 1290 BP 
GO:0009203 ribonucleoside triphosphate catabolic process 0.00560 42 967 BP 
GO:0009207 purine ribonucleoside triphosphate catabolic process 0.00560 42 967 BP 
GO:0009146 purine nucleoside triphosphate catabolic process 0.00574 42 970 BP 
GO:0030660 Golgi-associated vesicle membrane 0.00578 4 36 CC 
GO:0009143 nucleoside triphosphate catabolic process 0.00596 42 974 BP 
GO:0007131 reciprocal meiotic recombination 0.00626 4 33 BP 
GO:0035825 reciprocal DNA recombination 0.00626 4 33 BP 
GO:0006152 purine nucleoside catabolic process 0.00627 42 978 BP 
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Category Name p value over-
representation 





GO:0046130 purine ribonucleoside catabolic process 0.00627 42 978 BP 
GO:0046128 purine ribonucleoside metabolic process 0.00641 46 1138 BP 
GO:0042454 ribonucleoside catabolic process 0.00666 42 988 BP 
GO:0009150 purine ribonucleotide metabolic process 0.00675 50 1269 BP 
GO:0042278 purine nucleoside metabolic process 0.00699 46 1140 BP 
GO:0032373 positive regulation of sterol transport 0.00714 3 15 BP 
GO:0032376 positive regulation of cholesterol transport 0.00714 3 15 BP 
GO:0009164 nucleoside catabolic process 0.00756 42 999 BP 
 
 
5.5.5 Candidate CpG site methylation (cardiovascular symptoms) 
Of seven sites located within CYP1A2 with methylation data available, none had a significant association with cardiovascular symptoms before or after 
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5.6 Discussion: Adverse reactions to clozapine 
To explore the effects of clozapine on DNA methylation associated with adverse reactions, I used 
multi-level models to analyse between-individual variation in the experience of increased 
appetite/weight, drowsiness and cardiovascular symptoms as predictors of DNA methylation 
trajectories over time. Systems involved in signal transduction, immune function and inflammation, 
neuronal development, energy metabolism, glycogen, and cholesterol are implicated. 
5.6.1 Increased appetite/weight 
 Analysis of the association between epigenome-wide DNA methylation and increased 
appetite/weight identified three DMPs that were significant at the epigenome-wide threshold 
(cg10966876, ch.6.163729680F and cg21097199) and two hundred and fifty one other DMPs 
showing trends towards significance. The majority of the top ten DMPs showed additional decreases 
in methylation over time associated with not experiencing increased appetite/weight. Those who 
didn’t experience adverse reactions showed a pretty stable global DNA methylation while those who 
did started at a higher level which decreased then increased above baseline. Eight of the top ten 
sites were located within a gene. 
Interpreting the overlap in biological processes implicated by models of both response and 
increased appetite/weight can be a challenge. In this sample, while non-significant, there was a 
trend for participants with a greater response to clozapine to have a higher likelihood of weight gain. 
It may be that one model is confounded by the other, but it also may be that there is a meaningful 
association in both models due to a shared underlying mechanism.   
The first and seventh ranked DMP are located within TWIST2 and UNKL, two genes associated 
with the immune system, the former involved in cytokine repression. Immune dysfunction has been 
discussed above in relationship with schizophrenia and clozapine; however inflammation and 
immune dysfunction are also independently associated with weight gain. Adipose tissue releases 
cytokines and some have hypothesised that this weight related inflammatory response (particularly 
increased levels of tumour necrosis factor-α (TNF-α)) leads to metabolic disruption such as insulin 
resistance (J. Yudkin, 2007). Obesity has been reliably associated with reduced immune response, 
such as impaired response to flu vaccines (Sheridan et al., 2012), increased infection and reduced 
host defences such as lower lymphocyte numbers (Milner & Beck, 2012). Similarly, the fifth ranked 
DMP is within GGT7, a gene associated with glutathione function. Glutathione is an antioxidant 
which protects against oxidative stress, and oxidative stress has been associated with obesity. 
Furukawa et al., (2004) report that fat accumulation correlates with systemic oxidative stress in 
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studies of humans and animal models, with increased production of reactive oxygen species and 
decreased antioxidant enzymes (including glutathione peroxidase), and dysregulation of cytokines 
such as IL-6.  Genetic variation in glutathione s-transferases (GSTs) genes has also been associated 
with obesity (Almoshabek, Mustafa, Al-Asmari, Alajmi, & Al-Asmari, 2016).  
Looking at the literature on immune changes and inflammation associated with response to 
antipsychotics and weight gain, both indicate reduced immune function, which may be a common 
mechanism underlying therapeutic response to clozapine and clozapine-induced weight gain.  
TWIST2 is also associated with energy metabolism and glycogen storage, more direct 
mechanisms for weight gain and metabolic dysfunction. Glycogen is the product of excess 
carbohydrates becoming stored for a secondary source of energy, after those needed are 
metabolised to release energy; if there is further excess, they will be converted to fat and eventually 
adipose tissue.  
TWIST2, POLQ – in which the third DMP was located – and FOXN3 are all associated with 
different aspects of gene expression regulation (transcription regulation and repression, DNA 
polymerase) and pathway analysis also indicated overrepresentation of DMPs involved in translation 
in response to exogenous stress. As with previous models, this suggests clozapine may have an 
indirect effect associated with metabolic symptoms via methylation of regulatory genes.   
Candidate gene testing provided support for an association between increased appetite/weight 
and methylation within NPY gene, with increase in methylation at cg11653966 for those who didn’t 
experience increased appetite/weight. Neuropeptide Y, encoded by the NPY gene, is a 
neurotransmitter which has been shown to stimulate food intake (Pomonis, Levine, & Billington, 
1997) and is also involved in storage of energy as fat, so altered regulation of this gene has a clear 
potential mechanism for weight gain and increased appetite; increased methylation in those who 
don’t experience increased appetite/weight may be driving reduced expression of this gene and 
reduced stimulation of food intake. SNPs within NPY have previously been associated with 
antipsychotic induced weight-gain (In patients primarily treated with clozapine or olanzapine) (Tiwari 
et al., 2013), suggesting that future work should integrate genetic and epigenetic data on the 
association between this gene and increased appetite/weight driven by clozapine.  There was weak 
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5.6.2 Drowsiness 
Analysis of the association between epigenome-wide DNA methylation and drowsiness 
identified two DMPs that were significant at the epigenome-wide threshold (cg12155676 and 
cg21399492) and one hundred and eighty nine other sites showing trends towards significance. The 
majority of the top ten DMPs show additional increases in methylation over time in those without 
drowsiness. Those who did not experience drowsiness show a relatively stable global DNA 
methylation with slight increase while those who do show an initial drop and then increase above 
baseline. Five of the top ten differentially methylated sites are located outside of genes, with five 
located within genes. 
 The fourth ranked DMP was within EFHA1, a gene associated with calcium ion binding and 
mitochondrial calcium uptake; disruption in calcium signalling in schizophrenia and the ability of 
clozapine to normalise this is discussed above. The ninth ranked DMP was located within PTPN14, 
and this gene, as well as the first ranked pathway, implicates association with cell growth, cell 
migration and cell adhesion as well as lamellipodium, a cytoskeletal protein projection which 
facilitates cell migration, propelling cells forward. PTPN14 and other overrepresented pathways also 
implicate differential methylation in genes associated with antioxidant activity and lymphatic 
development. The seventh DMP was located in MAST, a gene associated with kinase signalling. 
Additionally, the sixth and eighth ranked DMPs are located within POLQ and ZSCAN which is 
associated with regulation of gene expression - DNA and RNA polymerase, nucleic acid binding, and 
transcription factor activity – as is PTPN14. Unfortunately, there is very minimal research studying 
causes of individual variation in antipsychotic induced sedation which makes it difficult to place 
these findings in context; this may be because drowsiness is difficult to define and measure, and 
differentiate from negative symptoms and issues with motivation, but also because it is considered 
low risk.  However, it is incredibly common and can have a significant impact on quality of life – as 
Miller, (2004) notes, drowsiness can cause difficulties when reintegrating and interfere with 
treatment and adherence. These preliminary findings may be a starting point for pursuing a better 
understanding of why some patients experience greater sedation in response to clozapine. While 
none of the above mentioned CpG sites were statistically significant, one interesting thing to note is 
the systems implicated – calcium signalling, cell migration, cell adhesion, inflammation and kinase 
signalling – were all implicated in analysis of therapeutic response to clozapine also. 
Candidate gene testing provided only weak support for an association between CYP1A2 
methylation and drowsiness; no associations survived correction for multiple testing. 
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5.6.3 Cardiovascular symptoms 
Analysis of the association between epigenome-wide DNA methylation and cardiovascular 
symptoms identified no DMPs that were significant at the epigenome-wide threshold but eighty two 
trending towards significance. Over the top ten DMPs there was an additional increase in 
methylation associated with not experiencing cardiovascular symptoms. Those who experience 
cardiovascular symptoms showed lower starting levels of global DNA methylation which gradually 
increase, while those who do not experience these adverse reactions start with higher levels which 
decrease then increase and end at a similar level to baseline levels. Four of the top ten DMPs are 
located outside of genes, with six are located within genes.  
The seventh and eight ranked DMPs are located within FAM60A and SMAD9, two genes involved 
in TGF-beta activity (a cytokine involved in cell growth, proliferation and death), and pathway 
analysis also indicates overrepresentation of DMPs involved interferon beta production, again 
implicating the immune system which has been discussed numerous times throughout this thesis. 
Cardio-vascular problems have been linked to inflammation and immune function in the same way 
that obesity has (J. S. Yudkin, Kumari, Humphries, & Mohamed-Ali, 2000); in particular, myocarditis – 
a known adverse reaction to clozapine – is an infection of heart muscle.  
SMAD9 is also associated with hypertension, often a precursor to cardiovascular damage or itself 
classified as heart disease.  
The ninth ranked DMP was located in PTCH1, a gene involved in cholesterol binding, and 
pathway analysis also indicated overrepresentation of DMPs involved in cholesterol regulation; 
there is a strong association between cholesterol levels and cardiovascular health, with high levels of 
low-density lipoprotein cholesterol associated with increased risk of cardiovascular health problems 
(SCANDINAVIAN SIMVASTATIN SURVIVAL Study Group, 1994) and high levels of high-density 
lipoprotein cholesterol associated with reduced risk (Gordon et al., n.d.). Antipsychotics have been 
shown to alter cholesterol levels, so this may be a mechanism via which clozapine modulates risk of 
cardiovascular symptoms (Hennekens, Hennekens, Hollar, & Casey, 2005). 
Candidate gene testing found no support for any association between CYP1A2 methylation and 
cardiovascular symptoms.  
5.6.4 Summary 
There were three epigenome-wide significant hits for increased weight/appetite - cg10966876 in 
TWIST2 (a transcription factor involved in cytokine expression, glycogen storage and energy 
metabolism), ch.6.163729680F, and cg21097199 in POLQ (encodes DNA polymerase theta)– and two 
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for drowsiness - cg12155676 and cg21399492.  Participants with increased appetite/weight and 
drowsiness showed an initial decrease in global DNA methylation and then an increase above 
baseline, whereas participants without remained stable. Participants with cardiovascular symptoms 
showed a lower baseline global DNA methylation which increased with time, whereas those without 
started higher and this decreased and then returned to baseline levels. This analysis is limited by the 
less powered between-participant analysis, especially for the cardiovascular analysis with only four 
participants who reported cardiovascular symptoms. It is likely that those with the most serious 
adverse reactions or risk of adverse reactions discontinue clozapine early or are never commenced 
on clozapine, and are therefore not represented in this sample. 
There is much less literature on adverse responses to antipsychotics than therapeutic response, 
however some of these findings coincide with our existing understanding of these adverse reactions, 
such as an association between increased appetite/weight and DMPs involved in energy metabolism 
and glycogen function and an association between cardiovascular symptoms and DMPs involved in 
cholesterol function.  
Interestingly, there is also significant overlap between systems implicated by my analysis of both 
therapeutic response to clozapine and adverse reactions to clozapine: immune function, 
inflammation and antioxidant activity (metabolic, drowsiness and cardiovascular), signal 
transduction including calcium signalling (metabolic and drowsiness), nervous system development 
and migration (metabolic and drowsiness), kinase signalling (drowsiness), and ATP activity 
(cardiovascular). This suggests that mechanism of action of therapeutic response to clozapine may 
also be related to adverse reactions. For example, clozapine’s regulation of calcium signalling may 
help normalise aberrant signalling in some systems leading to improved symptoms but create 
aberrant signalling in other systems leading to drowsiness and metabolic effects. Similarly, the 
reduction of elevated immune function may have beneficial effects on psychotic symptoms but be 
directly linked to increased risk of numerous adverse reactions  
Some methodological caveats should be considered when interpreting the results and the 
strength of the conclusions that can be drawn. Firstly, even with optimal collection of GASS-C data, 
the cause of self-reported adverse reactions is undetermined and cannot be definitively attributed 
to clozapine. Physical sensations such as changes in heart rate or appetite may relate to changes in 
psychiatric symptoms (e.g. anxiety and depressive symptoms, respectively), changes in lifestyle, or 
may relate to comorbid illness or adjunctive medications, psychiatric or otherwise. While changes in 
psychiatric medication were included as variables within the analysis, numerous confounding 
variables remain. Secondly, while the original intention was to look at change in GASS-C scores so 
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that baseline scores were accounted for, due to significant missing data at baseline the analysis only 
takes into account cross-sectional report of adverse events at 12 weeks. Therefore, any attribution 
of these adverse events to clozapine is even more uncertain, as they may have preceded the 
initiation of clozapine or may even have reduced during clozapine treatment. The analysis simply 
reflects differences between clozapine patients who report or do not report experiencing these 
symptoms at 12 weeks; we cannot confidently state that they are experiencing clozapine-induced 
adverse events. 
Additionally, as with symptomatic response, the question remains whether these changes in 
methylation are causal mechanisms or simply reflections of the biological processes underlying 
adverse reactions.  
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6 General Discussion  
In this chapter, I will first provide an overview of the key findings from the previous results 
chapters, highlighting areas of overlap. I will then discuss the strengths and limitations of the study 
and analysis approach, and the subsequent limitations for interpreting the results. Finally, I will put 
my findings in context of the previous literature on epigenetic studies of antipsychotics and 
schizophrenia, and schizophrenia aetiology as a whole, before making suggestions for the future 
research needed to establish the causal role of DNA methylation in clozapine’s mechanism of action.  
6.1 Summary of findings 
This thesis has used Illumina 450k DNA methylation data from twenty-two participants who 
provided a total of eighty five samples of peripheral blood at four time-points over the first six 
months of their clozapine initiation. This data has been analysed to address associations between 
changes in DNA methylation and three broad areas: exposure to clozapine, therapeutic response to 
clozapine and adverse reactions to clozapine. This is the first research to investigate numerous time-
points within six months after clozapine initiation, the first to report on categorical comparison 
between responder and non-responders, numerous measures of therapeutic response and adverse 
reactions to clozapine, and the first to have rigorous modelling methods controlling for numerous 
known confounders and using strict correction for multiple testing. The findings implicate a wide 
variety of biological systems known to be disrupted in schizophrenia as systems showing differential 
methylation associated with exposure to and response to clozapine.  
Exposure to clozapine across models was associated with differential methylation in loci involved 
in signal transduction, G-coupled protein receptors, AMPAR function, immune function, glucose 
homeostasis, beta-tubulin and regulation of gene expression, with four epigenome-wide significant 
DMPs. Candidate gene testing identified an association between clozapine level and methylation at a 
locus on PVALB, encoding parvalbumin which is involved in calcium signalling at GABAergic 
interneurons. Change in response to clozapine across models was associated with differential 
methylation in loci similarly involved in signal transduction, ion channels (especially calcium), G-
coupled protein receptors, glutamatergic function, immune function, glucose homeostasis, 
microtubules, and regulation of gene expression, but additionally neuronal precursors and cell 
adhesion; there were five epigenome-wide significant DMPs.  Symptom severity was similarly 
associated with differential methylation in loci involved in signal transduction, ion channels, receptor 
function, immune function, cell adhesion and regulation of expression, but additionally neuronal 
development and glycine function; there were twenty two epigenome-wide significant DMPs, mostly 
associated with negative symptom severity. Finally, adverse reactions to clozapine across models 
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were also associated with differential methylation in loci involved in signal transduction, calcium 
channels, immune function, cell adhesion, neuronal development and regulation of gene expression 
–suggesting an association between systems involved in therapeutic response and adverse reaction - 
but additionally increased appetite/weight gain was associated with energy metabolism and 
glycogen function and cardiovascular adverse reactions were associated with cholesterol function; 
there were five epigenome-wide significant DMPs. Candidate gene testing identified an association 
between increased appetite/weight and methylation at a locus on NPY, a gene involved in regulation 
of food intake. 
Signal transduction was a common theme throughout the results, with numerous aspects 
implicated (ion channels and signalling including potassium and calcium, G-coupled protein 
receptors, kinase signalling, Wnt signalling, GTP activity, ATP activity, as well as various aspects of 
neuronal development); regarding specific neurotransmitter systems, AMPAR function was 
associated with exposure to clozapine and psycho- social functioning, NMDAR and GABA receptor 
function was associated with response status, and glycine receptor function was associated with 
symptom severity. Immune function was another common theme, also with numerous aspects 
implicated – cytokines including interleukins, inflammation response, antioxidant activity, T-cells, 
interferon gamma signalling and major histocompatibility complex.   
Of note is that 41% of the top ten DMPs for all models associated with clozapine exposure and 
response have been previously reported to have a significant correlation between methylation in 
peripheral blood and brain tissue (70.59% of those in TSS15000 regions and 55.56% of those within 
5’UTR regions); while a minority of DMPs, this is a substantial minority and indicates an enrichment 
of DMPS that have correlated methylation in peripheral blood and brain tissue.  
6.2 Strengths and limitations 
 A significant and novel strength of this research is the repeated longitudinal sampling within-
individuals over a six month period, as for the analyses of clozapine exposure and within-individual 
symptom variation this controls for all between-individual variation, increasing the statistical power 
and simplifying interpretation of the findings by removing numerous potential confounding variables 
including mQTLs. It also provides information on methylation trajectories, as opposed to a static 
data point or a simple before and after; this contribution to the literature can be built upon to 
construct a more complete picture of the consequences of clozapine exposure, and how these relate 
to therapeutic response and adverse reactions. 
 Another strength is the collection of phenotypic data included in analysis: smoking status at 
each time point, clozapine levels for a significant proportion of samples, medication history and 
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medication usage at each time point, and numerous measures of symptom severity, psychosocial 
functioning and quality of life at each time point. Further phenotypic information on clinical history 
was also available to help characterise the patient group.  
Cell count data was also estimated from the methylation data and acted as another 
covariate which helps limit the potential for confounding due to tissue composition heterogeneity; 
Jaffe & Irizarry, (2014) found that cell composition correlates strongly with global DNA methylation 
and that longitudinal changes in cell composition had confounded a number of previous studies 
investigating age-related changes in DNA methylation, leading to false positives. However, while 
predicted cell counts do reduce this bias, Shakhbazov et al., (2016) report that they do not fully 
account for this bias. Unfortunately, cell count data collected by clinical teams was not available to 
our research team as expected but future studies should seek to obtain observed cell proportions to 
ensure accurate correction of results.   
 This is one of the first studies to utilise the blood-brain DNA methylation comparison tool to 
assess Illumina 450k results and report the predicted association between changes in methylation 
within our peripheral tissue sample and changes in methylation in post mortem blood for each DMP, 
assisting in interpretation of the findings. While peripheral blood was the only realistic option to 
enable longitudinal sampling over the period of clozapine initiation, only 41% (37/90) of the top ten 
DMPs for all models were reported to have a significant correlation between methylation in 
peripheral blood and brain tissue, and many of these correlations - despite being statistically 
significant - were weak correlations with low effect sizes. This raises the question of whether the 
methylation changes reported in this analysis do reflect meaningful changes occurring in the brains 
of the participants studied. However, 41% of DMPs showing a blood-brain correlations represents a 
much higher proportion than expected based on previous studies, and is significantly higher than the 
7.9% reported by others (Walton et al., 2015), suggesting optimism for the relevance of these 
findings. Also, while acknowledging the appropriate caveats for peripheral blood, the caveats for 
other available options cannot be ignored: post-mortem tissue is likely to have accumulated 
numerous epigenetic changes associated with illness (Pidsley & Mill, 2011) and could not have 
enabled longitudinal analysis, and animal studies cannot provide complete models of schizophrenia 
and represent the complex experience of psychotic symptoms in humans. All of these approaches 
benefit from validation using alternative approaches, to identify consistent findings and build a 
complete picture of the mechanisms at work. 
The Illumina 450k array also has limitations. It is not the gold standard of bisulfite genomic 
sequencing which covers the complete DNA methylome (Dedeurwaerder et al., 2011). While 
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providing a high through-put method of epigenome-wide methylation data, the 450k array only 
includes a small proportion of the full range of CpG sites and it is unclear whether we should be 
focusing on other regions across the epigenome; it is heavily weighted towards promoter regions, 
but intergenic CpG sites may show more differential methylation and may act as alternate 
promotors for some genes, particularly those without CpG islands in their promoter regions (Sarda 
et al., 2017). A number of intergenic CpG sites were identified as top DMPs within my analysis, and 
developing our understanding of the function of CpG sites such as these is worth pursuing. Some 
have proposed using methods such as methyl-capture sequencing, which still has significantly lower 
costs then whole genome sequencing while identifying a greater number of CpG sites then the 
Illumina 450k array, but it appears to be less sensitive to small effect sizes and thus less suitable for 
this analysis (Teh et al., 2016).  
Some of the other issues raised with the Illumina 450k, such as potential errors from probe 
cross-hybridization (Teh et al., 2016), batch effects (Leek et al., 2010), SNPs contained in probes 
(Dedeurwaerder et al., 2011) and incomplete bisulfite conversion (D. P. Chen, Lin, & Fann, 2016) can 
be accounted for, and have in this analysis; cross-hybridising probes, probes containing SNPs, and 
samples with below 90% bisulfite conversion were removed, and array design and analysis 
controlled for batch effects. Also, despite the limitations with array-based technologies, they are the 
most popular - in 2016, (D. P. Chen et al., 2016) reported that over 566 publications have used the 
Illumina 450k array - and this enables direct comparison between study findings, the use of 
standardised statistical packages and pipelines, and the use of tools such as the blood-brain 
correlation tool. Additionally, comparison of methylation profiles obtained using the 450k array and 
methylation profiles obtained from other arrays and whole-genome bisulfite sequencing suggest 
high accuracy and reproducibility (Bibikova et al., 2011; Dedeurwaerder et al., 2011). However, the 
caveat that these microarrays only include a very small fraction of all CpG sites should not be 
forgotten. Additionally, methylation cannot be differentiated from hydroxymethylation, another 
chemical modification of cytosines which appears to be most prevalent in adult neuronal cells (Hao 
Wu & Zhang, 2014) and may have differing epigenetic consequences; high levels of 
hydroxymethylcytosine are more commonly associated with highly expressed genes  (Johnson et al., 
2016; Wu et al., 2011).  
The relatively small sample size is another concern; while every effort was made to identify 
and recruit all eligible participants due to commence clozapine within our NHS Trust, the time-
sensitive nature of the eligibility combined with the requirement for numerous clinical interviews 
and retention over follow up, in a highly symptomatic patient group, made recruitment challenging. 
This is in contrast to GWAS in which a single sample and basic phenotypic data are collected and 
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often at least one of these is collected retrospectively (due to the static nature of DNA sequence), 
allowing for vast samples of thousands of participants.  
For the within-participant analysis this is less of a concern because within-participant 
analysis has increased statistical power, but the between-participant analysis of therapeutic 
response at twelve weeks and the comparison of patients with and without adverse reactions is less 
reliable due to the small number in each group; this is particularly true for the adverse reactions 
analysis in which some of the groups had especially low numbers, whereas the responder vs non-
responder categorisation was more evenly split.  
The small sample also raises issues of generalisability; patterns of DNA methylation in our 
participants may not be applicable to the broader population of patients with schizophrenia. For 
example, our sample had a high number of non-responders, potentially due to the clinical teams we 
recruited through. Also, while gender and smoking were included as covariates, our sample was 
predominantly male and had a surprisingly low number of smokers. More broadly, while replication 
of results should always be  a strong priority in science to avoid drawing conclusions based on false 
positives, it becomes even more acutely necessary in a small sample such as this one where the 
likelihood of spurious findings is increased. 
Because of the relatively small sample analysed, it was not feasible to do reliable analysis of 
predictors within the baseline data. Similarly, I could not control for additional covariates such as 
drug and alcohol use, as this may have led to overfitting the model; therefore, I selected the 
covariates with the strongest justification for inclusion (such as smoking status and cell counts which 
are known confounders in methylation studies), and those with most variability over the six months 
(e.g. I focused on including more sensitive variables of medication use at each time point than 
history of medication use).     
The issue of sample size raises the issue of p-values and significance testing. On one hand, 
epigenome-wide studies run the risk of false positives due to the huge number of CpG sites being 
assayed, hence the need for a threshold of p<1*10-7 to be considered epigenome wide significant 
(Lehne et al., 2015). In fact, a very recent analysis (published after the current analysis was 
conducted) accounts for correlation between neighbouring CpG sites and indicates that a slightly 
less conservative significance threshold of 2.4 x 10-7 is appropriate for the 450k array (;they also 
show that a hypothetical genome-wide EWAS array would require a more stringer statistical of 
3.6x10-8, highlighting that the literature standard for significance thresholds will need to be dynamic 
and adjust with developing technology (Safarri et al., 2018). Still, support from broader literature 
and pathway analysis is of great assistance in determining the likelihood of a false positive: broader 
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literature can provide plausible mechanisms for a causal relationship as well as give some general 
support for the involvement of a system in clozapine’s mechanism of action; and it is less likely that a 
combination of numerous positions from the same pathway are of greater significance by chance 
than an individual position being of greater significance by chance.  
The effect sizes for many of the models are also very small, however this should be 
understood in the context of the measurement scales for other variables; for example, when 
reporting findings for analysis of time on clozapine, each effect size reported relates to the change 
predicted for just an additional week on clozapine.  
While the within-subject analyses holds many variables constant, it does not eliminate the 
possibility of changes in unmeasured variables such as diet, sleep, social interactions etc.; these are 
likely to improve with improved symptoms (which would in turn be associated with greater 
clozapine levels, greater response, greater time exposed to clozapine), and could have consequences 
for DNA methylation and therefore become a potential confound. Furthermore, a number of the 
analyses are between-subject; while I have controlled for basic demographic and clinical variables 
and group comparisons find no significant differences, it is possible that other unmeasured 
between-group differences including mQTLs could account for the different trajectories associated 
with therapeutic response or adverse reactions. A particular concern for between-group genetic 
analysis is the effect of ethnicity and population stratification, in which between-group differences in 
genetic variables (and therefore epigenetic variables) are driven by differences in the underlying 
genetic structure of the populations i.e. different proportions of different ethnicities, rather than the 
group difference of interest. In this sample, there were no significant differences in racial 
classifications for any of the analyses, but these may have been overly crude categorisations. Also, 
differences may have had a meaningful impact despite being non-significant; for example, there 
appears to be a higher proportion of black patients in the group of patients who experienced 
increase appetite or weight gain, and though this did not meet thresholds for statistical significance 
it may still have impacted on the results of the analysis. As discussed in the previous chapter, the 
adverse events analysis is also affected by the lack of baseline data and inability to determine 
whether adverse events can be attributed to clozapine or other confounding variables. 
The time-points chosen may not be the most appropriate; the most relevant changes in DNA 
methylation may occur within hours of the first exposure to clozapine, or may occur after chronic 
use extending beyond six months of clozapine use. However, as an early study in the area, the time 
points have clinical relevance for when therapeutic blood levels are reached, when response to 
clozapine is determined, and after a period of relatively stable long-term use. Many CpG sites appear 
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to show different directions of change within the first six weeks compared to the rest of the six 
months; this may indicate an immediate methylation change which is then regulated by subsequent 
feedback to attenuate the initial reaction, or may indicate that the early direction of effect is a 
continuation of methylation fluctuation before clozapine was introduced, which then changes once 
clozapine has been maintained at therapeutic levels for a sustained period. Further studies exploring 
longer study periods before and after clozapine initiation, and exploring more fine-tuned short term 
study periods after clozapine initiation are needed. It also may have been valuable to record and 
analyse norclozapine levels, as a pharmacologically active metabolite of clozapine which has been 
speculated to underlie some of clozapines unique effects.  
Our study did not include healthy volunteers as a control group, either on or off clozapine. 
We would not have been able to include healthy volunteers on clozapine as a control group, to 
separate out schizophrenia-related changes, due to the significant ethical concerns about 
prescribing unnecessary long-term antipsychotic treatment with potential adverse reactions with no 
clinical benefit to volunteers. We did not include healthy volunteers or patients with schizophrenia 
off clozapine as a control group, which would potentially enable separation of non-clozapine related 
changes over-time, because in a small non-randomised sample there would likely be vast group 
differences and different variables changing over time, adding significant noise to any-between 
participant analysis; therefore, we chose to focus efforts on obtaining data to allow within-
participant comparisons and conduct analyses such as the clozapine level and change in symptom 
severity model, which are unlikely to reflect natural changes over time. However, future analysis 
could investigate comparisons to datasets of longitudinal DNA methylation changes in healthy 
controls, and larger scale studies could seek to recruit appropriate control groups to aid 
interpretation of the results.   
A significant caveat is that, as Pidsley and Mill (2011) state: “statistical evidence of an interaction 
reveals little about the molecular pathologic mechanisms underlying psychosis”. While the 
longitudinal design of the study is an improvement over cross-sectional designs for inferring 
causality, this limitation remains relevant. This is especially pertinent when methylation across CpG 
sites is highly correlated, and associations with changes at one probe may reflect a true mechanistic 
change at another locus. Even if methylation at a specific CpG site is correctly identified as pertinent 
to clozapine’s mechanism of action, a) this may not be associated with expression of the gene it is 
located in/nearby and b) it is currently unclear how this might lead to downstream effects on 
symptoms and adverse reactions in schizophrenia. 
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Furthermore -as Lappalainen & Greally, (2017) note - while a change in DNA methylation is likely 
to be reflective of cellular reprogramming, it is not necessarily directly involved or mediating this 
process; it may simply reflect low transcription factor occupancy, instead of actual cellular changes 
reflected directly in methylation. In the current analysis, these alternative explanations cannot be 
distinguished.  A better understanding of the functional implications of methylation changes induced 
by clozapine is critical; firstly, investigating whether these translate to altered gene expression as 
expected, but then in vitro and animal model work is required to experimentally determine the 
effect on relevant biological symptoms and subsequent behaviour.   
Another caveat to the current research is that it studies DNA methylation in isolation, whereas 
evidence suggests that DNA methylation does not act independently from histone modifications. 
Incorporating data on histone modifications induced by clozapine could therefore provide a more 
complete picture; however, currently there is not the same readily available technology for 
identifying epigenome-wide histone modifications.  
Another consideration is the heterogeneity of schizophrenia – in treatment-resistance, a key 
distinction may be between early onset resistance and delayed onset resistance (Demjaha et al., 
2017) - with the potential for numerous aetiologies pathways underlying small subsets of the 
population of schizophrenia. This is one motivator for research into rare genetic variants within 
schizophrenia, and this may be equally fruitful with epigenetic research. (Dempster et al., 2011) 
found some large methylation changes specific to one or a few twin pairs, suggesting some rare 
epigenetic alternations of large effect may be associated with schizophrenia in individuals. 
Responses to clozapine treatment may be similarly heterogeneous; changes in certain biological 
pathways may be more relevant in certain individuals than others and these individual differences 
may get lost when looking for consistent patterns among patients. The apparent outliers evident in 
some of the analyses may reflect this, though they may also be spurious.   
The interpretation of this data and the pathway analysis also rests upon the gene annotation 
databases. All pathway analysis approaches share certain limitations (Khatri, Sirota, Butte, Kim, & 
Woo, 2012), namely limited information about which transcripts are active in each pathway and the 
consequences for each pathway, but also incomplete and potentially inaccurate annotation; much is 
derived from indirect evidence, though this improves with each new version. There are also 
concerns that pathway analysis is biased towards certain pathways, with some much more heavily 
annotated due to previous research interest, which may lead to false positive errors (pathways 
implicated simply due to heavy annotation) or false negative errors (novel pathways or locus 
dismissed due to their limited annotation) (Haynes, Tomczak, & Khatri, 2017). To reduce concerns of 
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false positive errors, the statistical package I used in this analysis – GOSeq (M. D. Young, Davidson, 
Wakefield, Smyth, & Oshlack, 2016) – accounts for pathways which have an existing bias in 
annotation using probability weighting functions; this makes a significant differences to results when 
compared to approaches which assume equality of pathways (M. D. Young, Wakefield, Smyth, & 
Oshlack, 2010). 
6.3 Comparison to broader literature 
Based on the previous studies reporting epigenetic changes induced by clozapine (Aoyama et al., 
2013; Dong et al., 2008; Huang et al., 2007; Kinoshita et al., 2017), candidate gene testing was done 
for all available probes on GAD1, PVALB, RELN, GRIN2A, GRIN2D and GRM7 in association with 
exposure to clozapine (time or levels). The only DMP which survived correction for multiple testing 
was cg19136704 within a promoter region of the PVALB gene, where there was a positive 
association between methylation and clozapine levels; however, the previous study of clozapine had 
found increased mRNA expression which is not generally associated with increased methylation of 
promoter regions. Altered parvalbumin activity, particularly dysfunction of parvalbumin-expressing 
GABAergic interneurons, has been reliably demonstrated in schizophrenia and linked to underlying 
cognitive impairments (Gonzalez-Burgos et al., 2015; Stedehouder & Kushner, 2016), and 
understanding the impact of clozapine on parvalbumin is worth pursing further.  
More broadly, pathway analysis of the categorical response model indicated that there was an 
over-representation of DMPs involved in regulation of GABA transport associated with response to 
clozapine, which provides support for the proposal (Guidotti et al., 2012) that clozapine response 
may be driven by a normalisation GABAergic gene methylation and gene expression. This also 
coincides with the study by Kinoshita et al., (2017). Broadly speaking, the systems implicated by 
Kinoshita – GABA, glutamate and cell-adhesion – are also implicated by my analysis; these coinciding 
results provide support for the involvement of these systems in clozapine’s mechanism of action. 
However, some of the specific findings receive no support from our analysis: they report 
demethylation at GAD1, which we tested in our candidate gene analysis and did not find, and they 
report an association between CREBBP (a binding protein involved in histone acetyltransferase 
activity and stabilising protein interactions) and changes in symptom severity, which we did not find 
associated with response. 
Based on our systematic review of all gene-association studies of clozapine response, candidate 
gene testing was done for all probes on the gene with independent replication of an association with 
response to clozapine - DRD3, 5HTR2A, 5HTT/SLC6A4, and GNB3 - in association with categorical 
response classification to clozapine in our data. None of these survived correction for multiple 
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testing. This need not dismiss these variants as relevant; loci that have relevant genetic variance may 
not have relevant epigenetic variance and vice versa.   
Despite a number of studies suggesting that valproate, a histone deacetylase, enhances the 
epigenetic effects of clozapine e.g. (Dong et al., 2008) we were not able to conduct statistical 
analysis on this within the current sample as there were only two instances of patients taking 
adjunct valproate.  
Considering sites of differential methylation associated with schizophrenia identified by a review 
of peripheral blood studies (Teroganova et al., 2016), we found differential methylation trajectories 
associated with clozapine response (higher baseline levels and further increases in responders) in a 
gene previously associated with hyper methylation in schizophrenia – DLG4. But more broadly, this 
review indicated aberrant methylation of genes involved in glutamate, GABA, signal transduction, 
calcium signalling, potassium channels, microtubule associated proteins, kinase signalling, insulin 
related genes, glial cells, and immune function, all of which were also implicated by analysis of DMPs 
associated with exposure and/or response to clozapine.  Similarly, considering studies of post-
mortem of methylation differences in schizophrenia, these have implicated glutamatergic and 
GABAergic function, cell proliferation, GCPRs, potassium channels and protein-kinase signalling (Mill 
et al., 2008; Ruzicka et al., 2015), all of which were systems we found to be associated with exposure 
and/or response to clozapine.  
Cumulatively, while a formal comparison to previously identified genetic variants associated with 
schizophrenia risk was not conducted, my analysis of methylation changes associated with exposure 
to clozapine and subsequent response implicates systems associated with a wide array of 
hypotheses regarding schizophrenia. This is not a problem, many of these hypotheses are 
complementary, focusing on specific dysfunctional systems but acknowledging their interaction with 
other systems. Drawing ideas from a number of studies (Berridge, 2016; Feigensona et al., 2014; O. 
Howes, McCutcheon, & Stone, 2015; Landek-Salgado, Faust, & Sawa, 2016; Leza et al., 2015; Lidow, 
2003)– we could conceptualise the neurodevelopmental pathway of schizophrenia in the following 
way: 
Inflammation and disrupted cytokine levels, caused by exposure to risk factors early in 
development and/or dysfunction of genes involved in the immune system, lead to altered 
development of the central nervous system.  This inflammation and associated oxidative stress leads 
to dysregulation of the cytoskeleton – the structural proteins which guide the function and 
morphology of dendrites and synapses, such as beta-tubulin – perhaps mediated by dysfunctional 
microglial regulation of these processes. The ubiquitin proteasome pathway, which targets proteins 
General Discussion 
- 318 - 
 
for degradation and regulates a wide array of functions around the body, is also disrupted. This leads 
to alterations in neurogenesis, synaptic pruning, ATP metabolism, synapse regulation, dendritic 
spine density, ion channels, white matter development and connectivity and cell adhesion. This 
could all be exacerbated by polymorphisms in neuroplasticity-related genes such as RELN and DISC1. 
Stress in childhood or adolescence may further exacerbate this inflammatory state, perhaps via 
activation of the HPA axis leading to even higher levels of cytokines, and stress could contribute to 
increased synaptic pruning through increased subcortical dopamine release. The disrupted 
development and formation of neurons leads to dysfunction in the signalling of multiple 
neurotransmitter systems, and the altered immune function also directly leads to this via 
interactions between microglia and NMDA and T cells and dopamine receptors.  
Polymorphisms in genes regulating calcium signalling activity may enhance or mediate some of 
these effects, as disrupted calcium signalling leads to disrupted regulation of: dopamine synaptic 
uptake, NMDAR inhibition and subsequent GABAergic inhibitory interneuron function, myelination 
proteins and formation of synaptic connections and cell maintenance.  
Abnormalities in AMPAR regulation may lead to disrupted depolarisation of post-synaptic 
membranes, a prerequisite for NMDAR activity at glutamate synapses, therefore leading to altered 
NMDA signalling. Calmodulin dysfunction may exacerbate the disruption of AMPAR, increasing their 
sensitivity. NMDAR dysfunction may be further exacerbated by reductions in levels of glycine, which 
is also required for NMDAR signalling, and by low levels of GABA caused by GABA risk genes. NMDA 
receptor hypofunction leads to diminished inhibition of the glutamatergic system – in the short term 
this leads to increased glutamate and hyperactivation of other glutamate receptors, but long term 
may lead to reductions in glutamate and an upregulation of NMDAR to compensate. This 
glutamatergic dysfunction may also lead to subsequent mesolimbic dopaminergic hyperactivity and 
frontal dopaminergic hypoactivity, perhaps through further reductions in GABA synthesis due to 
inhibition of inhibitory GABA interneurons and/or via inhibition of AMPA receptor desensitisation.  
In turn, reduced NMDAR signalling reduces the body’s antioxidant response and therefore its 
protection against inflammation, leading to further damage. Similarly, dopamine activity increases 
oxidative stress and affects pyramidal spine density. Over time, this may lead to reductions in grey 
matter and neuronal density.  
It has already been suggested that DNA methylation could play a role in this chain of events from 
an early stage with hypermethylation occurring alongside inflammatory processes (Davis, Moylan, 
Harvey, Maes, & Berk, 2014)  or hypermethylation caused by inflammatory processes (Khojasteh-
Fard, Tabrizi, & Amoli, 2011). The results of this thesis provide supporting evidence that clozapine 
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exposure and response is associated with changes in DNA methylation at loci implicated in nearly all 
aspects of this chain of events. This may be a mechanism for triggering normalisation of these 
dysfunctional systems, it may be a mediating mechanism in the normalisation, or it could be simply a 
reflection of normalisation that has occurred.  Either way, the vast array of aetiologically relevant 
systems and processes seemingly affected by clozapine treatment, as indicated by these results, may 
explain clozapine’s unique effectiveness and ability to address a broader range of the symptoms 
seen in schizophrenia. Previous literature supports the complex and extensive effects of clozapine, 
with evidence of clozapine’s ability to: supress immune response (Song et al., 2000), regulate T cells 
(Fernandez-Egea et al., 2016), influence Wnt signalling (Sutton et al., 2007) and signal transduction 
cascades (Browning et al., 2005), normalise G-protein dysfunction (Avissar, Barki-Harrington, et al., 
2001) and calcium and potassium channel system disruption (Park et al., 2015; Peltola et al., 2016), 
influence AMPAR function (Schmitt et al., 2003) and NMDAR function (Schwieler, Linderholm, 
Nilsson-Todd, Erhardt, & Engberg, 2008; Tanahashi et al., 2012), activate glycine receptors (Harvey & 
Yee, 2013), antagonise GABA receptors (Ohno-Shosaku et al., 2011), increase white matter integrity 
(Steiner et al., 2014), and normalise disruption of axonal growth processes and dendritic spine 
deficits (Barros et al., 2009; Critchlow et al., 2006; Park et al., 2015). Kedracka-Krok et al., (2015) 
report that clozapine induces changes in proteins across all aspects of the cytoskeleton, neuronal 
and non-neuronal cells, regulatory and synaptic proteins  and comment that the robust efficacy of 
clozapine may be due to the fact it has “one of the most complex pharmacological profiles” with a 
unique receptor binding profile.  
Broadly speaking, these results provide optimism that longitudinal psychiatric epigenetic studies 
can identify within-participant changes in methylation in disease-relevant loci, with enrichment of 
DMPs previously shown to have correlating methylation in brain and blood.   
6.4 Future research   
There are two broad avenues for future research on DNA methylation and clozapine use.  
Firstly, research which enables more robust conclusions about the causal and mechanistic 
processes induced by clozapine and associated with clinical outcomes. An initial step is investigating 
whether differential methylation trajectories associated with clozapine exposure or response are 
associated with equivalent changes in gene expression at the same loci or whether different genes 
are regulated by these CpG sites. Further research should then integrate numerous strands of 
evidence, to enable a complete picture of the causal relationship between genetic variants, 
epigenetic modifications including DNA methylation but also histone modifications, gene expression, 
protein expression, downstream effects and changes in phenotype; for example, providing a 
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connection between findings of differential methylation in genes associated with GABAergic 
receptors and findings of altered GABAergic transmission. Experimental work to determine the 
consequences of methylation at individual CpG sites is particularly warranted. Additional 
longitudinal studies using different timeframes surrounding clozapine initiation would also be of 
utility to provide a fine-grained temporal resolution of the methylation trajectories induced by 
clozapine and seen prior to clozapine initiation. Studies could also look at methylation changes 
related to levels of norclozapine, the pharmacologically active metabolite of clozapine. In general, 
research in other larger samples should be used to replicate these findings and different methylation 
profile techniques and whole genome sequencing should be used to validate these findings and the 
pathways implicated. Both replication and validation are of utmost importance to ensure the 
findings are not compromised by the limitations of the small sample size and the caveats regarding 
Illumina 450k analysis. Larger samples would also allow for more covariates to be included in the 
analysis (in particular, they should consider population stratification) and generally reduce the 
chance of spurious findings. This strand of research could enable a greater understanding of the 
underlying dysfunction of schizophrenia itself, or treatment-resistant schizophrenia specifically, 
particularly if formal comparisons to datasets indicating genetic variants associated with 
schizophrenia were conducted. This could highlight the genetic dysfunction which clozapine works to 
normalise, and which mediates psychotic experiences and improvement in symptoms.   
Secondly, while this sample was not large enough to identify predictive DMPs at baseline, future 
studies should aim to explore the potential for DNA methylation in peripheral blood to act as a 
biomarker for clinical outcomes including both therapeutic response and adverse reactions. 
Research in this direction will have to consider whether there are consistent predictors and markers 
across individuals, or whether the most meaningful variation is specific to individuals or sub-groups. 
Assuming consistent markers can be identified, this research would not be hindered by many of the 
limitations associated with use of peripheral blood, the Illumina 450k array or bisulfite sequencing in 
general, such as uncertainty about whether we are actually identifying hydroxymethylation and 
whether differential methylation is also seen in brain tissue; a biomarker is useful if it is reliable 
predictor, regardless of the underlying causal relationship or whether it reflects the “true” 
mechanism. There would be significant immediate benefit to prediction of both favourable and 
adverse outcomes of clozapine. Reducing the time spent with inadequate or ineffective 
antipsychotics would reduce both the economic cost of drug treatment, and more importantly the 
suffering to patients as their symptoms endure and life circumstances potentially worsen while 
taking a trial and error approach to their medication. Prior knowledge of adverse outcomes would 
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allow patients to make informed choices about their medications, and could assist clinicians in 
proactively preventing or treating adverse reactions. 
7 Conclusions 
In conclusion, my analysis of longitudinal samples of peripheral blood taken from patients over 
the first six months of clozapine treatment identified numerous differentially methylated positions in 
DNA associated with clozapine exposure, therapeutic response to clozapine and adverse reactions 
(thirty-three of which were epigenome wide significant). The results suggest that clozapine’s 
mechanism of action may involve differential methylation at genes involved in signal transduction, 
GPCRs, glutamatergic systems (including NMDARs and AMPARs), GABAergic systems, glycine 
receptor function, calcium signalling, glucose homeostasis, immune function, neuronal 
development, beta tubulin and microtubules, cell adhesion and regulation of transcription; and 
additionally, that some of these systems may also be involved in adverse reactions to clozapine. The 
within-participant design, exploration of clinical outcomes, and enrichment of positions which have 
evidence of correlated methylation in brain and blood provides some confidence that these findings 
are not spurious and are relevant to clozapine’s efficacy. However, replication is required and DNA 
methylation is only one piece of the puzzle: the complete mechanistic picture of casual processes 
leading to clozapine’s remarkable efficacy remains unclear.  
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